2 0 1 3 N 1 6 1 6 4 9 _ 0 3 C O N FI D E N TI A L
Vii V H e alt h c ar e a n d T h e Gl a x o S mit h Kli n e gr o u p of c o m p a ni e s I N G 1 1 7 1 7 2 
1TI T L E P A G E 
Di visi o n: W orl d wi de De vel o p me nt 
I nf or m ati o n T y pe: Pr ot oc ol A me n d me nt 
Title: A P hase III b, ra n d o mize d, o pe n-la bel st u d y of t he safet y a n d 
efficac y  of d ol ute gra vir/a baca vir/la mi v u di ne o nce dail y  
c o m pare d t o ataza na vir a n d rit o na vir pl us te n of o vir /e mtricita bi ne 
o nce dail y i n HI V -1 i nfecte d a ntiretr o viral t hera p y naï ve w o me n 
C o m p o u n d N u m ber: G S K 1 3 4 9 5 7 2 + G R 1 0 9 7 1 4 + GI 2 6 5 2 3 5 
( G S K 2 6 1 9 6 1 9) 
Effecti ve D ate: 1 9- J U N -2 0 1 8 
Pr ot oc ol A me n d me nt N u m ber:  [ADDRESS_1255656]: HI V i nfecti o n, i nte grase i n hi bit or, d ol ute gra v ir/a baca vir/la mi v u di ne fi xe d d ose 
c o m bi nati o n, o nce dail y, ataza na vir, rit o na vir, te n of o vir/e mtricita bi ne, a ntiretr o viral 
t hera p y naï ve, w o me n 
A ut h or s:  
C o p y ri g ht 2 0 1 8 t he Vii V Healt hcare a n d Gla x o S mit h Kli ne gr o u p of c o m pa nies.  All 
ri g hts reser ve d.   U na ut h orise d c o p yi n g or use of t his i nf or mati o n is pr o hi bite d. P P D 
2013N161649_03 CONFIDENTIA L
ViiV Healthcare and The GlaxoSmithKline group of companies ING117172
2Revision Chronology:
2013N161649_00 2013- MAY -[ADDRESS_1255657] Management at Week 24, to differentiate between the two 
scenarios for re -testing HIV -1 RNA levels.
2013N161649_02 2014 -AUG-11 Amendment No. 2
Changes made to the [LOCATION_006] country  specific informat ion on study  duration (Appendix 5) to 
comply  with requests from the [LOCATION_006] MHRA. The medical monitor contact [CONTACT_895643]
2013N161649_03 [ADDRESS_1255658] in infants born to women with 
exposure to dolutegravir at the time of conception.
The Risk Assessment table (Section 1.3.1.) was updated to include language 
regarding risk and mitiga tion of neural tube defects.
Inclusion criterion #2 (Section 4.2.) was updated to exclude the double barrier method 
of contraception, and refer to the Modified List of Highl y Effective Methods for 
Avoiding Pregnancy  in Females of Reproductive Potential .
The withdrawal criteria (Section 4.5.) were updated to include a reminder that 
females of reproductive potential who change their minds and desire to be pregnant , 
or who state they  no longer are willing to compl y with the approved pregnancy  
avoidance methods, should also be withdrawn from the study .
The Time and Events table (Section 6.1 .)wasupdated to include a reminder for 
investigators to check at every  visit that females of reproductive potential are 
avoiding pregnancy .
Appendix 6was added: Modified L ist of Highl y Effective Methods for Avoiding 
Pregnancy  in Females of Reproductive Potential
Administrative updates were made .
P P D 
P P D P P D P P D 
P P D 
[ADDRESS_1255659] u d y I de ntifier: I N G [ADDRESS_1255660] u d y .
S p o ns or Le g al Re gistere d A d dress: 
Vii V Healt hcare 
[ADDRESS_1255661] R oa d 
Bre ntf or d 
Mi d dlese x 
T W 8 9 G S 
U K 
Tele p h o ne:  + 4 4 ( 0) [ADDRESS_1255662] A d dress: 
Vii V Healt hcare 
Fi ve M o ore Dri ve 
Researc h Tria n gle Par k, N ort h Car oli na U S A 
2 7 7 0 9 - 3 3 9 8 
Tele p h o ne:  + 1 8 7 7 8 4 4 8 8 7 2 
I n s o me c o u ntries, t he cli nical trial s p o ns or ma y  be t he l ocal Vii V Healt hcare affiliate 
c o m pa n y ( or desi g nee). W here a p plica ble, t he details of t he S p o ns or a n d c o ntact pers o n 
will be pr o vi de d t o t he rele va nt re g ulat or y  a ut h orit y  as part of t he cli nical trial 
s u b missi o n. 
Me di c al M o nit or C o nt act I nf or m ati o n a n d Seri o us A d verse E ve nts ( S A E) C o nt act 
I nf or m ati o n : 
 M D 
Vii V Healt hcare, 
5 M o ore Dri ve, 
Researc h Tria n gle Par k, N C 2 7 7 0 9, U S A 
M o bile: 
Facsi mile: 
e- mail: 
Re g ul at or y A ge nc y I de ntif yi n g N u m bers: 
U S I N D: 1 1 4, 8 2 0 
E u dra C T: [ADDRESS_1255663] to ensure that site 
staff receives the appropriate information throughout the study . 
Investigator Name:  _____________________________
Investigator Signature [CONTACT_1782]
2013N161649_03 CON FIDENTIA L
ING117172
6TABLE OF CONTENTS
PAGE
LIST OF ABBREVIATION S........................................................................................... [ADDRESS_1255664] of Potential Drug -Drug Interaction .................................... 19
[IP_ADDRESS]. Use of calcium and iron supplements with 
dolutegravir ................................................................ 19
1.3. Benefit:Risk Assessment ............................................................................ 20
1.3.1. Risk Assessment ......................................................................... 21
1.3.2. Benefit Assessment ..................................................................... 26
1.3.3. Overall Benef it:Risk Conclusion ................................................... [ADDRESS_1255665] and Other Study Treatment .................................... 38
5.1.1. Tablet Formulation of DTG/ABC/3TC FDC .................................. 39
5.1.2. Tablet Formulations of ATV, RTV, TDF/FTC FDC ....................... [ADDRESS_1255666] Accountability ................................................................................ 40
5.5. Treatment Compliance................................................................................ 40
5.6. Concomitant Medications and Non -Drug Therapi[INVESTIGATOR_014] .................................... 40
5.6.1. Permitted Medications and N on-Drug Therapi[INVESTIGATOR_014] .......................... 41
5.6.2. Prohibited Medications and Non -Drug Therapi[INVESTIGATOR_014] ......................... 41
[IP_ADDRESS]. Prohibited medications for subjects 
randomized to DTG/ABC/3TC FDC ............................ 42
[IP_ADDRESS]. Prohibited medications for subjects 
randomized to ATV+RTV + TDF/FTC FDC ................. 42
5.7. Treatment after the End of the Study .......................................................... 43
5.8. Treatment of Study Treatment Overdose .................................................... 43
2013N161649_03 CON FIDENTIA L
ING117172
76.STUDY ASSESSMENTS AN D PROCEDURES ..................................................... 44
6.1. Time and Events Schedule ......................................................................... 44
6.2. Critical Baseline Assessments .................................................................... 47
6.2.1. Screening Assessments .............................................................. 47
6.2.2. Baseline (Day 1) Assessments .................................................... 47
6.2.3. Subjects infected with Hepatitis B (HBV) and/or 
Hepatitis C(HCV) ........................................................................ 48
6.3. Efficacy ....................................................................................................... 48
6.3.1. Efficacy Evaluations ..................................................................... 48
6.3.2. Primary Endpoint ......................................................................... 48
6.3.3. Secondary Efficacy Endpoints ..................................................... 49
6.4. Safety ......................................................................................................... 49
6.4.1. Safety Evaluations ....................................................................... 49
6.4.2. Safety Endpoints .......................................................................... 51
6.4.3. Toxicity Management ................................................................... 51
6.4.4. Specific Toxicities/Adverse Event Management ........................... 52
[IP_ADDRESS]. Liver Chemistry Stoppi[INVESTIGATOR_895620] ........................................................................ 53
[IP_ADDRESS]. Restarting Investigational Product .............................. 55
[IP_ADDRESS]. ATV related hyperbilirubinemia ................................... 56
[IP_ADDRESS]. Hypertriglyceridemia/Hypercholesterolemia ................ 56
[IP_ADDRESS]. CPK Elevation ............................................................ 56
[IP_ADDRESS]. Decline in Renal Function ........................................... 56
[IP_ADDRESS]. Proteinuria .................................................................. 57
[IP_ADDRESS]. Allergic Reaction ........................................................ 57
[IP_ADDRESS]. Abacavir Hypersensitivity Reaction (ABC HSR) .......... 58
[IP_ADDRESS]. Skin reactions without other symptoms that are 
typi[INVESTIGATOR_895621] .................................................... 59
6.4.5. Adverse Events ............................................................................ 60
[IP_ADDRESS]. Definition of an AE ...................................................... 60
[IP_ADDRESS]. Definition of an SAE ................................................... 61
6.4.6. Laboratory and Other Safety Assessment Abnormalities 
Reported as AEs and SAEs ......................................................... 62
6.4.7. Cardiovasc ular Events ................................................................ .63
6.4.8. Death Events ............................................................................... 63
6.4.9. Disease -Related Events and/or Disease- Related 
Outcomes Not Qualifying as SAEs ............................................... 63
6.4.10. Suicidality Monitoring ................................................................... 64
6.4.11. Pregnancy ................................................................................... 64
[IP_ADDRESS]. Pregnancy Testing ...................................................... 64
[IP_ADDRESS]. Action to be Taken if Pregnancy Occurs ..................... 65
[IP_ADDRESS]. Time Period for Collecting P regnancy 
Information ................................................................ .65
6.4.12. Time Period and Frequency of Detecting AEs and SAEs ............. 65
6.4.13. Method of Detecting AEs and SAEs ............................................. 65
6.4.14. Prompt Reporting of Serious Adverse Events and Other 
Events to [COMPANY_004] ............................................................................. 66
[IP_ADDRESS]. Regulatory Reporting Requirements for SAEs ............ [ADDRESS_1255667] a n .................................................... 7 6 
8. 3. 5. 1. Effi c a c y A n al y s e s ....................................................... 7 6 
8. 3. 5. 2. S af et y A n al y s e s .......................................................... 7 7 
8. 3. 5. 3. H e alt h O u t c o m e s A n al y s e s ........................................ 7 8 
8. 3. 5. 4. Vir al G e n ot y pi n g/ P h e n ot y pi n g A n al y s e s ..................... [ADDRESS_1255668] er s ............ 7 8 
9. 2. R e g ul at or y a n d Et hi c al C o n si d er ati o n s, I n cl u di n g t h e I nf or m e d 
C o n s e nt Pr o c e s s ........................................................................................ 7 9 
9. 3. Q u alit y C o ntr ol ( St u d y M o nit ori n g) .............................................................. [ADDRESS_1255669] er s a n d P u bli c ati o n .................... 8 1 
1 0. R E F E R E N C E S ....................................................................................................... 8 2 
1 1. A P P E N DI C E S ........................................................................................................ 8 5 
1 1. 1. A p p e n di x 1: C D C Cl a s s ifi c ati o n S y st e m f or HI V -1 I nf e cti o n s ( 1 9 9 3) ........... 8 5 
1 1. 2. A p p e n di x 2: Di vi si o n of AI D S T a bl e f or Gr a di n g t h e S e v erit y of A d ult 
a n d P e di atri c A d v er s e E v e nt s ..................................................................... 8 8 
1 1. 3. A p p e n di x 3: P h ar m a c o g e n eti c R e s e ar c h.................................................. 1 0 7 
1 1. 4. A p p e n di x 4: Li v er S af et y Dr u g R e st art or R e c h all e n g e G ui d eli n e s ............ 1 1 3 
1 1. 5. A p p e n di x 5: C o u ntr y S p e cifi c R e q uir e m e nt s ............................................. 1 1 9 
1 1. 6. A p p e n di x 6: M o difi e d Li st of Hi g hl y Eff e cti v e M et h o d s f or A v oi di n g 
Pr e g n a n c y i n F e m al e s of R e pr o d u cti v e P ot e nti al ( F R P) ........................... 1 2 0 
1 1. 7. A p p e n di x 7: Pr ot o c ol C h a n g e s .................................................................. 1 2 1 
1 1. 7. 1. Pr ot o c ol A m e n d m e nt 0 1 ( 1 2 -A U G -2 0 1 3) ................................... 1 2 1 C CI 
2013N161649_03 CON FIDENTIA L
ING117172
911.7.2. Protocol changes for Amendment 02 (11 -AUG -2014) from 
Amendment 01 (12 -AUG -2013) ................................................. 125
11.7.3. Protocol changes for Amendment 03 (19 -JUN-2018) from 
Amendment 02 (11 -AUG -2014) ................................................. [ADDRESS_1255670] OF A BBREVIATIONS
3TC Lamivudine, EPI[INVESTIGATOR_227302] R
AE Adverse Event
ABC Abacavir, ZIAGEN
ABC/3TC Abacavir/Lamivudine, EPZICOM , KIVEXA
AIDS Acquired immunodeficiency  syndrome
ALT Alanine Aminotransferase
ART Antiretroviral Therap y
AST Aspartate Amin otransferase
ATV Atazanavir, Rey ataz
BID Twice Dail y
BUN Blood urea nitrogen
c/mL Copi[INVESTIGATOR_014]/milliliter
CC Calcium carbonate
CD4+ Helper -inducer T -lymphocy te having surface antigen CD4 (cluster of 
differentiation 4)
CDC Centers for Disease Control and P revention
CI Confidence Interval
CMH Cochran -Mantel -Haenszel
COBI Cobisistat
CPK Creatine Phosphokinase
CrCL Creatinine clearance
CRF Case Report Form
CSR Clinical Study  Report
C-SSRS Columbia Suicidality  Severity  Rating Scale
DAIDS Division of Ac quired Immunodeficiency  Syndrome
DILI Drug Induced Liver Injury
DNA Deox yribonucleic Acid
DTG Dolutegravir
ECG Electrocardiograph
EFV Efavirenz
ELV Elvitegravir
EMA European Medicines Agency
FDA Food and Drug Administration
FDC Fixed dose combination
FF Ferrous Fumerate
FRP Females of Reproductive Potential
FTC Emtricitabine
GCP Good Clinical Practices
GCSP Global Clinical Safety  and Pharmacovigilance  
GFR Glomerular filtration rate
GI Gastrointestinal
[COMPANY_004] GlaxoSmithKline
HBsAg Hepatitis B Virus surface Antigen
HBV Hepatitis B Virus
HCV Hepatitis C Virus
HDL High Density  Lipoprotein
2013N161649_03 CON FIDENTIA L
ING117172
11HIV-1 Human Immunodeficiency  Virus Ty pe 1
HIVTSQ HIV Treatment Satisfaction Questionnaire
HLA Human Leukocy te Antigen
HRQoL Health Related Quality  of L ife
HSR Hypersensitivity  Reaction
IB Investigator’s Brochure
ICH International Conference on Harmonization 
IDMC Independent Data Monitoring Committee
IEC Independent Ethics Committee
INI Integrase inhibitor
IP Investigational Product
IRB Institutio nal Review Board
IRIS Immune Reconstitution Inflammatory  Syndrome
ITT Intent to Treat
IUD Intrauterine Device
LDH Lactic Deh ydrogenase
LDL Low Density  Lipoprotein
LLOD Lower Limit of Detection
LSLV Last subject’s last visit
MAA Marketing Applicatio n Authorisation
MCS Mental Component Summary
MCV Mean Corpuscular Volume
MSDS Material Safet y Data Sheet 
mg Milligram
mL Milliliter
NCEP National Cholesterol Education Program
NRTI Nucleoside Reverse Transcriptase Inhibitor
PCS Physical Component Summary
PGx Pharmacogenetic
PK Pharmacokinetic
Pol Polymerase
PP Per Protocol
PRO Protease
PRTD Proximal Renal Tubule Dy sfunction
PSRAE Possible Suicidality  Related Adverse Event
QT C Corrected QT interval
RAL Raltegravir, Isentress
RAP Reporting and Anal ysis Plan
RBC Red Blood Cells
RNA Ribonucleic acid
RT Reverse Transcriptase
RTV Ritonavir, Norvir
SAE Serious Adverse Event
SF-[ADDRESS_1255671] Upper limit of normal
VSL C ViiV Safety and Labeling Committee
WBC White blood cells
Trademark Information
Trademarks of ViiV Healthcare Trademarks not owned by [CONTACT_227380][INVESTIGATOR_895622] 
(efavirenz/tenofovir/emtricitabine)
EPZICOM Complera (rilpi[INVESTIGATOR_12979]/ tenofovir/ 
emtricitabine )
KIVEXA GenoSure
TRIZIV IR Isentress (raltegravir)
ZIAGEN Monogram Biosciences
Norvi r (ritonavir)
Phenosense
Quest Diagnostics
Reyataz (atazanavir)
Stribild (elvitegravir/cobicistat/ 
tenofovir/emtricitabine)
Truvada (tenofovir/emtricitabine)
2013N161649_03 CON FIDENTIA L
ING117172
13PROTOCOL SUMMA RY
Rationale
The dolutegravir, abacavir and lamivudine fixed dose combination (DTG/ABC/3TC 
FDC) may  provide a better treatment option for women infected with Human 
Immunodeficiency  Virus Ty pe 1 (HIV -1) due to its robust antiviral activity , safet y 
profile, high barrier to resistance, low potential for drug-drug interac tions, and 
administration as a once -daily  single tablet regimen (STR). Currently  available integrase 
inhibitors (I NIs), elvitegravir (ELV) and raltegravir (RAL), have limitations including the 
development of clinical resistance, the need for a twice dail y (BID) regimen for RAL 
administration, and a pharmacokinetic (PK) booster for ELV administration, which leads 
to an increased potential for drug -drug interactions including with oral contraceptives.  
Only  limited data on DTG in women are available in Phase III studies due to lower 
enrollment of women compared with men. Therefore, a powered stud y of DTG in a 
single tablet regimen with ABC and 3TC will be conducted in women to provide robust 
data on safety  and efficacy  in this population.  
Study  ING117172 is a Phase IIIb trial designed to demonstrate the non -inferior antiviral 
activity  of DTG/ABC/3TC FDC once daily compared to atazanavir plus ritonavir 
(ATV+RTV) and tenofovir disoproxil fumarate/emtricitabine fixed dose combination 
(TDF/FTC FDC) all administer ed once daily  in HIV -1 infected, antiretroviral therap y 
(ART) -naïve women over 48 weeks.  This study  will also characterize the safet y and 
tolerability  of DTG/ABC/3TC FDC compared to ATV+RTV+TDF/FTC FDC.  
Objectives
Primary  Objective
To demonstrate the no n-inferior antiviral activity  of DTG/ABC/3TC FDC once dail y 
compared to ATV+RTV+TDF/FTC FDC each administered once dail y over 48 
weeks in HIV -1 infected ART -naïve women.
Secondary  Objectives
To evaluate the antiviral and immunological activity  and incidenc e of disease 
progression (HIV -associated conditions, acquired immunodeficiency  syndrome 
[AIDS] and death) of DTG/ABC/3TC FDC once daily  compared to 
ATV+RTV+TDF/FTC FDC once dail y over time;
To compare the safety , tolerability , and laboratory  parameters of DTG /ABC/3TC
FDC once daily  to ATV+RTV+TDF/FTC FDC once dail y over time;
To assess the development of viral resistance in subjects who meet confirmed 
virologic withdrawal criteria ;
To evaluate renal markers (in urine and blood), and bone markers (in blood) in 
subjects treated with DTG /ABC/3TC FDC compared to ATV+RTV+TDF/FTC FDC;
2013N161649_03 CON FIDENTIA L
ING117172
14To assess treatment satisfaction, and change in health- related qualit y-of- life for 
subjects treated with DTG /ABC/3TC FDC compared to ATV+RTV+TDF/FTC FDC;
To evaluate the effect of patient characteristics (i.e., demographic factors, HIV-1 
subty pe, Baseline CD4) on response to DTG/ABC/3TC FDC compared to 
ATV+RTV+TDF/FTC FDC over time.
Stud y Design
This study  is a Phase IIIb  randomized, open -label, active -controlled, multicenter, paralle l 
group, non -inferiority  study .  The study will be conducted in approximately 474 HIV -1 
infected ART -naïve women. Subjects will be randomized 1:1 to receive a FDC of DTG 
50mg/ ABC 600mg/ 3TC 300mg once dail y or ATV 300mg plus RTV 100mg and TDF 
300mg/ FTC 2 00mg FDC each administered once daily . Randomization will be stratified 
by [CONTACT_339250] -1 RNA ( 100,000 copi[INVESTIGATOR_014]/mL  [c/mL ] or >100,000 c/mL ) and 
CD4+ cell count ( 350cells/mm3or >350 cells/mm3).  The study  will comprise a 
Screening Phase (approxima tely 14-28 day s), a Randomized Phase (48 weeks), and a 
Continuation Phase. The primary  anal ysis will take place after the last subject completes 
48 weeks of therap y. No dose reductions, modifications in dosage, or changes in the 
frequency  of dosing of any  components of each regimen will be allowed in this study .  
Subjects randomized to receive DTG/ABC/3TC FDC who successfull y complete 
48weeks of treatment will continue to have access to DTG/ABC/3TC FDC 
(Continuation Phase) until it is either locally  appro ved and commerciall y available, the 
patient no longer derives clinical benefit, the patient meets a protocol -defined reason for 
discontinuation, or development of DTG/ABC/3TC FDC is terminated.  Subjects 
randomized to the ATV+RTV +TDF/FTC arm will receive A TV+RTV+TDF/FTC FDC 
through their Week [ADDRESS_1255672] to access antiretroviral medication. 
Stud y Endpoints/Assessments
The primary  endpoint for this study  will b e the proportion of subjects with plasma HIV-1 
RNA <50 c/mL at Week 48 using the Snapshot algorithm (Missing, Switch or 
Discontinuation = Failure) for the intent -to-treat exposed (I TT-E) population.
Secondary  efficacy  endpoints will include: the proportion of subjects with plasma HIV -1 
RNA <50 c/mL and <400 c/mL  over time; absolute values and change from Baseline in 
plasma HIV -1 RNA over time; absolute values and changes from Baseline in CD4+ cell 
counts over time, and incidence of disease progression (HIV -associated conditions, AI DS 
and death).
Safety  endpoints will include: i ncidence and severity  of adverse events (AEs) and 
laboratory  abnormalities; the proportion of subjects who discontinue treatment due to 
AEs; absolute values and changes over time in la boratory  parameters; change from 
Baseline in fasting lipi[INVESTIGATOR_442093]; changes from Baseline in renal and bone markers. 
2013N161649_03 CON FIDENTIA L
ING117172
15Heath outcomes endpoints will include: Change from Baseline in health related quality  of 
life using SF -12 at Week 48, and treatment s atisfaction (using the HIV Treatment 
Satisfaction Questionnaire) for subjects treated with DTG/ABC/3TC FDC and those 
treated with ATV+RTV+ TDF/FTC FDC at weeks 4, 12, 24, and 48 (or withdrawal from 
the study ).
Virology  endpoints will include the incidence o f treatment emergent genot ypic and 
phenoty pic resistance in subjects who meet confirmed virologic withdrawal criteria .
2013N161649_03 CON FIDENTIA L
ING117172
161. INTRODUCTION
1.1. Background
Integrase inhibitors (INIs) are a relatively  new class of antiretroviral drugs designed to 
block the action of th e integrase viral enzy me, which catal yzes several key  steps in the 
human immunodeficiency virus t ype 1 (HIV -1) life cy cle and is responsible for insertion 
of the viral genome into the DNA of the host cell. Since integration is a vital step in 
retroviral re plication, it is an attractive target for HIV therap y.  The first HIV INI, 
raltegravir (RAL, [ Ise ntress Package Insert, 2013 ; Isentress , Summary  of Product 
Characteristics, 2013]), was a pproved by  [CONTACT_3133] (FDA) 
and European Medicines Agency  (EMA) in 2007.  Elvitegravir (ELV), another HIV INI, 
was approved b y the US FDA in 2012 as part of a single tablet regimen (STR) with 
cobicistat (COBI), tenofovir (TDF), and emtricitabine (FTC, [ Stribild Package Insert, 
2012]).  
While RAL  and ELV have shown potent antiviral activity  in treatment -naïve and 
treatment -experienced patients, there are limitations to both these medications.  Cl inical 
resistance to both RAL and EL V has been reported from Phase II studies in treatment -
experienced patients [ Hazuda , 2007; McColl , 2007] and from Phase III studies in both 
treatment -experienced [ Cooper , 2008; Molina J , 2012] and treatment -naïve subjects 
[Lennox , 2010; Sax , 2012; DeJesus , 2012].  I n addition, RAL  requires twice dail y (BID) 
dosing and is currently not available in a fixed dose combination (FDC) regimen. ELV 
requires co -administration with a pharmacokinetic (PK) booster, such as rit onavir (RTV) 
or COBI. Furthermore, ELV -containing regimens had higher rates of gastrointestinal (GI) 
adverse events (AEs) than a RAL -containing regimen and Atripla (a FDC of efavirenz 
[EFV]/TDF/FTC [ Atripla , April 2013]) in treatment -experienced and treatment -naïve 
patients, respectivel y [Molina J , 2012; Sax, 2012]; Stribild is also not recommended for 
patients with creatinine clearance (CrCL) under 70 mL/min.  Because of the cobicistat in 
Stribild, there are also numerous drug interactions due to inhibition of cy tochrome P450 
3A4. Therefore, development of new INIs with an improved safet y and resistance profile, 
and improved dosing administration is des irable.
Dolutegravir ( DTG ) is a next -generation INI with low -moderate inter- subject 
pharmacokinetic variability , a predictable exposure -response relationship and a 14- hour 
plasma half -life that supports once dail y dosing without the need for the PK booster s that 
are required with ELV (and therefore lacks the associated drug interactions, specificall y 
with oral contraceptives) .  
To date, the efficacy , pharmacokinetics, safet y and drug interaction potential of DTG 
have been evaluated in an extensive program of Phase I to III clinical trials. Data are 
summarized in the DTG Investigator Brochure (IB [GlaxoSmithKline Document Number
[[COMPANY_004] Document Number RM2007/[ZIP_CODE]/ 11,[COMPANY_004] Document Number
2017N352880_00, [COMPANY_004] Document Number 2017N352880_01]).  I n both antiretroviral 
therap y (ART) -naïve and ART -experienced (INI -naïve) patients, the safet y profile for 
DTG 50 mg once daily  was comparable to RAL and generall y favorable to Atripla and 
EFV (studies ING113086 [SPRI NG-2], ING114467 [SI NGLE] and ING111762 
2013N161649_03 CON FIDENTIA L
ING117172
17[SAILING]). The most frequently observed AEs across patient populations were 
diarrhea, nausea, and headache, which were generally  Grade 1 or 2 in severity , and 
typi[INVESTIGATOR_1306] y did not lead t o discontinuation from studies.  With regards to antiviral efficacy , 
in treatment -naïve HIV -infected adult subjects, DTG 50 mg once dail y was shown to be 
an efficacious dose, and non-inferior to RAL in combination with a background regimen 
with dual n ucleo side reverse transcriptase inhibitor (NRTI) [SPRI NG-2]. When used in 
combination with abacavir/lamivudine (ABC/3TC, EPZICOM/KIVEXA™), DTG was 
shown to be superior to EFV/TDF/FTC, a result driven by  [CONTACT_895644] [SINGLE].   Phase III studies have also demonstrated excellent antiviral 
activity  of DTG in INI -naïve treatment experienced patients, and in patients with I NI 
resistance in studies ING111762 [SAILING] and ING112574 [VIKING -3], respectivel y.  
Furthermore, DTG [ADDRESS_1255673] a higher barrier to resistance in INI -naive 
patients, as suggested in the treatment -experienced (INI -naive) SAILING study  where 
significantl y fewer virologic failures and significantly  fewer subjects with INI resistance 
were observed when co mpared with RAL. Data from two further Phase III studies 
[SPRI NG-2 and SINGLE] in treatment -naive subjects are also supportive of a high 
barrier to resistance. 
HIV continues to be the leading cause of death and disease among women of 
reproductive age worldwide, particularl y among women of ethnic/racial minorities.  
While women comprise approximately  50% of patients infected with HIV globall y, the 
number of women in most HI V clinical trials remains low, and recruiting and retaining 
women into antiretroviral clinical studies remains a challenge.  The reasons are multiple, 
but may  reflect differences in lifesty le, care commitments, behavior and socioeconomics 
between women and men infected with HIV.  Additionally , comparator regimens in many  
studies do not inc lude commonly  recommended regimens for women of child bearing 
potential, so pregnancy  avoidance strategies are stringent.  
In Phase IIIa studies of DTG in treatment naïve subjects, women comprised 15% and 
16% respectively  of the randomized populations in the SPRING -2 and SINGL E studies, 
for a total of 130 women randomized to DTG.  In the SPRI NG-2 study , DTG was non-
inferior to RAL overall and similar efficacy was observed across gender.  In the SI NGLE 
study , DTG+ABC/3TC FDC demonstrated superior efficacy  to EFV/TDF/FTC, and the 
treatment differences b y gender were consistent with the overall treatment difference.  
The GRACE study  is the only  prospective clinical study  with published data to date 
powered to assess gender differences in efficacy  and safet y [Currier 2010].  I n this study  
of darunavir and RTV (DRV+RTV) in combination with optimized background therap y 
in ART -experienced subjects, the virologic response rate was lower in women than in 
men, and women had significantly  higher rates of discontinuation (33%) compared to 
men (23%).  Nausea and vomiting was also more common in women.  Other non -
powered studies have seen increased rates of discontinuation and AEs in women 
compared to men (e.g., the CASTL E study  [Molina , 2008]).
Evaluation of the safet y, tolerability  and efficacy  of antiretroviral agents in women is 
important to appropriately  inform clinicians and patients about their therapy .  Women 
may metabolize and respond to antire troviral agents differentl y than men; women may  
have higher drug exposure, be at greater risk for some adverse events (i.e., lactic acidosis, 
2013N161649_03 CON FIDENTIA L
ING117172
18hepatotoxicity /rash, and osteoporosis), and have a higher potential for drug interactions 
(i.e., oral hormonal con traceptives/or estrogen).
FDCs and STRs have greatly  simplified the treatment of patients with HIV, and may  be 
of greater importance in patients with lifesty les or care commitments that may  impair 
adherence to dosing schedules, including some women and tho se in underserved 
populations.  In a stud y by [CONTACT_895645]. al. [ Paterson, 1999], a linear relationship between 
levels of adherence and viral load suppression was observed. Adherence to therap y is 
essential to achieve viral suppression and prevent emergence of resistance mutations. 
Among regimens of comparable efficacy , phy sicians and HIV- [ADDRESS_1255674] significant challenge. 
DTG/ABC/3TC FDC is bein g developed to address the needs for a FDC with an I NI and 
ABC/3TC.
1.2. Rationale
The DTG/ABC/3TC FDC may  provide a better treatment option for women infected with 
HIV-[ADDRESS_1255675] data on safety  and efficacy  in this population.  
Study  ING117172 is a Phase IIIb trial designed to demonstrate the non-inferior antiviral 
activity  of DTG/ABC/3TC FDC once dail y to atazanavir plus ritonavir ( ATV+RTV) and 
TDF/FTC FDC all administered once daily  in HIV -1 infected, ART-naïve women over 
48 weeks.  This study  will also characterize the safety  and tolerability  of DTG/ABC/3TC 
FDC compared to ATV +RTV+TDF/FTC FDC.  
The rationale for selection of the active comparator, ATV+RTV with TDF+FTC, is 
provided in the Section 3.2.
1.2.1. Principle of Dose Selection
Dose selection was determined in I NG112276 (SPRI NG-1). This was a dose -ranging 
Phase IIb stud y to evaluate the long- term antiviral activity  and safet y of DTG at doses of 
10, 25, and [ADDRESS_1255676] in to further evaluation in INI-naive 
subjects. If comparable efficacy , safety  and tolerability  were observed across all three 
DTG doses, the 50 mg dose would be selected for furt her investigation in Phase III.  
2013N161649_03 CON FIDENTIA L
ING117172
19Based on comparison of virological markers of HIV infection in the SPRI NG-1 study , the
proportion of subjects who achieved the primary endpoint (HIV -1 RNA <50 copi[INVESTIGATOR_014]/mL  
[c/mL ], by [CONTACT_895646] [TLOVR] algorithm) b y Week 16 was 
consistently high across the DTG dose arm s (≥90%) with a low rate of confirmed 
virologic failure.  As summarized in the DTG IB, this activity  has been maintained in all 
three dosing arms through Week 96 [[COMPANY_004] Document Number RM2007/[ZIP_CODE]/ 11, [COMPANY_004] 
Document Number 2017N352880_00, [COMPANY_004] Document Number 2017N352880_01].  
DTG was well tolerated across all doses studied. A good safet y and tolerability profile 
with a low discontinuation rate due to AEs was observed in all three dose arms with no 
significant dose -dependent trends in safet y parameters. Hence, the DTG [ADDRESS_1255677] of Potential Drug -Drug Interaction
Due to a different route of elimination, no drug interaction is expected between DTG and 
ABC/3TC.  DTG is metabolized through UGT1A1.  3TC is primarily  eliminated b y renal 
mechanisms with the ma jority  of drug eliminated unchanged in the urine.  ABC is 
metabolized by  [CONTACT_895647] 2% 
excreted in the urine as unchanged parent.  ABC does not have inhibitory  activity  on 
UGT pathway s and is metabolized pri marily  through UGT2B7.  Onl y 25-36% of ABC is 
glucuronidated, indicating it is not a substrate sensitive route.  Furthermore, UGT is a 
high capacit y enz yme system and the fraction metabolized by [CONTACT_895648] 50%.  Finall y, no differences in DTG PK were 
observed for subjects receiving TDF/FTC versus ABC/3TC in SPRI NG-1 (ING112276).
For further information refer to the most current version of the IB for DTG [[COMPANY_004] 
Document Number RM2007/[ZIP_CODE]/ 11,[COMPANY_004] Document Number 2017N352880_00, [COMPANY_004] 
Document Number 2017N352880_01] .  Relevant data on use of calcium and iron 
supplements with DTG are provided below.
[IP_ADDRESS]. Use of calcium and iron supplements with dolutegravir
Study ING116898 was a Phase I, open label, randomized, four -period crossover study  to 
evaluate the effects of calcium carbonate (CC) 1200 mg and ferrous fumarate (FF) 
325mg on PK of DTG 50 mg in health y adult subjects. 
Study Design : 12 subjects were enrolled into one of the two cohorts and received each of 
four treatments in a randomized fashion: 1) A single dose of DTG 50 mg administered 
under fasted conditions; 2) A single dose of DTG 50 mg co -administered with a single 
dose of C C 1200 mg or FF 324 mg under fasted conditions; 3) A single dose of DTG 
50mg co -administered with a single dose of CC or FF with a moderate- fat meal; 4) A 
single dose of DTG [ADDRESS_1255678] 
2013N161649_03 CON FIDENTIA L
ING117172
207days between treatments. Serial PK samples were collected during each treatment 
period for the measurement of plasma DTG concentrations.
Results : Under fasted conditions, co -administration of CC reduced DTG exposure by  37-
39% and FF reduced DTG exposure by  54-57%; food (a moderate fat meal) and [ADDRESS_1255679] of calcium carbonate on DTG 
exposure. 
Table 1 Statistical Comparison of Plasma DTG Pharmacokinetic Parameters 
(Calcium Carbonate Cohort)
Comparison Ratio of GLS Means (90% CI)
DTG + CC vs DTG 
Alone (fasted)DTG + CC (fed) vs 
DTG Alone (fasted)DTG 2hr prior to 
CC vs DTG Alone 
(fasted)DTG + CC (fed) vs 
DTG+ CC (fasted)
AUC(0 -t) 0.61 (0.48, 0.79) 1.10 (0.84, 1.43) 0.95 (0.73, 1.24) 1.79 (1.37, 2.33)
AUC(0 - ) 0.61 (0.47, 0.79) 1.09 (0.84, 1.43) 0.94 (0.72, 1.23) 1.78 (1.36, 2.33)
Cmax 0.63 (0.50, 0.81) 1.07 (0.83, 1.38) 1.00 (0.78, 1.29) 1.70 (1.32, 2.18)
C24 0.61 (0.47, 0.80) 1.08 (0.81, 1.42) 0.90 (0.68, 1.19) 1.76 (1.33, 2.33)
CI = confidence int erval
Table 2 Statistical Comparison of Plasma DTG Pharmacokinetic Parameters 
(Ferrous Fumarate Cohort)
Comparison Ratio of GLS Means (90% CI)
DTG + FF vs DTG 
Alone (fasted)DTG + FF (fed) vs 
DTG Alone (fasted)DTG 2hr prior t o FF 
vs DTG Alone 
(fasted)DTG + FF (fed) vs 
DTG+ FF (fasted)
AUC(0 -t) 0.45 (0.37, 0.54) 0.98 (0.81, 1.19) 0.94 (0.78, 1.14) 2.18 (1.80, 2.64)
AUC(0 - ) 0.46 (0.38, 0.56) 0.97 (0.80, 1.19) 0.95 (0.78, 1.15) 2.12 (1.75, 2.58)
Cmax 0.43 (0.35, 0.52) 1.03 (0.85, 1.26) 0.99 (0.81, 1.21) 2.40 (1.97, 2.94)
C24 0.44 (0.36, 0.54) 0.99 (0.80, 1.22) 0.92 (0.74, 1.13) 2.25 (1.83, 2.77)
Conclusions: DTG can be given concurrentl y with calcium or iron supplements with 
food; without food, DTG should be given 2 hours prior to or 6 hours after calcium or iron 
supplements. 
1.3. Benefit:Risk A ssessment
Summaries of findings from both clinical and non-clinical studi es conducted with DTG 
can be found in the most current version of the DTG IB.  The following section outlines 
the risk assessment and mitigation strategy  primarily  for DTG in the DTG/ABC/3TC 
FDC in this protocol.  For ABC, 3TC, ATV, RTV and TDF/FTC, the ap proved country  
product labels should be referenced.  T he comparator regimen, ATV+RTV + TDF/FTC 
FDC, is a preferred/recommended treatment regimen for HIV -infected ART naive 
subjects according to current guidelines [ DHHS ,2013; EACS , 2012].
2013N161649_03 CON FIDENTIA L
ING117172
211.3.1. Risk A ssessment
There are no shared metabolism pathway s between the components of DTG/ABC/3TC, 
and no common target organs were identified in respective pre -clinical studies.  As such, 
there is no pharmacologic data that would predict increased safety  risk for the 
DTG/ABC/3TC formulation bey ond that identified for the individual active moieties 
DTG, ABC and 3TC.  Early  in clinical development, no drug -drug interaction between 
DTG and ABC/3TC was appar ent given the safety and efficacy  profile observed in the 
Phase IIb stud y ING112276 [SPRI NG-1] in which 67 subjects received DTG in 
combination with ABC/3TC for up to 96 weeks.  Clinical safety  data from the subjects 
treated with DTG + ABC/3TC in the pi[INVESTIGATOR_895623]114467 [SI NGLE] and supporting study  
ING113086 were consistent with the safet y profile of the individual active moieties.
All medications have AE profiles that must be assessed prior to use, allowing for an 
appropriate risk/benefit assessment.  Consi derations when using DTG/ABC/3TC are as 
follows:
2013N161649_03 CONFIDENTIA L
ING117172
22Potential Risk 
of Clinical 
SignificanceData/Rationale for Risk Mitigation Strategy1
Investigational Product (IP) [DTG/ABC/3TC] 
Refer to IB for additional information on DTG and DTG/ABC/3TC
Refer to approved country product label for additional information on ABC/3TC
Hypersensitivity 
(including abacavir 
hypersensitivity 
reaction [ABC 
HSR]) and rashA well characterised, idiosyncratic, drug -related HSR is the most important risk 
associated with ABC (Section [IP_ADDRESS] ).  Exclusion of individuals found to carry 
the Human Leukocyte Antigen (HLA) -B*5701 allele from ABC therapy reduces 
the risk of HSR.  Rash, including Stevens- Johnson Syndrome (SJS), Toxic 
Epi[INVESTIGATOR_13084] (TEN) and Erythema Multiforme have been reported in 
patients taking ABC (See Section [IP_ADDRESS] and Section [IP_ADDRESS] ).  
HSR has been observed uncommonly with D TG.  Rash was commonly reported 
in DTG Phase IIb/III clinical trials; epi[INVESTIGATOR_691701]; no epi[INVESTIGATOR_473385], such as SJS, TEN and Erythema 
Multiforme were reported.  Data on HSR for DTG and DTG+ABC/3TC FDC 
sugges t that there will not be additional risk from HSR in HLA -B*5701 negative 
subjects receiving the DTG/ABC/3TC FDCSubjects positive for HLA -B*5701 are excluded from participating.  
Additionally, subjects with history of allergy/sensitivity to any of the stud y 
drugs are excluded (Section 4.3).
Specific/detailed toxicity management guidance is provided for suspected 
HSR with DTG (Section [IP_ADDRESS] ) or ABC (Section [IP_ADDRESS] ), and skin 
reactions without systemic involvement (Section [IP_ADDRESS] ).
The subject informed consent form includes information on this risk and 
the actions subjects should take in the event of a HSR or associated signs 
and symptoms.  Subjects are to be reminded to read the ABC HSR 
Warning Card accompanying their study medication and of the importance 
of keepi[INVESTIGATOR_895624].
Drug induced liver 
injury ( DILI) and 
other clinically 
significant liver 
chemistry elevationsNon-clinical data suggested a possible, albeit low, risk for hepatobiliary toxicity 
with DTG.  Drug -related hepatitis is considered an uncommon risk for ART 
containing DTG regardless of dose or treatment population.  For subjects with 
hepatitis B virus (HBV) and/or hepatitis C virus (HCV) co -infection, improvements 
in immunosuppression as a result of HIV virologic and immunologic responses to 
DTG -containing ART, along with inadequate therapy for HBV co -infected 
subjects, likely contributed to significant elevations in liver chemistries. 
Current treatment guidelines [ DHHS , 2013; EACS 2012] do not recommend 
monotheraphy with 3TC for patients with HBV infection, which is what subjects 
randomized to DTG/ABC/3TC would effectively be receiving.  Additionally, 
discontinuation of 3TC in HBV coinfected subjects can result in severe 
exacerbations of HBV. Subjects meeting either of the following criteria during the screening period 
are excluded from participating (Section 4.3).
Alanine aminotransferase (ALT) 5 times the upper limit of normal 
(ULN) or ALT 3xULN and bilirubin 1.5xULN ( with >35 % direct 
bilirubin)
Subjects positive for HBV at screening (hepatitis B virus surface 
antigen positive [+HBsAg]), or with an anticipated need for HCV 
therapy during the study
Specific/detailed liver stoppi[INVESTIGATOR_895625] e 
is provided for suspected DILI or other clinically significant liver chemistry 
elevations (Section [IP_ADDRESS] ).  
2013N161649_03 CONFIDENTIA L
ING117172
23Potential Risk 
of Clinical 
SignificanceData/Rationale for Risk Mitigation Strategy1
Theoretical serious 
drug interaction with 
dofetilideCo-administration of DTG may increase dofeti lide plasma concentration via 
inhibition of OCT2 transporter, resulting in potentially life -threatening toxicity. The co -administration of DTG with dofetilide is prohibited in the study 
(Section 5.6.2 ).
GI int olerance Non-clinical studies showed upper and lower GI toxicity, including vomiting, 
diarrhea and gastric erosions observed in monkey toxicology studies (thought to 
be related to local and not systemic toxicity).  
Mild to moderate GI intolerance (mainly diarrhea and nausea) is associated with 
DTG treatment in a small proportion of subjects; however there were no 
indications of an increased risk for peptic ulcers or serious erosions.Routine monitoring of GI symptoms will be performed.
Renal function Mild elevations of creatinine have been observed with DTG which are related to 
a likely benign effect on creatinine secretion with blockade of OCT -[ADDRESS_1255680] on glomerular filtration rate 
(GFR) or effective r enal plasma flow. Measurement of albumin/creatinine ratio 
confirmed there was no difference in the effect of DTG on albumin excretion 
compared with EFV or RAL. 3TC is eliminated by [CONTACT_503374]. Due to requirements for dose reduction of 3TC in patients with renal 
dysfunction, subjects with a CrCL <50 mL/min are excluded (Section 4.3).
Specific/detailed toxicity management guidance is provided for subje cts 
who develop a decline in renal function (including proximal renal tubule 
dysfunction; Section [IP_ADDRESS] ) and/or proteinuria (Section [IP_ADDRESS] ).  
Psychiatric 
disor dersPsychiatric disorders including suicide ideation and behaviors are common in 
HIV infected patients. The psychiatric profile for DTG (including suicidality, 
depression, bipolar and hypomania, anxiety and abnormal dreams) was similar 
or favorable compar ed with other ART. 
The reporting rate for insomnia was statistically higher for blinded 
DTG+ABC/3TC compared to EFV/TDF/FTC  in ING114467; however, this was 
not duplicated in any other Phase IIb/III study conducted with DTG.  Subjects who in the investig ator’s judgment, poses a significant suicidality 
risk, are excluded from participating (Section 4.3).
Because of the elevated risk in the HIV -infected population, treatment 
emergent assessment of suicidality wi ll be monitored during this study.  
Investigators are advised to consider mental health consultation or referral 
for subjects who experience signs of suicidal ideation or behavior (Section 
6.4.10 ).
Creatine 
Phosphokinase 
(CPK)  elevationsAsymptomatic CPK elevations mainly in association with exercise have been 
reported with DTG therapy.  .Specific detailed toxicity management guidance is provided for subjects 
who develop Grade 3 to 4 CPK elevations (Section [IP_ADDRESS] ).
2013N161649_03 CONFIDENTIA L
ING117172
24Potential Risk 
of Clinical 
SignificanceData/Rationale for Risk Mitigation Strategy1
Increased 
occurrence of 
Immune 
reconstitution 
inflammatory 
syndrome (IRIS)With rapid HIV -1 RNA decline and early recovery of CD4+ cell counts there 
could theoretically, be an increase in cases of IRIS.
The increased risk for HBV and HCV IRIS with DTG -containing ART is 
addressed above; there was a low rate of other medical conditions frequently 
implicated in IRIS cases.  Subjects positive for HBsAb at screening or with active HCV illness 
(anticipated to require therapy) are excluded from participating. Subjects 
will have routine laboratory monitoring 
Use in pregnancy The safe use of DTG in human pregnancy has not been established.  DTG has 
been shown to cross the placenta in reproductive toxicity stu dies in animals.  
DTG has not been associated with findings in animal reproductive studies. Women who are pregnant will be excluded from the study (Section 4.3).
Females of childbearing potential are required t o have a negative 
pregnancy test at both Screening and Day [ADDRESS_1255681] pregnancy tests 
performed at all scheduled clinic visits.  Pregnant women will be withdrawn 
from this study and their pregnancy followed to determine outcome 
(including premature termination) and status of mother and child.  
DTG: Neural tube 
defectsIn one ongoing birth outcome surveillance study in Botswana, early results from 
an unplanned interim analysis show that 4/426 (0.9%) of women who were 
taking DTG when they became pregnant had babies with neural tube defects 
compared to a background rat e of 0.1%.1.A female subject is eligible to participate if she is not pregnant , not 
lactating, and, if she is a f emale of r eproductive potential, agrees to 
follow one of the options listed in the Modified List of Highly Effective 
Methods for Avoiding Pregnancy in Females of Reproductive Potential 
(FRP) (see Appendix 6, Sect ion11.6), until at least 2 weeks after 
discontinuation of IP
2.Women who are breastfeeding or plan to become pregnant or 
breastfeed during the study are excluded;
3.Women who become pregnant, or who desire to be pregnant while in 
the study , or who state they no longer are willing to comply with the 
approved pregnancy avoidance methods, will have study treatment 
discontinued and withdrawn from the study.
4.Females of reproductive potential are reminded re: pregnancy 
avoidance and adherence to contraception requirements at every 
study visit.
5.Pregnancy status is monitored at every study visit
2013N161649_03 CONFIDENTIA L
ING117172
251.Careful monitoring of events will be co nducted using serious adverse event (SAE) reports and alerts for Grade 3/4 laboratory toxicities (per Division of Acquired Im munodeficiency 
Syndrome [DAIDS] toxicity gradings for HIV infected patients). Serious/severe events will be managed appropriately i ncluding, but not limited to, withdrawal of investigational 
product (IP), and will be followed to resolution as per Sponsor’s standard Medical Monitoring practices  Clinical Safety Data will be routinely reviewed in GlaxoSmithKline ([COMPANY_004]) 
Safety Review Team meetings. This will include in -stream review of data from this clinical trial on approximately a  monthly basis (switching to approximately quarterly review s upon 
reaching the primary endpoint); review of aggregate data on a protocol and program basis whe n available; and review of competitor data from the literature
2013N161649_03 CONFIDENTIA L
ING117172
261.3.2. Benefit A ssessment
The DTG/ABC/3TC FDC provides a convenient once dail y STR, without need for a PK 
booster or food/fluid restrictions, and with limited safet y implications resulting from 
theoretical or actual drug: drug interactions compared to other antiretroviral agents 
(including EFV and those requiring a PK booster).  
A regimen comprised of DTG administered with ABC/3TC has been shown to be highl y 
efficacious and well tolerated in treatm ent-naive subjects.  In the Phase 3 double -blind 
SINGLE study  (ING114467), 833 therap y-naive adults were randomized to DTG 50 mg 
plus ABC/3TC once daily  or a guidelines-preferred STR of EFV/TDF/FTC once dail y.  
At Week 48, the proportion of subjects with H IV-1 RNA <50 c/mL in the 
DTG+ABC/3TC arm (88%) was superior to the EFV/TDF/FTC arm (81%), P=0.003.  
Time to viral suppression (median 28 vs. 84 day s; P<0.001) and increases in CD4 cell 
counts ([PHONE_18586] vs. [PHONE_18587] cells/mm3; P<0.001) also favored DTG+ABC/3TC. No 
subjects on DTG+ABC/3TC had detectable antiviral resistance; 1 TDF -associated and 4 
EFV -associated mutations were detected in EFV/TDF/FTC subjects with viral failure.  In 
a by [CONTACT_895649], Week 48 responses in women (85%) were higher in recipi[INVESTIGATOR_895626] + ABC/3TC when compared to EFV/TDF/FTC (75%). The overall proportion of 
subjects discontinuing for adverse events was lower with DTG+ABC/3TC (2%) than 
EFV/TDF/FTC (10%); rash and neurops ychiatric events (including abnormal dreams, 
anxiety , dizziness , and somnolence) were significantly  more common on EFV/TDF/FTC, 
whereas insomnia was reported more frequentl y on DTG+ABC/3TC.  
Study  participants may  also benefit from the medical tests and screening procedures 
performed as part of the study .
1.3.3. Overall Ben efit:Risk Conclusion
Taking into account the measures taken to minimize risk to subjects participating in this 
study , the potential risks identified in association with the DTG/ABC/3TC FDC are 
justified by  [CONTACT_895650] w omen with HIV infection.
2. OBJECTIVES
Primary  Objective
To demonstrate the non -inferior antiviral activity  of DTG/ABC/3TC FDC once dail y
compared to ATV+RTV+TDF/FTC FDC each administered once dail y over 48 
weeks in HIV -1 infected ART naïve women.
Secondary  Objectives
To evaluate the antiviral and immunological activity  and incidence of disease 
progression (HIV -associated conditions, AIDS and death) of DTG/ABC/3TC FDC 
once dail y compared to ATV+RTV+TDF/FTC FDC once dail y over time;
2013N161649_03 CONFIDENTIA L
ING117172
27To compare the safety , toler ability , and laboratory  parameters of DTG /ABC/3TC
FDC once daily  to ATV+RTV+TDF/FTC FDC once dail y over time;
To assess the development of viral resistance in subjects who meet confirmed 
virologic withdrawal criteria ;
To evaluate renal markers (in urine an d blood), and bone markers (in blood) in 
subjects treated with DTG /ABC/3TC FDC compared to ATV+RTV+TDF/FTC FDC;
To assess treatment satisfaction, and change in health- related qualit y-of- life for 
subjects treated with DTG /ABC/3TC FDC compared to ATV+RTV+TDF /FTC FDC;
To evaluate the effect of patient characteristics (i.e., demographic factors, HIV -1 
subty pe, Baseline CD4) on response to DTG/ABC/3TC FDC compared to 
ATV+RTV+TDF/FTC FDC over time.
3. INVESTIGA TIONAL PLA N
3.1. Stud y Design
This study  is a 48 week Phase I IIb randomized, open- label, active -controlled, 
multicenter, parallel group, non- inferiorit y study. The study will be conducted in 
approximately  474 HIV -1 infected ART -naïve women. Subjects will be randomized 1:1 
to receive a DTG/ABC/3TC FDC 50mg/600mg/300m g once dail y or ATV 
(300mg) +RTV (100mg) +TDF/FTC FDC (300mg/200mg) all administered once dail y.  
The primary  anal ysis will take place after the last subject completes 48 weeks on therap y. 
No dose reductions, modifications in dosage, or changes in the freq uency  of dosing will 
be allowed in this study .
The study  design is summarized in Figure 1and comprises the following Phases:
Screening Period
Randomization may  occur as soon as all Screening procedures have been c ompleted and 
results are available and on file. The 14- day screening period may  be extended to 28 day s 
to allow receipt of all Screening assessment results and to accommodate scheduling. 
Randomized Phase: Day 1 to Week 48
Subjects who fulfill eligibility  requirements will be randomized 1:1 to receive 
DTG/ABC/3TC FDC once dail y or ATV+RTV+TDF/FTC FDC each administered once 
daily .  In order to achieve balance across the two treatment groups of the study , 
randomization will be stratified by  [CONTACT_895651] H IV-1 RNA ( 100,000 c/mL  or 
>100,000 c/mL), and CD4+ cell count ( 350cells/mm3or >350 cells/mm3).  
During the Randomized Phase, s ubjects will attend the clinic at Baseline/Day  1 and at 
Weeks 4, 12, 24, 36 and 48 of treatment.  Additional contacts will be made at Weeks 8, 
18, 30 and 42 of treatment, primarily  to confirm subjects’ understanding of the study  
2013N161649_03 CONFIDENTIA L
ING117172
28procedures and management of the treatment regimen; these contacts may  be conducted 
via telephone, or as clinic or home visits (or other ty pe of visit a s agreed with [COMPANY_004]).
DTG/A BC/3TC FDC Continuation Phase
Subjects randomized to receive DTG/ABC/3TC FDC who successfull y complete [ADDRESS_1255682] access to DTG/ABC/3TC FDC (Continuation 
Phase) until it is either locally  approved a nd commerciall y available, the patient no longer 
derives clinical benefit, the patient meets a protocol-defined reason for discontinuation, 
or development of DTG/ABC/3TC FDC is terminated.  Subjects randomized to the 
ATV+RTV+ TDF/FTC arm will receive ATV+R TV+TDF/FTC FDC through their Week 
[ADDRESS_1255683] completed the study  ifthey satisfy  one of the following:
Randomized to ATV+RTV+TDF/FTC FDC and completed the Randomized Phase 
including the Week 48 Study  Visit;
Randomized to DTG/ABC/3TC FDC, completed the Randomized Phase including the 
Week 48 Visit, and did not enter the Con tinuation Phase;
Randomized to DTG/ABC/3TC FDC, completed the Randomized Phase, including 
the Week 48 study  visit, entered and completed the Continuation Phase (defined as 
remaining on stud y until commercial supplies of DTG/ABC/3TC become locally 
available or development of DTG/ABC/3TC is terminated).
Follo w Up
Subjects with ongoing AEs or laboratory  abnormalities will attend a Follow -up visit 
approximately  four weeks after their last dose of investigational product (DTG /ABC/3TC 
FDC or ATV+RTV+TDF/FTC FDC). Assessments at the Follow -up visit should reflect 
any ongoing complaints (e.g., blood draws to follow a laboratory  abnormality ). The 
Follow -Up visit is not required for successful completion of the study .
2013N161649_03 CONFIDENTIA L
ING117172
29Figure [ADDRESS_1255684] information not mandated to be present in this protocol is 
provided in the accompany ing Study  Procedures Manual (SPM). The SPM will provide 
the site personnel with administrative and detailed technical information that does not 
impact subject safet y.
3.2. Discussion of Design
The design of this study  (1:1 randomized, active -controlled, multicenter, parallel group) 
is well established for confirming the non -inferiority  of an investigational agent 
compared to an active comparator and is generally accepted b y regulatory  authorities as 
rigorous proof of antiviral activity  [CDER , 2002].
The primary  endpoint, proportion of subjects at Week 48 with plasma HIV -1 RNA below 
the assay  lower limit of detection (LLOD, i.e., <50 c/mL ), is also a well- established 
surrogate endpoint for prognosis of HIV -1 infection and disease progression. 
Boosted protease inhibitors such as ATV+RTV are commonly  used in women.  The use 
of ATV+RTV as the active comparator in therap y-naïve women is justified based on its 
indication as an appropriate agent as first line therapy  in treatment -naïve HIV -1 infected 
adults, with specific data in HIV infected pregnant women [ ReyatazPackage Insert, 
2013] .  ATV+RTV is recommended as a preferred first -line regimen in the treatment 
guidelines for women [ DHHS , 2013; EACS , 2012; I nternational AIDS Society  (IAS), 
2010].  With other ART ag ents, there are concerns with regard to teratogenicity  (e.g., 
efavirenz), drug -drug interactions with oral contraceptives (e.g., Stribild), or efficacy  in 
patients with a viral load greater than 100,000 c/mL (e.g. Complera, a single tablet 
regimen of rilpi [INVESTIGATOR_12979], TDF and FTC [ Complera Package Insert, 2013]. Boosted PI s 
2013N161649_03 CONFIDENTIA L
ING117172
30possess a high genetic barrier to resistance, thus are commonly  used in subjects at higher 
risk of virologic failure (e.g. patients with lifesty les or car e commitments possibly  
impairing adherence to dosing schedules).
The open- label design best suits the objectives of this study, and is consistent with other 
pi[INVESTIGATOR_895627].  Blinding of the protease inhibitor component (particularly  RTV, with its 
trademark embossed on the marketed tablet) is a substantial logistical hurdle.  ATV -
associated h yperbilirubinemia could also lead to unblinding of treatment arms. Moreover, 
in a doubl e-dummy  design, [ADDRESS_1255685] line HIV -1 ART according to 
global treatment guidelines, and both TDF/FTC and ABC/3TC are indicated for use in 
first line therap y globall y.
Given the open -label design, study  population and endpoints in this study , an 
Independent Data Monitoring Committee (IDMC) will not be implement ed. The safet y 
of DTG has been assessed in blinded studies during the Phase III program in which an 
IDMC was utilized and no issues were highlighted necessitating review of this study  by 
[CONTACT_41774] .
4. SUBJECT SELECTION A ND WITHDRA WAL CRITERI A
4.1. Number of Subjects
Sufficient subjects will be screened in order to ensure a total of approximately  474 
subjects will be randomized, approximately  237 to each study  arm. Subjects will be 
enrolled from multiple geographic regions. 
Subjects
Screened ~675
Randomized ~474
Completed/Evaluable ~[ADDRESS_1255686] labels, and/or local 
prescribing information .
2013N161649_03 CONFIDENTIA L
ING117172
31Deviations from inclusion criteria are not allowed because they  can potentially  jeopardize 
the scientific integrity of the study, regulatory acceptability or subject safety. Th erefore, 
adherence to the criteria as specified in the protocol is essential. 
Subjects are allowed to re -screen for this study  one time; this will require a new subject 
number. A single repeat test (re -test) per anal yte or assessment is allowed during the
Screening period to determine eligibility  (with the exception of a disqualified Screening 
genot ype which may  not be retested).
The following are stud y specific eligibility  criteria unless stated otherwise.  In addition 
to these criteria, Investigators mus t exercise clinical discretion regarding selection of 
appropriate study subjects, taking into consideration any local treatment practices 
or guidelines and good clinical practice (GCP).   
Eligible subjects must:
be able to understand and comply  with protoc ol requirements, instructions, and 
restrictions;
be likely  to complete the study  as planned;
be considered appropriate candidates for participation in an investigative clinical 
trial with oral medication (e.g. no active substance abuse, acute major organ, 
disease, or planned long term work assignments out of the country , etc.).  
Laboratory  results from the central laboratory  services provided by  [CONTACT_339249] .  If results from central laboratory  services (e.g., hematology / 
chemistry  results) will delay  screening bey ond the defined [ADDRESS_1255687] meet all of the following criteria:
1. HIV-1 infected females (gender at birth) ≥ 18 years of age;
2. A female, may  be eligible to enter and participate in the study  if she: 
a.is of non -child- bearing potential either defined as post -menopausal (12 months of 
spontaneous amenorrhea and ≥ 45 y ears o f age) or phy sicall y incapable of 
becoming pregnant with documented tubal ligation, hy sterectom y or bilateral 
oophorectom y or, 
b. is of child -bearing potential with a negative pregnancy  test at both Screening and 
Day 1 and agrees to use one of the following methods of contraception to avoid 
pregnancy :
Refer to Appendix 6, Section 11.6: Modified L ist of Highl y Effective 
Methods for Avoiding Pregnancy  in Females of Reproductive Potential. 
Any contraception method must be used consistently , in accordance with the approved 
product label and for at least 2 weeks after discontinuation of I P.  The investigator is 
responsible for ensuring that subjects understand how to properl y use these methods of 
contraception .
2013N161649_03 CONFIDENTIA L
ING117172
32All subjects participating in the study  should be counseled on safer sexual practices 
including the use of effective barrier methods (e.g. male condom/spermicide).
3. HIV -1 infection as documented by  [CONTACT_339250] -1 RNA ≥500 c/mL ;
4. Documentation that the subject is negative for the HLA- B*5701 allele;
5. Antiretroviral -naïve ( 10 day s of prior therapy  with any  antiretroviral agent following 
a diagnosis of HIV -1 infection);
6. Signed and dated written informed consent is obtained from the subject or the subject’s 
legal representative prior to screening;
7. Subjects enrolled in [LOCATION_009]: a subject will be eligible for inclusion in this study  only 
if either affilia ted to or a beneficiary of a social security  category .
4.3. Exclusion Criteria
Deviations from exclusion criteria are not allowed because they  can potentially  
jeopardize the scientific integrit y of the study, regulatory acceptability or subject safet y. 
Therefor e, adherence to the criteria as specified in the protocol is essential. 
A single repeat test (re -test) per anal yte is allowed during the Screening period (with the 
exception of a disqualify ing Screening genotype which may  not be retested).  
Subjects meet ing an y of the following criteria must not be enrolled in the study :
Exclusionary medical conditions
1.Women who are pregnant or breastfeeding;
2.Women who plan to become pregnant during the first [ADDRESS_1255688] who has had a medical inter vention for gender reassignment;
4.Any evidence of an active Centers for Disease Control and Prevention (CDC) 
Category  C disease ( Section 11.1).  Exceptions include cutaneous Kaposi’s sarcoma 
not requiring s ystemic therap y and historic CD4+ cell counts of <200 cells/mm3.
5.Subjects with any  degree of hepatic impairment; 
6. Subjects positive for hepatitis B (+HBsAg) at Screening, or anticipated need for 
HCV therapy during the study;
7.History  or presence of allergy  to the study  drugs or their components or drugs of 
their class;
8.Ongoing malignancy  other than cutaneous Kaposi's sarcoma, basal cell carcinoma, or 
resected, non -invasive cutaneous squamous cell carcinoma, or cervical intraepi[INVESTIGATOR_26507] ; other localized ma lignancies require agreement between the investigator 
and the Study  medical monitor for inclusion of the subject;
2013N161649_03 CONFIDENTIA L
ING117172
339. Subjects who in the investigator’s judgment, poses a significant suicidality  risk. 
Recent history  of suicidal behavior and/or suicidal ideatio n may  be considered as 
evidence of serious suicide risk;
10.History  of osteoporosis with fracture or requiring pharmacologic therapy  with 
bisphosphonates (e.g., alendronate, ibandronate, risedronate, zoledronic acid), 
antiresorptive medications (e.g., denosumab, strontium ranelate, teriparatide), and 
estrogen receptor modulators (e.g., raloxifene, tamoxifen). Use of calcium and 
vitamin D is permitted.
Exclusionary Treatments prior to Screening or Day 1
11.Treatment with an HIV -1 immunotherapeutic vaccine within 9 0 day s ofScreening;
12.Treatment with an y of the following agents within 28 days of Screening: radiation 
therap y; cytotoxic chemotherapeutic agents; an y immunomodulators that alter 
immune responses (a detailed list is provided in the SPM);
13.Treatment with an yagent, except recognized ART as allowed above (Section 4.2), 
with documented activity against HIV -[ADDRESS_1255689] dose of I P;
14.Exposure to an experimental drug or experimental vaccine within e ither [ADDRESS_1255690] dose of I P;
15.Subjects enrolled in [LOCATION_009]: the subject has participated in any  study  using an 
investigati onal drug during the previous [ADDRESS_1255691] will participate simultaneously  in 
another clini cal stud y.
Exclusionary Laboratory Values or Clinical Assessments at Screening
16.Any evidence of primary viral resistance based on the presence of any  major 
resistance -associated mutation [ IAS[LOCATION_003] , 201 3] in the Screening result or, if known, 
anyhistorical resistance test result. Note: retests of Screening genot ypes are not
allowed;
17.Any verified Grade 4 laboratory  abnormality , with the exception of Grade 4 lipid 
abnormalities (total cholesterol, trigl ycerides, High Density  Lipoprotein (HDL ) 
cholesterol, Low Density L ipoprotein (LDL) cholesterol). A single repeat test is 
allowed during the Screening period to verify  a result); 
18.Any acute laboratory  abnormality  at Screening, which, in the opi[INVESTIGATOR_684], would preclude the subjec t’sparticipation in the study  of an 
investigational compound;
19.Alanine aminotransferase (ALT) 5 times the upper limit of normal (ULN), or 
ALT3xULN andbilirubin ≥ 1.5xUL N (with >35% direct bilirubin);
20.Subject has CrCL  of <50 mL /min via Cockroft- Gault method;
21.Corrected QT interval (QTc (Bazett)) ≥450msec or QTc (Bazett) ≥480msec for 
subjects with bundle branch block
2013N161649_03 CONFIDENTIA L
ING117172
34The QTc is the QT interval corrected f or heart rate according to Bazett’s formula 
(QTcB).
Notwithstanding these minimum inclusion and exclusion criteria, Investigators must 
also follow country specific guidelines where they exist when making decisions about 
subjects who are eligible for stud y participation.
4.4. Other Eligibility  Criteria Considerations
To assess an y potential impact on subject eligibility  with regard to safet y, the Investigator 
must refer to the DTG IB and supplements, approved product labels, and/or local 
prescribing information for detailed information regarding warnings, precautions, 
contraindications, AEs, drug interactions, and other significant data pertaining to the IPs.
4.5. Withdrawal Criteria
Subjects permanently discontinuing study treatments prior to Week 48 are considered to 
be withdrawn from the study  treatments and also from the study . Similarly , subjects in 
the DTG/ABC/3TC FDC arm who enter the Continuation Phase but permanently  
discontinue participation in the Continuation Phase prior to commercially available 
DTG/ABC/3TC FDC, are considered to be withdrawn from the study  treatments and also 
from the study .
A subject may  voluntarily  discontinue participation in this study  at any  time. The 
Investigator may  also, at their discretion, discontinue the subject from participat ing in this 
study  at an y time. Withdrawn subjects will not be replaced.
Subjects may be prematurely discontinued from the study for any of the following 
reasons:
Subject or Investigator non -compliance;
At the request of the subject, Investigator, or Sponso r;
The subject requires concurrent prohibited medications during the course of the 
study . The subject may  remain in the study  if in the opi[INVESTIGATOR_895628], such medication will not interfere with the conduct or 
interpretati on of the study  or compromise the safety  of the subject.
Subjects must be discontinued from the study for any of the following reasons:
Virologic withdrawal criteria as specified in Section 4.5.1 are met.
Subjec t requires substitution or dose modification of DTG, ABC, 3TC, ATV, RTV 
TDF or FTC;
Liver toxicity  where stoppi[INVESTIGATOR_895629] [IP_ADDRESS] are met and no 
compelling alternate cause is identified;
2013N161649_03 CONFIDENTIA L
ING117172
35Grade 4 clinical AE considered causall y related to I P (See Section 6.4.3);
Renal toxicity  as specified in Section [IP_ADDRESS] and Section [IP_ADDRESS] are met and no 
compelling alternate cause is identified;
Clinically  suspected ABC HSR as described in Section [IP_ADDRESS] .
Rash criteria as described in Section [IP_ADDRESS] are met and no compelling alternate 
cause is identified.
Pregnancy  (intrauterine), regardless of termination status of pregnancy .As a 
reminder, females of reproductive potential who changed their minds and desire to 
be pregnant ,or who state they  no longer are willing to compl y with the approved 
pregnancy  avoidance methods, should also be withdrawn from the study .
If a subject is prematurely or permanently  withdrawn from the study , perform the 
procedures described in the Time and Events Table (Section 6.1) for the Withdrawal visit 
and if necessary  the Follow Up visit. All data from the Withdrawal visit will be recorded, 
as they  comprise an essential evaluation that should be done prior to disch arging an y 
subject from the stud y.  A Follow -up visit may  occur approximately  [ADDRESS_1255692] wishes to and/or should continue in the 
study  based on previous non- compliance.  In cases where the subject does not return for 
the rescheduled visit or cannot be reached to reschedule the missed visit, the site should 
make eve ry effort to regain contact [CONTACT_1155] (e.g. via telephone calls and/or 
sending a certified letter to the subject’s last known mailing address) so that they  can 
appropriatel y be withdrawn from the stud y.  These contact [CONTACT_152832] i n the subject’s medical record.  Should the subject continue to be 
unreachable, then he/she will be considered to have withdrawn from the study  with a 
primary  reason of “Lost to Follow -up”.  For all other subjects withdrawing from the 
study , an alternative reason for discontinuation should be recorded in the electronic case 
report form (eCRF).
Subjects are not obligated to state the reason for withdrawal. However, the reasons for 
withdrawal, or failure to provide a reason, must be documented b y the Investig ator on the 
Completion/Withdrawal section of the CRF. Every  effort should be made by  [CONTACT_895652] . In the event that a 
subject is prematurel y discontinued from the study at an y  time due to an AE (see 
Section 6.4.3 ) the procedures stated in the Time and Events Table (Section 6.1) must be 
followed. Subjects who are withdrawn from the study  will not be replaced. 
Subje cts may have a temporary  interruption to their study  treatment for management of 
toxicities (Section 6.4.3 ).
2013N161649_03 CONFIDENTIA L
ING117172
364.5.1. Virologic Criteria for Subject Management and Viral 
Resistance Testing
Subjects with plasma HIV -1 RNA levels  50c/mL at Week [ADDRESS_1255693] 
HIV-1 levels re -assessed using the algorithms below ( Figure 2 and Figure 3) which detail 
protocol defined clinical management for subjects who either require more careful
monitoring (meet “ 4 to 6 week HIV -1 RNA testing criterion”) or have met a 
“suspected or confirmed virologic withdrawal criterion”.  I nvestigators should not 
schedule re -assessment blood draws in the presence of factors that could be associated 
with virologic blips, such as intercurrent infection, treatment interruption due to toxicity  
management or non -compliance, or vaccination.  Subjects should have received full 
doses of I P for at least 2 weeks at the time of HIV -1 RNA re -assessment for an y HIV -1 
RNA level  50c/mL .
2013N161649_03 CONFIDENTIA L
ING117172
37Figure [ADDRESS_1255694] Management at Week 24
Week 24 Visit
HIV-1 RNA is <50 c/mL HIV-1 RNA is 50c/mL but <400 c/mL HIV-1 RNA is 400c/mL
Maintain scheduled visit 
at Week 36Perform an unscheduled visit in approximately [ADDRESS_1255695] has met “4 to 6 Week HIV -1 RNA Testing 
Criterion”
Proceed to Figure 3Perform an unsc heduled visit in approximately 
4-[ADDRESS_1255696] has met “Suspected Virologic 
Withdrawal Criterion”
Proceed to Figure 3
Figure 3 Virologic Criteria for Subjec t Management after Week 24
Any Visit (scheduled or unscheduled) after Week 24
Current HIV -1 RNA <50 c/mLCurrent HIV -1 RNA 50 but 
<400 c/mLCurrent HIV -1 RNA ≥400 c/mL
Regardless of previous HIV -1 RNA 
result, proceed to next scheduled visit 
per Time and Events TableRegardless of previous HIV -1 RNA 
result, perform an unscheduled visit 
in approximately 4 -6 weeks to 
reassess plasma 
HIV-1 RNA*
Subject has met “4 to 6 Week 
HIV-1 RNA Testing Criterion”If previous HIV -1 RNA was 
<400 c/mL, perform an unscheduled 
visit in approximately 4 -6 weeks to 
reassess plasma HIV -1 RNA*
Subject has met “ Suspected 
Virologic W ithdrawal Criterion ”If previous HIV -1 RNA was 
400c/mL, discontinue subject 
from study once resistance test 
results are available
Subject has met “Confirmed 
Virologic Withdrawal Criterion”
*If current visit is Week 48 scheduled visit, perform unscheduled visit in 2 -4 weeks rather than 4 -6 weeks for assessment of primary endpoint.
2013N161649_03 CONFIDENTIA L
ING117172
38If HIV -1 RNA level is ≥400 c/mL  on two consecutive assessments, a plasma for storage 
sample from the “suspected virologic withdrawal criterion” visit will be used f or HIV -1 
genot ype/phenot ype testing.  Subjects may continue to receive IP at the discretion of the 
Investigator until results of resistance testing are available at which time the subject must 
be discontinued from the study .  If a subject is prematurely  discontinued from the study , 
the Investigator must make every  effort to perform the evaluations outlined in the Time 
and Events Table (Section 6.1).  These data will be recorded as they  comprise essential 
evaluati ons needed to be done before discharging any  subject from the study .
Note: Plasma samples with <400 c/mL  of HIV -1 RNA will not be analyzed, as the 
protease/reverse transcriptase/integrase assay s used in this study  are not validated for 
plasma HIV -1 RNA levels <400 c/mL .
4.6. Screening Failures
A subject is considered a screen failure if after providing informed consent, the subject’s 
circumstances or conditions change or the outcome of a test or assessment becomes 
available which results in the subject’s failure to meet one or more of the entry  criteria, or 
results in the investigator deciding that the subject is no longer an appropriate study  
candidate.
Subjects are allowed to re -screen for this study  one time; this will require a new subject 
number. There is no timeline restriction for re- screening.  A single repeat test (re -test) per 
analyte or assessment is allowed during the screening period to determine eligibility  (with 
the exception of a disqualified Screening genot ype which may  not be retested).  
Laborat ory results from the central laboratory  services provided by  [CONTACT_339249] .  If results from central laboratory  services (e.g., chemistry  or 
hematology  results) will delay  screening bey ond the defined [ADDRESS_1255697] and Other Study  Treatment
IP in this protocol refers to the investigational study  drug DTG/ABC/3TC FDC and the 
comparator drugs AT V, RTV and TDF/FTC FDC.  All I P will be supplied by  [CONTACT_23983].
Under normal conditions of handling and administration, investigational product is not 
expected to pose significant safety risks to site staff.  A Material Safet y Data Sheet 
(MSDS) describing the occupational hazards and recommended handling precautions will 
be provided to site staff if required b y local laws or will otherwise be available from [COMPANY_004] 
upon request.
Investigational product must be stored in a secure area under the appropriate phy sical 
conditions for the products.  Access to and administration of the investigational product 
will be limited to the investigator and authorized site staff.  Investigational product must 
2013N161649_03 CONFIDENTIA L
ING117172
39be dispensed or administered onl y to subjects enrolled in the study  and in a ccordance 
with the protocol.
The contents of the label will be in accordance with all applicable regulatory  
requirements.
5.1.1. Tablet Formulation of DTG/A BC/3TC FDC
DTG/ABC/3TC FDC tablets, 50 mg/600 mg/300 mg are purple, oval, biconvex tablets 
debossed with ‘572 Trı’ on one side and plain on the other side. The tablets contain 
52.6 mg dolutegravir sodium which is equivalent to 50 mg dolutegravir free acid, 702 mg 
abacavir sulphate which is equivalent to 600 mg abacavir and 300 mg lamivudine. The 
tablets are pac kaged into high densit y polyeth ylene (HDPE) bottles with child- resistant 
closures that include induction seals. The bottles contain a desiccant.  Tablets must be 
stored in the original package with the bottle tightly  closed. Desiccants must be kept in 
the bottle to protect from moisture.
5.1.2. Tablet Formulations of A TV, RTV, TDF/FTC FDC
Atazanavir (ATV [Rey ataz] will be supplied by  [CONTACT_339258].  Each 
capsule contains 300 mg atazanavir as atazanavir sulphate.  Rey ataz is manufactured by  
[CONTACT_895653].
Tenofovir disoproxil fumarate/ emtricitabine fixed dose combination (TDF/ FTC FDC 
[Truvada ])will be provided by  [CONTACT_339258].  Each tablet of Truvada 
contains 200 mg of emtricitabine and 300 mg of tenofovir disoproxil fumarate (which is 
equivalent to 245 mg of tenofovir disoproxil). Truvada is manufactured b y [COMPANY_009] 
Sciences. 
Ritonavir (RTV [Norvir] will be supplied by  [CONTACT_339258].  Each tablet 
contains 100 mg ritonavir. Norvir is manufactured by  [CONTACT_117952].
5.1.3. Dosage and Administration
The study  has an open- label design.  Details of dosing for both randomized arms are 
outlined in the following table:
Treatment Arm Investigational Product Dose and Dose Interval
DTG/ABC/3TC DTG/ABC/3TC FDC 1 x 50 mg/600 mg/300 mg tablet on ce daily
ATV+RTV+TDF/FTC ATV 1x 300 mg capsule once daily
RTV 1 x 100 mg tablet once daily
TDF/FTC FDC 1 x 300 mg/ 200mg tablet once daily
DTG/ABC/3TC FDC may be administered with or without food.  ATV+RTV+ TDF/FTC 
FDC must be taken with food.
2013N161649_03 CONFIDENTIA L
ING117172
405.2. Treatm ent A ssignment
Informed consent must be obtained prior to an y study  procedures, including an y 
Screening assessment.
Subjects will be assigned to study  treatment in accordance with the randomization 
schedule.  Randomization will be conducted via a central r andomization procedure 
following confirmation of fulfillment of study  entry  criteria. Subjects will be assigned 
(1:1) to study  treatment in accordance with the computer generated randomization 
schedule. The central randomization schedule, including stratif ication, will be generated 
using the [COMPANY_004] validated randomization software RANDALL. Study  site personnel will 
be required to contact [CONTACT_895654] a unique 
identifier (designating the subject’s randomization code) for each subject participating in 
the study . A unique treatment number will be assigned for each subject participating in 
the study .  Subjects will maintain the assigned treatment group throughout the 
Randomized Phase (up to Week 48) and if applicable the Conti nuation Phase (after Week 
48 for subjects randomized to the DTG/ABC/3TC arm).
Subjects who are randomized into the trial and subsequently  withdrawn may  not be re -
screened.
5.3. Blinding
As this is an open- label study , blinding is not required.
5.4. Product A ccountab ility
In accordance with local regulatory  requirements, the investigator, designated site staff, 
or head of the medical institution (where applicable) must document the amount of 
investigational product dispensed and/or administered to study  subjects, the amount 
returned b y stud y subjects, and the amount received from and returned to [COMPANY_004], when 
applicable.  Product accountability  records must be maintained throughout the course of 
the study .
5.5. Treatment Compliance
Treatment compliance will be evaluated using p ill counts of unused IP. This assessment 
will be conducted each time the subject receives a new (refill) supply  of study  medication 
through the Withdrawal visit or study  completion. These data will be recorded in the 
subject’s CRF, but will not be summariz ed for analy sis purposes.  
5.6. Concomitant Medications and Non -Drug Therapi[INVESTIGATOR_895630] y current or proposed 
concomitant medication, whether prescribed or over- the-counter, because of the potential 
for inter actions between such treatments and the study  medications. All concomitant 
2013N161649_03 CONFIDENTIA L
ING117172
41medications taken during the study  will be recorded in the CRF. The minimum 
requirement is that the drug name [CONTACT_160531].
5.6.1. Permitted Medications and Non -Drug Therapi[INVESTIGATOR_278788] (prescription and non- prescription) should be administered 
only as medically  necessary  during the study  (except prohibited medications described in 
Section 5.6.2 ).  Chemoprophy laxis for HIV-associated conditions is encouraged, if 
appropriate, at the discretion of the subject and their phy sician. All concomitant 
medications, blood products, and vaccines taken during the stud y will be recorded in the 
CRF with dates of administration.
Because non- HIV vaccines may  cause a temporary  increase in the level of HIV -[ADDRESS_1255698] been drawn. This approach will 
minimize the risk of non- specific increases in the level of HIV -1 plasma RNA at the next 
scheduled assessment.
DTG /ABC/3TC FDC should be administered 2 hours before or 6 hours after taking 
antacid products or sucralfate containing dival ent cations (e.g. aluminum and 
magnesium). Proton pump inhibitors and H2- antagonists may  be used in place of antacids 
with no scheduling restrictions. Concurrent administration with multivitamins is 
acceptable.
DTG/ABC/3TC FDC can be co -administered with calcium or iron supplements if taken 
with a meal. Under fasted conditions, DTG/ABC/3TC FDC should be given 2 hours prior 
to OR 6 hours after calcium or iron supplements.
Metformin concentrations may  be increased by  [CONTACT_473390]. Subjects should be monitored 
during therapy  and a metformin dose adjustment may  be required.
5.6.2. Prohibited Medications and Non- Drug Therapi[INVESTIGATOR_895631] y time during the study  (see 
Section 5.6.1 for guidanc e regarding non -HIV vaccines). Other experimental agents, 
antiretroviral drugs not otherwise specified in the protocol , cyt otoxic chemotherapy , or 
radiation therap y may not be administered (see Exclusion Criteria, Section 4.3). 
Systemically administered immunomodulators that directly  affect immune responses are 
prohibited. HCV therap y during the stud y will not be permitted as approved HCV 
therapi[INVESTIGATOR_895632].
Chronic use of s ystemic (oral or parenteral) glucocorticoids must be avoided; however, 
short treatment courses (for example, 10 days or less) and topi[INVESTIGATOR_2855], inhaled, or intranasal 
use of glucocorticosteroids will be allowed.
Acetaminophen is not to be used in patients with acute viral hepat itis.
For a detailed list of prohibited medications, please consult the SPM.
2013N161649_03 CONFIDENTIA L
ING117172
[IP_ADDRESS]. Prohibited medications for subjects randomized to DTG/A BC/3TC FDC
For subjects randomized to DTG/ABC/3TC FDC , the following medications or their 
equivalents must not be administer ed concurrentl y:
barbiturates
carbamazepi[INVESTIGATOR_050]
oxcarbazepi[INVESTIGATOR_050]
phenobarbital
pheny toin
St. John’s wort
dofetilide
rifampin
Dofetilide is prohibited as DTG may  inhibit its renal tubular secretion resulting in 
increased dofetilide concentrations and potential for toxicity .
Methadone - due to potential for decreased plasma concentrations, subjects should be 
monitored for signs of withdrawal and methadone dose adjusted as appropriate.
[IP_ADDRESS]. Prohibited medications for subjects randomized to A TV+RTV + 
TDF/FTC FDC
For subjec ts randomized to ATV+RTV+TDF/FTC FDC , the following medications or 
their equivalents must not be administered concurrently :
alfuzosin
rifampin
irinotecan
triazolam
midazolam (oral)
dihydroergotamine
ergotamine
ergonovine
methy lergonovine
cisapride
St John’ s wort
lovastatin
simvastatin
pi[INVESTIGATOR_3924]
sildenafil
For information on concurrent therapi[INVESTIGATOR_339172] y in the regimen, please consult the local prescribing information.
2013N161649_03 CONFIDENTIA L
ING117172
435.7. Treatment after the End o f the Study
The investigator is responsible for ensuring that consideration has been given to the post -
study  care of the patient’s medical condition whether or not [COMPANY_004] is providing specific 
post study  treatment.
Subjects randomized to DTG/ABC/3TC FDC
To pr ovide continued access to unapproved investigational drug to subjects deriving 
therapeutic benefit, subjects randomized to receive DTG /ABC/3TC FDC and who have 
successfull y completed 48 weeks of treatment in the Randomized Phase will be given the 
opportuni ty to continue to receive DTG /ABC/3TC FDC until one of the following 
occurs:
DTG/ABC/3TC FDC is locally  approved and commerciall y available,
The subject no longer derives clinical benefit from receipt of DTG/ABC/3TC FDC,
The subject meets a protocol- define d reason for discontinuation or
The development of DTG/ABC/3TC FDC is discontinued.
Subjects randomized to ATV+ RTV + TDF/FTC FDC
As subjects randomized to receive ATV+RTV+TDF/FTC FDC complete the Week [ADDRESS_1255699] 
make arrangements for provision of ATV, RTV and FTC/TDF FDC or their 
individual components to all subjects early during the study to ensure subject access 
to medication post study. 
5.8. Treatment of Study  Treatment Overdose
Any tablet intake exceeding the randomized daily  number of tablets for IP will be 
considered an overdose.
For the purposes of this study , an overdose is not an AE (Refer to Section [IP_ADDRESS] ) unless 
it is accompanied b y a clinical manifestation associated with the overdose. If the clinical 
manifestation presents with serious criteria, the event is a SAE, see Section [IP_ADDRESS] .
If an overdose occurs and is associated with a n adverse event requiring action, all study  
medications should be temporarily  discontinued until the adverse event resolves. 
The Investigator should use clinical judgment and also refer to the prescribing 
information for approved ARTs, as appropriate in treating overdose, as [COMPANY_004] is unable to 
recommend specific treatment.
2013N161649_03 CONFIDENTIA L
ING117172
446. STUDY A SSESSMENTS A ND PROCEDURES
6.1. Time and Events Schedule
Table [ADDRESS_1255700] at 
Wk 8 18, 
30, 42rEvery 12 
weeks after 
Week 48Week
4Week
12Week
24Week
36Week
48
Clinical and Other Assessments
Written informed consent X
Inclusion/Exclusion criteriab X X
Demogr aphy X
Prior ART history X
Medical historyc X
Current medical conditions X
HIV risk factors and mode of 
transmissionX
CDC HIV -[ADDRESS_1255701] at 
Wk 8 18, 
30, 42rEvery 12 
weeks after 
Week 48Week
4Week
12Week
24Week
36Week
48
Confirm understanding of study  and 
management/tolerability of regimenX X X X X X X X
Laboratory Assessments
Plasma for HIV genotypi[INVESTIGATOR_007] X
Quantitative plasma HIV -1 RNA X X X X XnXnXnXn X
Lymphocyte subset X X X X X X X X X X
Plasma for storagee X X X X X X X X X X
HLA-B* 5701 testingq X
Clinical chemistry X X X X X X X X X X
Hematology X X X X X X X X X X
Fasting lipi[INVESTIGATOR_895633] X X X X X
Urinalysis and spot urine for protein 
analysisgX X X XpXm X
Pregnancy testh S U S S S S S S S
HBsAg and hepatitis C antibody X
Pharmacogenetic samplei X
Bone marker analytes (blood )v X X X
Investigational Product
IVRS X X X X X X X X X X
Dispense IP X X X X X Xo X
IP accountability (pi[INVESTIGATOR_10685]) X X X X X X X
2013N161649_03 CONFIDENTIA L
ING117172
46a. The 14- day Screening period maybe extended to 28 days.  Randomization may occur as soon as all Screenin g results are available.
b. Inclusion/exclusion criteria will be fully assessed at the Screening visit.  Changes between the screening visit and the Day 1 visit should be assessed to ensure eligibility, 
including additional assessments performed at Day 1.
c. Full medical history will be collected. Targeted medical history assessments will include cardiovascular, metabolic (e.g., Type I or II DM), psychiatric (e.g, depression) and renal 
(e.g., nephrolithiasis, nephropathy, renal failure) disorders.
d. Assessment for cardiovascular risk will include height, weight, blood pressure, smoking history, medical conditions, and family history of p remature cardiovascular disease
e. Plasma samples for storage will be collected at each visit for possible future analyses (including but not limited to HIV -1 RNA genotypic and phenotypic analyses, HIV -1 RNA 
levels, and immunological parameters).  These samples will be used when needed such as when samples are lost or arrive at the laboratory unevaluable.  Additionally, these 
samples wi ll be used for genotypic and/or phenotypic analyses when subjects meet confirmed virologic withdrawal criteria (see Section 4.5.1 ).
f. An overnight fast is preferred, however a minimum of a [ADDRESS_1255702] is acceptabl e.
g. A morning specimen is preferred.
h. Pregnancy testing. Women of childbearing potential only. S=serum, U=urine .  Remind females of reproductive potential of the need to avoid pregnancy while in study and 
adherence to the study’s contraception requirements .
i. Informed consent for optional pharmacogenetics (PGx) research must be obtained before collecting a sample. Collection of the PGx sample at Day [ADDRESS_1255703] will be collected between obtaining informed consent and administra tion of IP at Day 1.
k. For subjects who completed randomized DTG/ABC/3TC FDC through Week 48 and entered into DTG/ABC/3TC FDC Continu ation Phase: subjects completing the 
DTG/ABC/3TC FDC Continuation Phase must return to the clinic when transitioning to commercial supplies.  Conduct study assess ments as specified per the Week [ADDRESS_1255704] what is considered medi cally necessary to assess the event(s).
m. Conduct assessments at Week 48 OR at the Withdrawal visit for subjects who discontinue from the study prior to Week 48, but n ot both.
n. Beginning at Week 24, subjects with plasma HIV- 1 RNA 50 but <400 c/mL who elect t o remain in study must return every 4 -6 weeks for collection of samples for HIV -1 RNA 
determination and plasma for storage. Genotype and phenotype testing will only be performed with confirmed HIV -1 RNA ≥400 c/mL.
o. For subjects receiving DTG/ABC/3TC FDC in Continuation Phase only
p. Will be tested every 24 weeks (not every 12 weeks)
q. Documentation that the subject had been screened for, and is negative for the HLA- B*5701 allele is acceptable.
r. Contacts at Week 8,18, 30 and 42 are mandatory but may be conducted as a telephone, clinic or home visit (or other type of visit as agreed with [COMPANY_004]).
s. Limited physical examination to include blood pressure at Baseline (recorded in eCRF) for Framingham score assessment, and we ight at each visit (recorded in eCRF at 
Baseline an d on lab requisition at all visits) for determination of CrCL. Blood pressure to be measured after resting in a semi -supi[INVESTIGATOR_21683] 5 minutes.  
t. A 12-lead electrocardiograph (ECG) will be performed after resting in a semi -supi[INVESTIGATOR_21683] 5 minutes.  
u. On Day 1, the Columbia Suicidality Severity Rating Scale (conducted by [CONTACT_895655]) is to be administered prior to randomization.
v. Blood sample for bone marker assessment.  Only the result for 25 hydroxy -vitamin D will be rep orted to the investigator.
w. SF-12 and HIV Treatment Satisfaction Questionnaire (HIVTSQ) is recommended to be administered at the beginning of the visit. 
2013N161649_03 CONFIDENTIA L
ING117172
476.2. Critical Baseline A ssessments
Written informed consent must be obtained from each potentiall y eligibl e subject (or 
his/her legal representative) b y study site personnel prior to the initiation of an y 
Screening procedures as outlined in this protocol. The consent form must have been 
approved b y the Institutional Review Board/Independent Ethics Committee (I RB/IEC). 
After signing an informed consent, subjects will complete Screening assessments to 
determine subject eligibility . Each subject being screened for stud y enrolment evaluation 
will be assigned a subject number. This number will be given sequentially  in 
chronological order of subject presentation according to a numeric roster provided by  
[CONTACT_23983].
6.2.1. Screening A ssessments
Assessments to be conducted at Screening are provided in the Time and Events Table 
(Section 6.1).  
Eligible subjects may  be randomized as soon as all Screening assessments are complete 
and the results are available and documented. All subjects will complete a Screening 
period of approximately  14 day s prior to Baseline (Day  1) during which all clini cal and 
laboratory  assessments of eligibility  must be performed and reviewed.  The Screening 
period may  be extended to [ADDRESS_1255705] been screened an d be negative for the HLA -B*[ADDRESS_1255706] provide a plasma sample for determination of primary  viral resistance 
based on the presence of any  major resistance -associated mutation.  
Subjects who meet all entry  criteria are randomized and assigned a randomization 
number. Subjects not meeting all inclusion and exclusion criteria at initial screen may be 
re-screened (with the exception of a disquali fying viral phenoty pe) and receive a new 
subject number one time.  Subjects who are randomized into the trial and subsequently  
withdrawn from the study for an y reason, may not be re -screened.
6.2.2. Baseline (Day  1) Assessments
Assessments to be conducted at Base line (Day 1) are provided in the Time and Events 
Table (Section 6.1). 
At Day  [ADDRESS_1255707] be 
assessed and an y results required prior to randomizati on (e.g. Day [ADDRESS_1255708] 
for women of child bearing potential) must be available and reviewed.  
[ADDRESS_1255709] or y /ris k fact ors will be assesse d at Baseli ne, t o i ncl u de 
s m o ki n g stat us a n d hist or y  a n d fa mil y  hist or y  of car diac e ve nts . 
6. 2. 3. S u bj e ct s i nf e ct e d wit h H e p atiti s B ( H B V) a n d/ or H e p atiti s C( H C V) 
S u bjects i nfecte d wit h H B V or wit h a n a ntici pate d nee d f or H C V t hera p y d uri n g t he 
st u d y  ma y  n ot be e nr olle d i nt o t his st u d y . A p pr o ve d H C V t hera p y c urre ntl y  i ncl u des t he 
pr o hi bite d me dica ti o n i nterfer o n. 
6. 3. Effi c a c y 
6. 3. 1. Effi c a c y  E v al u ati o n s 
Pl a s m a HI V -1 R N A 
Plas ma f or q ua ntitati ve HI V- 1 R N A will be c ollecte d acc or di n g t o t he Ti me a n d E ve nts 
Ta ble ( Secti o n 6. 1 ).  Met h o ds t o be use d ma y  i ncl u de b ut are n ot li mite d t o t he A b b ott 
Real Ti me HI V -1 Assa y  l o wer li mit of detecti o n ( L L O D) 4 0 c/ m L. 
 
L y m p h o c y t e S u b s et s 
L y m p h oc y te s u bsets will be c ollecte d f or assess me nt b y  fl o w c y t o metr y  (t otal 
l y m p h oc y te c o u nts, perce nta ge a n d a bs ol ute C D 4 + l y m p h oc y te c o u nts) acc or di n g t o 
Ti me a n d E ve nts Ta ble ( Secti o n 6. 1 ). 
HI V A s s o ci at e d C o n diti o n s 
HI V- ass ociate d c o n diti o ns will be rec or de d as per Ti me a n d E ve nts T a ble.  HI V -
ass ociate d c o n diti o ns will be assesse d acc or di n g t o t he 1 9 9 3 C D C Re vise d Classificati o n 
S y ste m f or HI V I nfecti o n i n A d ul ts ( A p pe n di x 1 , Secti o n 1 1. 1 ).  I n dicat ors of cli nical 
disease pr o gressi o n are defi ne d as: 
C D C Cate g or y  A at e nr oll me nt Cate g or y  C e ve nt; 
C D C Cate g or y  B at e nr oll me nt Cate g or y  C e ve nt; 
C D C Cate g or y  C at e nr oll me nt Ne w Cate g or y  C E ve nt; 
C D C Cate g or y  A, B or C at e nr oll me nt Deat h. 
6. 3. 2. Pri m ar y  E n d p oi nt 
T he pri mar y  e n d p oi nt f or t his st u d y  will be t he pr o p orti o n of s u bjects wit h plas ma HI V - 1 
R N A < 5 0 c o pi[INVESTIGATOR_014]/ m L at Wee k 4 8 usi n g t he S na ps h ot al g ori t h m ( Missi n g, S witc h or 
Disc o nti n uati o n = Fail ure) f or t he I T T -E p o p ulati o n (see Secti o n 8. 3. 3. 1 ). C CI 
2013N161649_03 CONFIDENTIA L
ING117172
496.3.3. Secondary  Efficacy Endpoints
Proportion of subjects with plasma HIV -1 RNA <50 and <400 c/mL over time;
Absolute values and change from Baseline in plasma HIV- 1 RNA over time;
Absolute values and changes from Baseline in CD4+ cell counts over time;
Incidence of disease progression (HIV -associated conditions, AI DS and death).
6.4. Safet y
6.4.1. Safety  Evaluations
Safety  assessme nts will include the following:
Monitoring and recording all AEs and SAEs.  Additional information on the Time 
Period and Frequency  of Detecting AEs and SAEs is provided in Section 6.4.12 ;
Regular monitoring of hematology , blood chemistry  and fasting lipi[INVESTIGATOR_805] (parameters to 
be tested listed in Table 4below);
Physical exams should be conducted as part of normal routine clinical care but will 
not be collected s ystematically in the CRF.  Abnormalities noted during any exam 
must be recorded in the CRF (e.g., in the current medical conditions or AE logs);
Periodic assessment of urine/urinaly sis parameters as described below;
Evaluation and documentation of all concomitant medic ations and blood products;
Suicidality  monitoring using the Columbia Suicide -Severit y Rating Scale (Section 
6.4.10).
Any appropriately  qualified site personnel (e.g. Investigator, sub- Investigator or study  
coord inator/nurse) can perform assessments.  A central laboratory  chosen by  [CONTACT_895656] .  Refer to the 
central laboratory  manual for specific instructions on sample collection, processing, 
storage and shippi[INVESTIGATOR_227361].
2013N161649_03 CONFIDENTIA L
ING117172
50Table 4 Laboratory  Assessments
Hematology
Platelet Count Automated WBC Differential:
RBC Count Neutrophils
WBC Count (absolute) Lymphocytes
Hemoglobin Monocytes
Hematocrit Eosinoph ils
MCV Basophils
MCV = mean corpuscular volume, RBC = red blood cells, WBC = white blood cells
Clinical Chemistry
BUN Potassium AST Total bilirubina
Creatinineb Chloride ALT Albumin 
Glucose Total CO 2 Alkaline phosphatase Creatine phosphokinase
Sodium Lipase Phosphate
BUN = blood urea nitrogen
a. Direct bilirubin will be reflexively performed for all total bilirubin values > 1.5X ULN.
b. Glomerular Filtration Rate (GFR) will be estimated by [CONTACT_895657] -Gault method 
[Cockroft , 1976].
Fasting Lipid Panela
Total cholesterol
HDL cholesterol
LDL cholesterol
Triglycerides
a. For fasting lipi[INVESTIGATOR_684049], an overnight fast is preferred, however, a minimum of a [ADDRESS_1255710] is accep table 
Other tests 
Plasma HIV -1 RNA
CD4+ cell counts
Hepatitis B (HBsAg) and Hepatitis C (anti- HCV Ab)a
Pregnancy test for women of child bearing potential b
HLA-B*5701 screeninga
Urinalysis, urine albumin/creatinine ratio and urine protein/creat inine ratio 
Bone marker assessmentsc: bone specific alkaline phosphatase, Procollagen type [ADDRESS_1255711] on Day 1; serum pregnancy test at Screening and Weeks 4, 12, 24, 36 and 48 (and at 12 
weeks intervals thereafter if applicable).
c. Blood sample for bone marker assessments: since the intention is to utilize these data for research purposes, the 
Sponsor will not report the results of these assessments to the investigator, except for 25 hydroxy -vitamin D.
2013N161649_03 CONFIDENTIA L
ING117172
516.4.2. Safety  Endpoints
Incidence and severit y of AEs and laboratory  abnormalities; 
Absolute values and changes over time in laboratory  parameters;
Proportion of subjects who discontinue treatment due to AEs;
Change from Baseline in fasting lipi[INVESTIGATOR_442093];
Changes from Baseline in renal and bone markers.
6.4.3. Toxicity  Management
Adverse events that occur during the trial should be evaluated b y  the Investigator and
graded according to the Division of AIDS (DAIDS) toxicity  scales ( Appendix 2, Section 
11.2).Additional information regarding detecting, documenting and reporting AEs and 
SAEs are available in Section 6.4.[ADDRESS_1255712] to minimize the 
risk of development of resistance.
No toxicity -related dose reductions of IP will be allowed. I P should be restarted as soon 
as medicall y appropriate; in general, this should be no longer than 4 weeks after 
interruption (unless Grade [ADDRESS_1255713]). Decisions regarding sequential 
reintroduct ion of IP or temporary  interruption of one or more but not all drugs within the 
ART regimen should be made with the understanding that these changes may  result in 
incomplete viral suppression and selection of resistant virus. Guidance is provided below 
on general subject management and IP interruptions based on the severity  of the AE; for 
specific toxicities, please refer to Section 6.4.4 “Specific Toxicities/Adverse Event 
Management”. All changes in the I P must be accuratel y recorded in the subject’s eCRF.
NOTE : In the event of a discontinuation of DTG/ABC/3TC FDC for any  reason, 
reinitiation of this drug should be undertaken with caution. The investigator must obtain a
complete history  of the events surrounding the discontinuation of DTG/ABC/3TC FDC ,
evaluate for the possibility  of a clinicall y suspected HSR, and initiate subject 
management as outlined in the DTG IB ,regardless of a subject’s HLA -B*5701 status.
Grade 1 or Grade 2 Toxicity/Adverse Event
Subjects w ho develop a Grade 1 or Grade 2 AE or toxicity  may  continue IP at the
discretion of the Investigator. (NOTE: see Section 6.4.4 “Specific Toxicities/Adverse
Event Management” for exceptions to this guideline). Su bjects who choose to withdraw
from study  due to a Grade [ADDRESS_1255714] study  withdrawal and follow -up
evaluations completed.
2013N161649_03 CONFIDENTIA L
ING117172
52Grade 3 Toxicity/Adverse Event
Subjects who develop a Grade 3 AE or toxicity  should be managed as follows:
If the Investigat or has compelling evidence that the Grade [ADDRESS_1255715] the IP withheld and be rechecked each week
until the AE returns to Grade 2. Once the AE is Grade ≤2, IP may  be re -started.
Should the same Grade [ADDRESS_1255716] dose of IP.
Subjects with Grade 3 asymptomatic laboratory  abnormalities should be investigated for
all potential non -drug related causes, and, following discussion with the medical monitor, 
may continue IP if the Investigator has compelling evidence that the toxicity  is not related 
to IP. Exceptions are noted below for lipid abnormalities (Section [IP_ADDRESS] ).
Grade 4 Toxicity/Adverse Event
Subjects who develop a Grade [ADDRESS_1255717] IP permanently  discontinued.
However, if the Investigator has compelling evidence that the AE is not causally  related
to the I P, dosing may  continue after discussion with and assent from the medical monitor. 
Subjects should be rechecked each week until the AE returns to Grade 2.
Subjects experiencing Grade 4 AEs requiring permanent discontinuation of I P should be
followed weekly  until resolution of the AE and encouraged to complete the withdrawal
and follow -up study  evaluations as noted above.
Subjects with Grade 4 asymptomatic laboratory  abnormalities should be investigated for
all potential non -drug related causes, and, following discussion with the medical monitor, 
may continue therap y if the Investigator has compelling evidence that t he toxicity  is not 
related to IP. Exceptions are noted below for lipid abnormalities (Section [IP_ADDRESS] ).  A 
follow -up visit should be performed [ADDRESS_1255718] dose of study  medication if 
AEs or laboratory abnormalities are ongoing.
6.4.4. Specific Toxicities/Adverse Event Management
General guidelines for the management of specific toxicities that are considered to be
related or possibl y related to I P are provided below. 
Subjects who permanently discontinue IP f or reasons of toxicity  should be followed
weekl y until resolution of the AE and encouraged to complete the withdrawal and
Follow -Up study  evaluations as noted above.
2013N161649_03 CONFIDENTIA L
ING117172
[IP_ADDRESS]. Liver Chemistry  Stoppi[INVESTIGATOR_842461] w up Criteria
Liver chemistry  threshold stoppi[INVESTIGATOR_23892] a have been designed to assure subject safet y
and to evaluate liver event etiology  during administration of I P and the follow -upperiod. 
IP will be stopped if an y of the following liver chemistry  criteria are met:
ALT ≥ 3xULN and bilirubin ≥2xUL N (>35% direct bilirubin; bilirubin fractionation
required)
NOTE: serum bilirubin fractionation should be performed if testing is available.
If testing is unavailable, record presence of detectable urinary  bilirubin on
dipsti ck, indicating direct bilirubin elevations and suggesting liver injury. If
testing is unavailable and a subject meets the criterion of total bilirubin 
≥2xUL N, then the event meets liver stoppi[INVESTIGATOR_3418];
ALT ≥8xULN;
ALT ≥3xULN (if baseline ALT is < ULN) with symptoms or worsening of acute
hepatitis or hy persensitivity  such as fatigue, nausea, vomiting, right upper quadrant
pain or tenderness, fever, rash, or eosinophilia, OR;
ALT ≥3x baseline ALT with sy mptoms or worsening of acute hepatitis or 
hypersensi tivity  such as fatigue, nausea, vomiting, right upper quadrant pain or 
tenderness, fever, rash, or eosinophilia;
ALT ≥5xULN and <8xULN that persists  2 weeks (with bilirubin <2xULN and no
signs or s ymptoms of acute hepatitis or hy persensitivity );
ALT ≥5xU LN but <8xULN and cannot b e monitored weekly  for >2 weeks;
Subjects who develop ALT ≥5xULN should be followed weekl y until resolution or
stabilization (ALT <5xULN on 2 consecutive evaluations).
When liver chemistry stoppi[INVESTIGATOR_196140], do the followi ng:
Immediately  hold I P.  
Report the event to the medical monitor within 24 hours of learning its occurrence 
(seeTable 5and Table 6, Section 6.4.14 );
Complete the liver event eCRF and SAE eCRF, where applicable, (see Section 
6.4.14 );
Complete the liver imaging and/or liver biopsy  eCRFs if these tests are performed;
Perform liver event follow up assessments (described below), and monitor the 
subject until liver chemistries resolve, stabilize, or return to baseline values as
described below;
Make every  reasonable attempt to have subjects return to clinic within 24 hours for
repeat liver chemistries, liver event follow up assessments (see below), and close
monitoring;
A specialist or hepatology consultation is recommended;
2013N161649_03 CONFIDENTIA L
ING117172
54Monitor subjects twice weekl y until liver chemistries (ALT, aspartate 
aminotransferase (AST), alkaline phosphatase, bilirubin) resolve, stabilize or return 
to within baseline values;
Make every  attempt to carry  out the liver event follow up assessments described below:
Viral hepatitis serology  including:
Hepatitis A IgM antibody;
HBsAg and Hepatitis B Core Antibody  (IgM);
Hepatitis C RNA;
Cytomegalovirus IgM antibody ;
Epstein- Barr viral capsid antigen IgM antibod y (or if unavailable, obtain heterophile
antibody  or monospot testing);
Syphilis screening
Drugs of abuse screen including alcohol
Serum acetaminophen test (APAP adduct test). The site must contact [CONTACT_895658]. Please refer to the SPM .
Hepatitis E IgM antibody;
Blood sample for pharmacokinetic (PK) anal ysis, obtained within [ADDRESS_1255719] the date/time of the PK blood sample draw and the date/time of the last 
dose of IP prior to blood draw on the CRF.  If the date or time of the last dose is 
unclear, provide the subject’s best approximation.  If the date/time of the last dose 
cannot be approximated OR a PK sample cannot be collecte d in the time period 
indicated above, do not obtain a PK sample.  Instructions for sample handling and 
shippi[INVESTIGATOR_23915].
Serum CPK and lactate dehydrogenase (LDH);
Fractionate bilirubin, if total bilirubin is greater than 1.5xUL N;
Obtain complete blood count with differential to assess eosinophilia;
Anti- nuclear antibody , anti -smooth muscle antibody , and Ty pe 1 anti -liver kidney
microsomal antibodies;
Liver imaging (ultrasound, magnetic resonance, or computerized tomography ) to
evaluate liver disease ;
Record the appearance or worsening of clinical symptoms of hepatitis, or
hypersensitivity , fatigue, decreased appetite, nausea, vomiting, abdominal pain,
jaundice, fever, or rash as relevant on the AE report form;
Record use of concomitant medications, a cetaminophen, herbal remedies, other over
the counter medications, or putative hepatotoxins, on the concomitant medications
report form. Record alcohol use on the liver event alcohol intake case report form.
2013N161649_03 CONFIDENTIA L
ING117172
[IP_ADDRESS]. Restarting Investigational Product
Drug Restart/ Rechallenge Following Liver Events that are Possibly Related to IP
Approval b y the ViiV Safety and Labeling Committee (VSLC) for drug restart can be 
considered where:
The subject is receiving compelling benefit, benefit of drug restart exceeds risk, and 
noeffective alternative therap y is available. Ethics Committee or I nstitutional 
Review Board approval of drug restart/rechallenge must be obtained, as required.
If the restart/rechallenge is approved b y the VSLC in writing, the subject must be 
provided with a clear description of the possible benefits and risks of drug 
administration, including the possibility  of recurrent, more severe liver injury  or 
death.
The subject must also provide signed informed consent specificall y for the IP 
restart/rechallenge. Do cumentation of informed consent must be recorded in the 
study  chart.
Study  drug must be administered at the dose specified by  [CONTACT_339279] C.
Subjects approved b y the VSL C for rechallenge of I P must return to the clinic twice 
a week for liver chemistry  tests forone month or for as long as clinicall y indicated
and then laboratory  monitoring may  resume as per protocol.
Refer to Appendix 4, Section 11.4 for further details. 
Drug Restart Following Transient Resolvi ng Liver Events Not Related to IP 
Approval b y the VSLC for drug restart can be considered where:
Liver chemistries have a clear underl ying cause (e.g., biliary  obstruction, 
hypotension and liver chemistries have improved to normal or are within 
1.5 x baseline and AL T <3xULN). Ethics Committee or Institutional Review Board 
approval of drug restart/rechallenge must be obtained, as required.
If restart of drug is approved by  [CONTACT_339279] C in writing, the subject must be provided 
with a clear description of the possible benefits and risks of drug administration, 
including the possibility  of recurrent, more severe liver injury  or death.
The subject must also provide signed informed consent specificall y for the restart.  
Documentation of informed consent must be recor ded in the study  chart.
Study  drug must be administered at the dose specified by  [CONTACT_339279] C.
Subjects approved b y the VSLC for restarting IP must return to the clinic once a week for 
liver chemistry  tests for one month or for as long as clinically  indicated and then 
laboratory  monitoring may  resume as per protocol.  I f protocol defined stoppi[INVESTIGATOR_895634], study  drug must be stopped.
Refer to Appendix 4, Section 11.4 for further details. 
2013N161649_03 CONFIDENTIA L
ING117172
[IP_ADDRESS]. ATV related hy perbilirubinemia
For isolated  Grade 3 unconjugated hy perbilirubinemia attributed to ATV, ATV should 
be continued unless associated with jaundice or scleral icterus that presents an intolerable 
cosmetic concern to the subjec t.  For isolated elevations  Grade 3 that cannot be 
attributed to ATV or to a cause that is not study  drug -related, all study  medications 
should be held pending evaluation of etiology .  
In the event that an elevation in total bilirubin to  2x ULN (>35% direct bilirubin, 
bilirubin fractionation required) is accompanied by [CONTACT_638787] ≥3x ULN, then 
the instructions set out in Section [IP_ADDRESS] must be followed.
[IP_ADDRESS]. Hypertrigly ceridemia/Hypercholesterolemia
Sampl es for lipid measurements must be obtained in a fasted state according to the Time 
and Events table (Section 6.1). Subjects who experience asymptomatic trigly ceride or 
cholesterol elevations may continue to receive IP.
[IP_ADDRESS]. CPK Elevation
A Grade 3 or higher elevation in CPK should result in a repeat assessment within 2 -4
weeks to ensure the result is transient or due to exercise and will not require a change in
study  treatment. A history  regarding use of drugs known t o cause increase of CPK (such
as statins) phy sical activity  or exercise preceding the CPK evaluation should be obtained.
Grade [ADDRESS_1255720] has
abstained from exercise for >[ADDRESS_1255721] withdrawn from the study .
[IP_ADDRESS]. Decline in Renal Function
Subjects who experience an increase in creatinine from Baseline of 45 Mol/L  (or
0.5mg/dL) without associated evidence for proteinuria should return for a confirmatory  
assessment within 2 to 4 weeks.  A urinalysis and urine albumin/creatinine ratio should 
be done at this confirmatory  visit.  If the creatinine increase is confirmed, t he investigator 
should contact [CONTACT_895659] -up and medical 
management.
The following criteria are defined based on Cockcroft -Gault estimates of glomerular 
filtration rate. The criteria are based on recommendations for changes in dosing
administration for both DTG/ABC/3TC FDC and TDF/FTC FDC. The DTG IB and 
current local prescribing information for TDF/FTC FDC should be consulted for 
additional details on dosing in renally  impaired subjects.
Subjects who have a decli ne in CrCL  of >50% must return for a confirmatory  assessment 
as soon as possible. A urinaly sis and urine albumin/creatinine ratio should be done at this 
confirmatory  visit. If the estimated CrCL  has declined by  >50% (confirmed), then I P 
should be withheld and the investigator should contact [CONTACT_895660] 
2013N161649_03 CONFIDENTIA L
ING117172
57discuss the rationale for restarting stud y drugs (if appropriate).  Consideration for 
confounding factors (e.g., other medications, deh ydration, concurrent conditions) should 
be taken into ac count, and a nephrology  consult may  be obtained.  If IP is reinitiated, it 
should have been withheld for no more than [ADDRESS_1255722] be withdrawn.
Proximal Renal Tubule Dy sfunction (PRTD) is defined as:
Confirmed rise i n serum creatinine of ≥0.5mg/dL from Baseline AND serum
phosphate <2.0mg/dL ;
Either of the above accompanied by  [CONTACT_339283]:
Glycosuria ( ≥250mg/dL) in a non- diabetic;
Low serum potassium (<3mEq/L );
Low serum bicarbonate (<19mEq/L ).
Subjects me eting criteria for PRTD must return for a confirmatory  assessment within [ADDRESS_1255723] the
study  medical monitor to discuss the rationale for restarting study  drugs (if appropriate). 
If reinitiation of IP is planned, IP should be withheld for no more than 4 weeks.
[IP_ADDRESS]. Proteinuria
Subjects with an abnormal urine albumin/creatinine ratio (>0.3mg/mg, >300mg/g or 
>34mg/mmol ) that represents a change from Baseline and no associated increase in 
creatinine, should have a repeat spot urine albumin/creatinine ratio performed within 2 -4 
weeks. If confirmed, then consideration should be made for additional evaluation a fter 
consultation with the study  medical monitor. Additional evaluation may  include a 24 hr 
urine protein and creatinine measurement and nephrology  referral.
Subjects with an abnormal urine albumin/creatinine ratio (>0.3mg/mg, 300 mg/g 
or>34mg/mmol and rep resenting a change from Baseline) and a serum creatinine increase 
>45 Mol/L (or 0.5 mg/dL) should have confirmation of both results within 2 weeks.  If 
confirmed, the stud y medical monitor should be immediately contact[INVESTIGATOR_530].  Agreement on 
further management should be agreed between the investigator and medical monitor.
[IP_ADDRESS]. Allergic Reaction
Subjects may  continue IP for Grade [ADDRESS_1255724] the Investigator immediately  if
there is an y worsening of sy mptoms or if further systemic signs or s ymptoms develop.
Antihistamines, topi[INVESTIGATOR_11930], or antipruritic agents may  be prescribed.
Subjects with Grade ≥[ADDRESS_1255725] should be
withdrawn from the study. Subjects should be treated as clinicall y appropriate and
followed until resolution of the AE.
2013N161649_03 CONFIDENTIA L
ING117172
58Subjects receiving DTG/ABC/3TC FDC should be m anaged in terms of a clinically  
suspected ABC hypersensitivity , as described below.
[IP_ADDRESS]. Abacavir Hy persensitivity  Reaction (A BC HSR)
The most significant toxicity  associated with ABC is the well -characterized drug -related
HSR. A detailed clinical description of this reaction (including the type and severit y of 
events that can occur on re -challenge or reintroduction following ABC interruption for 
non-HSR reasons) and guidance regarding its management are included in the DTG IB.  
Investigators must familiarize th emselves with this information on ABC HSR in the IB 
for each of these products prior to initiating subjects on ABC therap y.
Studies have shown that carriage of the HLA -B*5701 allele is associated with a
significantl y increased risk of a HSR to ABC. In the prospective stud y CNA106030
(PREDI CT-1), the use of pre -therapy  screening for the presence of HLA -B*5701 and
subsequently  avoiding ABC in HLA -B*5701 positive patients, significantly reduced the
incidence of clinicall y suspected ABC HSR from 7.8% (66 of 847 ) to 3.4% (27 of 803)
(p<0.0001). In clinical studies EPZ108859 (ARIES) and CNA109586 (ASSERT), 0.8%
(4/515) and 3.1% (6/192) of subjects who were HLA -B*[ADDRESS_1255726] treated with ABC, the clinical diagnosis of suspected HSR (as
detailed in the IB) must remain the basis of clinical decision making. Regardless of 
HLA -B*5701 status, it is important to permanently discontinue ABC and not re-
challenge with ABC (i.e., ZIA GEN™, EPZICOM, KIVEXA, TRIZIVIR™ or 
DTG/ABC/3TC FDC) if a HSR cannot be ruled out on clinical grounds, due to the 
potential for a severe or even fatal reaction.
Essential Patient Information 
With reference to the IB and the ‘Subject Information and Consent Form’, Investigators 
must ensure that subjects are full y informed regarding the following information on the 
HSR prior to commencing ABC therapy :
Subjects must be made aware of the possibility  of a HSR to abacavir that may  result 
in a life- threatening re action or death and that the risk of a HSR is increased in 
individuals who are HLA -B*5701 positive.
Subjects must also be informed that HLA -B*[ADDRESS_1255727] their doctor 
IMMED IATELY.
Subjects who are h ypersensitive to abacavir should be reminded that they  must never
take an y abacavir containing medicinal products (e.g. DTG/ABC/3TC, ZIAGEN, 
EPZICOM, KIVEXA or TRIZIVIR) again, regardless of their HLA -B*5701 status.
In order to avoid restarting abacavir, subjects who have experienced a HSR should 
be asked to return an y remaining DTG/ABC/3TC FDC tablets to the Investigator or 
site staff.
2013N161649_03 CONFIDENTIA L
ING117172
59Subjects who have stopped abacavir for any  reason, and particularly  due to possible
adverse reactions or illness, must be advised to contact [CONTACT_895661]/ABC/3TC .
Each subject should be reminded to read the Abacavir Hy persensitivity  Warning 
Card accompan ying their study  medication and of the importance of keepi[INVESTIGATOR_895635].
Reporting of Hy persensitivity  Reactions
If a clinically  suspected case of HSR to ABC meets one of the International Conference 
on Harmonization (I CH)-E2A definitions of seriousness listed in Section [IP_ADDRESS], then, in 
addition to reporting the case as an SAE, the ABC HSR CRF should also be completed 
within one week of the onset of the h ypersensitivity  reaction.
[IP_ADDRESS]. Skin reactions wi thout other sy mptoms that are ty pi[INVESTIGATOR_12340] A BC HSR
Including serious skin reactions such as SJS, TEN, Erythema Multiforme or rash 
with significant liver dysfunction 
Subjects should be instructed to contact [CONTACT_339286] a rash while on study .
Subjects who develop rash of an y grade should be evaluated for the possibility  of an 
ABC HSR or a serious skin reaction such as SJS, TEN or Ery thema Multiforme. SJS, 
TEN and Ery thema Multiforme have been reported very  rarel y in pat ients taking ABC -
containing products.  These patients generally  do not have the cluster of additional 
symptoms (e.g., gastrointestinal and respi[INVESTIGATOR_696] ) that characterize the ABC HSR, but they  
do have features t ypi[INVESTIGATOR_227310].
If a s erious skin reaction develops, ABC (and / or all other concurrent medication(s) 
suspected in the Investigators causalit y assessment) should be discontinued, and the 
subject should not be re -challenged with an y ABC -containing medicinal product (i.e., 
DTG/AB C/3TC, ZIAGEN, TRIZIVIR, EPZICOM or KIVEXA).
As many  products other than abacavir also cause rash and/or serious skin reactions, all 
other medicinal products that the subject is receiving should also be reviewed and 
discontinued as appropriate.
Severe, pot entiall y life -threatening, and fatal skin reactions, including cases of SJS and 
TEN are listed events in the L ocal Country  Prescribing Information for the first marketed 
integrase inhibitor, RAL  [Isentress US Package Insert, April 2013; Isentress , EU 
Summary  of Product Characteristics, March 2013], and hy persensitivity  reactions have 
been reported with integrase inhibitors, including dolutegravir, and were characterized by  
[CONTACT_932], constitutional findings, and sometimes, organ dy sfunction, including liver injury . 
For additional information on rash associated with dolutegravir, please see the current 
version of the DTG IB[[COMPANY_004] Document Number RM2007/[ZIP_CODE]/ 11,[COMPANY_004] Document 
Number 2017N352880_00, [COMPANY_004] Document Number 2017N352880_01].
2013N161649_03 CONFIDENTIA L
ING117172
60SJS, ery thema multiforme, toxic skin eruptions and drug rash with eosinophilia and 
systemic s ymptoms (DRESS) sy ndrome have also been reported in patients receiving 
ATV [ ReyatazUS Package Insert, April 2013; Reyataz EU Summary  of Product 
Characteristics, September 2012].
The following guidance is provided for clinical manage ment of subjects who experience 
rash alone in the absence of accompan ying diagnosis of ABC HSR, sy stemic or allergic 
symptoms or signs of mucosal or target lesions.
Subjects with an isolated Grade 1 rash may  continue I P at the Investigator’s discretion. 
The subject should be advised to contact [CONTACT_8968] y if there is an y 
worsening of the rash, if any  systemic signs or s ymptoms worsen, or if mucosal 
involvement develops.
Subjects may  continue IP for an isolated Grade 2 rash. However, IP (and all other 
concurrent medication(s) suspected in the Investigators causalit y assessment) should be 
permanentl y discontinued for an y Grade ≥2 rash that is associated with an increase in 
ALT  (see Section [IP_ADDRESS] ).The subject should be advised to contact [CONTACT_895662] (after more than two weeks), if there is any  worsening 
of the rash, if an y systemic signs or allergic s ymptoms develop, or if mucosal 
involvement develops.
Subject s should permanently  discontinue IP (and all other concurrent medication(s) 
suspected in the Investigators causalit y assessment) for an isolated Grade [ADDRESS_1255728] should be withdrawn from the study . Subjects should be treated as clinically
appropriate and followed until resolution of the AE.
The rash and an y associated sy mptoms should be reported as adverse events (see 
Section 6.4.5 ) and appropriate toxicity  ratings should be used to grade the ev ents (see 
Appendix 2, Section 11.2).
If the etiology  of the rash can be definitely  diagnosed as being unrelated to IP and due to 
a specific medical event or a concomitant non -study  medication, routine mana gement 
should be performed and documentation of the diagnosis provided.
6.4.5. Adverse Events
The investigator or site staff will be responsible for detecting, documenting and reporting 
events that meet the definition of an AE or SAE.
[IP_ADDRESS]. Definition of an AE
Any unto ward medical occurrence in a patient or clinical investigation subject, 
temporally  associated with the use of a medicinal product, whether or not considered 
related to the medicinal product.
Note: An AE can therefore be an y unfavorable and unintended sign (including an 
abnormal laboratory  finding), s ymptom, or disease (new or exacerbated) temporally  
2013N161649_03 CONFIDENTIA L
ING117172
61associated with the use of a medicinal product.  For marketed medicinal products, this 
also includes failure to produce expected benefits (i.e., lack of efficac y), abuse or misuse.
Events meeting the definition of an AE include:
Exacerbation of a chronic or intermittent pre-existing condition including either an 
increase in frequency  and/or intensity  of the condition
New conditions detected or diagnosed after stu dy treatment administration even 
though it may  have been present prior to the start of the study
Signs, sy mptoms, or the clinical sequelae of a suspected interaction
Signs, sy mptoms, or the clinical sequelae of a suspected overdose of either study  
treatment or a concomitant medication (overdose per se will not be reported as an 
AE/SAE) unless this is an intentional overdose taken with possible suicidal/self -
harming intent.  This should be reported regardless of sequelae.
“Lack of efficacy ” or “failure of ex pected pharmacological action” per se will not be 
reported as an AE or SAE. However, the signs and sy mptoms and/or clinical sequelae 
resulting from lack of efficacy  will be reported if they  fulfil the definition of an AE or 
SAE.  
Events that do not meet t he definition of an AE include:
Medical or surgical procedure (e.g., endoscop y, appendectom y); the condition that 
leads to the procedure is an AE
Situations where an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospit al)
Anticipated day -to-day fluctuations of pre -existing disease(s) or condition(s) present 
or detected at the start of the study that do not worsen
The disease/disorder being studied, or expected progression, signs, or s ymptoms of 
the disease/disorder bein g studied, unless more severe than expected for the subject’s 
condition
[IP_ADDRESS]. Definition of an SA E
A serious adverse event is any  untoward medical occurrence that, at any  dose:
Results in death
Is life -threatening
NOTE:  The term 'life -threatening' in the defini tion of 'serious' refers to an event in 
which the subject was at risk of death at the time of the event.  It does not refer to an 
event, which h ypothetically  might have caused death, if it were more severe.
Requires hospi[INVESTIGATOR_23916]:  In general, hospi[INVESTIGATOR_5184] 
(usually  involving at least an overnight stay ) at the hospi[INVESTIGATOR_597090] 
2013N161649_03 CONFIDENTIA L
ING117172
62observation and/or treatment that would not have been appropriate in th e phy sician’s 
office or out -patient setting.  Complications that occur during hospi[INVESTIGATOR_23918].  If a complication prolongs hospi[INVESTIGATOR_23919], 
the event is serious.  When in doubt as to whether “hospi[INVESTIGATOR_059]” occurred or was 
necessary , the AE should be considered serious.
Hospi[INVESTIGATOR_5187] a pre-existing condition that did not worsen 
from baseline is not considered an AE.
Results in disability /incapacity , or
NOTE:  The term disability  means a substantial disruption of a person’s ability  to 
conduct normal life functions.  This definition is not intended to include experiences 
of relativel y minor medical significance such as uncomplicated headache, nausea, 
vomiting, diarrhea, influenza, and accidental trauma (e.g. sprained ankle) which may  
interfere or prevent everyday  life functions but do not constitute a substantial 
disruption.
Is a congenital anomal y/birth defect
Medical or scientific judgment should be exercised in deciding whether repo rting is 
appropriate in other situations, such as important medical events that may  not be 
immediately  life-threatening or result in death or hospi[INVESTIGATOR_895636] t he other 
outcomes listed in the above definition.  These should also be considered serious.  
Examples of such events are invasive or malignant cancers, intensive treatment in an 
emergency  room or at home for allergic bronchospasm, blood dy scrasias or convulsions 
that do not result in hospi[INVESTIGATOR_059], or development of drug dependency  or drug abuse.
All events of possible drug -induced liver injury  with hy perbilirubinaemia defined as ALT 
3xUL N andbilirubin 2xULN (>35% direct) (or ALT  3xUL N and INR>1.5, if INR 
measured) termed ‘Hy ’s Law’ events (INR measurement is not required and the threshold 
value stated will not apply to patients receiving anticoagulants).
NOTE: bilirubin fractionation is performed if testing is available. If testing is 
unavailable, record presence of detectable urinary  bilirubin on dipstick indicating 
direct bilirubin elevations and suggesting liver injury . If testing is unavailable and a 
subject meets the criterion of total bilirubin 2xULN, then the event is still reported 
as an S AE. If INR is obtained, include values on the SAE form. INR elevations >1.[ADDRESS_1255729] results (hematology , clinical chemistry , or urinaly sis) or 
other safet y assessments (e.g., ECG, radiological scans, vital signs measurements), 
including those that worsen from Baseline, and felt to be clinically  significant in the 
medical and scientific judgment of the investigator are to be recor ded as AEs or SAEs. 
However, an y clinicall y significant safet y assessments that are associated with the 
underly ing disease, unless judged by  [CONTACT_23996]’s condition, are notto be reported as AEs or SAEs .
2013N161649_03 CONFIDENTIA L
ING117172
63It is important to note that grading for laboratory  abnormalities (See Section 11.2) is an 
objective assessment conducted at the central laboratory  and does not translate directl y 
into similarly  graded AEs.
6.4.7. Cardiovascular Eve nts
Investigators will be required to fill out event specific data collection tools for the 
following AEs and SAEs:  
Myocardial infarction/unstable angina
Congestive heart failure
Arrh ythmias
Valvulopathy
Pulmonary  hypertension
Cerebrovascular events/stro ke and transient ischemic attack
Peripheral arterial thrombosis
Deep Venous Thrombosis
Revascularisation
This information should be recorded within one week of when the AE/SAE(s) are first 
reported.
6.4.8. Death Events
In addition, all deaths will require a speci fic death data collection tool to be completed.  
The death data collection tool includes questions regarding cardiovascular (including 
sudden cardiac death) and noncardiovascular death.
This information should be recorded within one week of when the death is first reported.
6.4.9. Disease -Related Events and/or Disease -Related Outcomes Not 
Qualify ing as SA Es
The events or outcomes listed in the CDC Classification Sy stem for HIV- 1 Infections 
(Appendix 1 , Section 11.1 [CDC , 1993]) will be recorded on the HIV Associated 
Conditions CRF page if they  occur.  However, these individual events or outcomes, as 
well as an y sign, s ymptom, diagnosis, illness, and/or clinical labora tory abnormality  that 
can be linked to an y of these events or outcomes are not reported to [COMPANY_004] as AEs and 
SAEs even though such event or outcome may  meet the definition of an AE or SAE, 
unless the following conditions apply :
the Investigator determines tha t the event or outcome qualifies as an SAE under part 
‘f’ of the SAE definition (see Section [IP_ADDRESS] ), or
2013N161649_03 CONFIDENTIA L
ING117172
64the event or outcome is in the I nvestigator’s opi[INVESTIGATOR_103650] , frequency  
or duration than ex pected for the individual subject, or
death occurring for an y reason during a stud y, including death due to a disease -
related event, will alway s be reported promptly .
Lym phomas and invasive cervical carcinomas are excluded from this exemption; they  
must be reported as SAEs even if they are considered to be HIV related.
6.4.10. Suicidality  Monitoring
Patients with HI V infection may  occasionall y present with sy mptoms of depression 
and/or suicidality  (suicidal ideation or behavior). Therefore, it is appropriate to mon itor 
subjects for suicidality  before and during treatment. I t is recommended that the 
Investigator consider mental health consultation or referral for subjects who experience 
signs of suicidal ideation or behavior.
Treatment emergent assessment of suicidal ity will be monitored during this study  using 
the Columbia Suicide Severity  Rating Scale (C -SSRS). The definitions of behavioral 
suicidal events used in this scale are based on those used in the Columbia Suicide History  
Form [ Oquendo , 2003]. Questions are asked on suicidal behavior, suicidal ideation and 
intensity  of ideation. Day 1 (Baseline) visit questions will be in relation to lifetime 
experiences and current experiences (within the past 2 months) and all subsequ ent 
questioning in relation to the last assessment. The C- SSRS is to be administered using an 
interactive voice response sy stem at the time -points specified in Section 6.1.
Additionally , the investigator will co llect information using the Possible Suicidality -
Related AE (PSRAE) eCRF form in addition to the AE (Non -serious or SAE) eCRF form 
on any  subject that experiences a possible suicidality -related adverse event while 
participating in this study. This may  include, but is not limited to, an event that involves 
suicidal ideation, a preparatory  act toward imminent suicidal behavior, a suicide attempt, 
or a completed suicide.  The investigator will exercise his or her medical and scientific 
judgment in deciding whe ther an event is possibly suicide -related.  PSRAE forms should 
be completed and reported to [COMPANY_004] within one week of the investigator diagnosing a 
possible suicidality -related adverse event.
6.4.11. Pregnancy
[IP_ADDRESS]. Pregnancy  Testing
Women of childbearing potential must ha ve a negative pregnancy  test at Screening and 
Day 1 to be eligible for administration of I P.  Pregnancy  testing will also be conducted as 
per the Time and Events Table (See Section 6.1) and at an ytime during the trial when 
pregnancy  is suspected.
Additionally , a pregnancy  test should also be performed prior to IP re -administration, 
when administration is disrupted for more than 7 day s (e.g. temporary interruption of I P).
2013N161649_03 CONFIDENTIA L
ING117172
[IP_ADDRESS]. Action to be Taken if Pregnancy  Occurs
Any female who becomes pregnant (intrauterine) while participating in this study  must be 
withdrawn from the study and discontinue I P.
Any pregnancy  that occurs during stud y participation must be reported using a clinical 
trial pregnancy  form.  To ensure subje ct safet y, each pregnancy  must be reported to [COMPANY_004] 
within [ADDRESS_1255730] be followed up to 
determine outcome (including premature termination) and status of mother and child.  
Pregnancy  complications and elective terminations for medical reasons must be reported 
as an AE or SAE.  Spontaneous abortions must be reported as an SAE.
Any SAE occurring in association with a pregnancy , brought to the investigator’s 
attention after the subject has completed the stud y and c onsidered by  [CONTACT_895663], must be promptly  reported to [COMPANY_004].
[COMPANY_004]’s central safet y department will also forward this information to the Antiretroviral 
Pregnancy  Registry . The international registry  is jointly  sponsored by  [CONTACT_339288]. Additional information and a list of participating 
manufacturers/licensees are available from http://apregistry .com/index.htm.
[IP_ADDRESS]. Time Period for Collecting Pregnancy  Information
Information on the occurrence of pregnancies in female subjects will be collected over 
the period starting at Screening and ending at the final on- study  or Follow -up visit. Only  
those pregnancies that occur following the first dose of IP will be reported to [COMPANY_004]. 
Follow -up information will only  be collected for pregnancies occurring from Day  [ADDRESS_1255731].  
SAEs will be collected over the same time period as stated above for AEs. However, any  
SAEs assessed as related to study  participation (e.g., study  treatment, protocol -mandated 
procedures, invasive tests, or change in existing therap y) or related to a [COMPANY_004] concomitant 
medication, will be recorded from the time a subject consents to participate in the study  
up to and inc luding an y f ollow up contact. All SAEs will be reported to [COMPANY_004] within [ADDRESS_1255732] be taken not to introduce bias when detecting AEs and/o r SAEs. Open -ended 
and non-leading verbal questioning of the subject is the preferred method to inquire about 
AE occurrence. Appropriate questions include:
2013N161649_03 CONFIDENTIA L
ING117172
66“How are you feeling?” 
“Have you had an y (other) medical problems since y our last visit/contact?”
“Have you taken an y new medicines, other than those provided in this study , since your 
last visit/contact?”
6.4.14. Prompt Reporting of Serious A dverse Events and Other Events 
to [COMPANY_004]
SAEs, pregnancies, and liver function abnormalities meeting pre- defined criteria w ill be 
reported promptl y by  [CONTACT_895664] 5and Table 6once 
the investigator determines that the event meets the protocol definition for th at event.
Table 5 Events and Reporting Time Periods for SA Es
Initial Reports Follow -up Information on a 
Previous Report
Type of Event Time Frame Documents Time Frame Documents
All SAEs 24 hours SAE data collection 
tool24 hours Updated SAE data 
collection tool 
ALT≥3xULN plus 
Bilirubin ≥2xULN (35% 
direct)24 hours1 SAE data collection 
tool Liver Event 
CRF and liver 
imaging and/or 
biopsy CRFs if 
applicable 24 hours Updated SAE data 
collection tool 
Updated Liver Event 
CRF2
2013N161649_03 CONFIDENTIA L
ING117172
67Table 6 Other E vents Requiring Prompt Reporting
Initial Reports Follow -up Information on a 
Previous Report
Type of Event Time Frame Documents Time Frame Documents
Pregnancy 2 Weeks Pregnancy 
Notification Form 2 Weeks Pregnancy Follow 
up Form 
Suspected ABC HSR 1Week ABC HSR CRF3 1 Week Updated ABC HSR 
CRF3
ALT≥5xULN that 
persists ≥2 weeks 24 hours1 Liver Event CRF2 24 hours Updated Liver Event 
CRF2
ALT ≥8xULN 24 hours1 Liver Event CRF2 24 hours Updated Liver Event 
CRF2
ALT ≥3xULN or ALT ≥[ADDRESS_1255733] safety
2. Liver Event Documents (i.e., “Liver Event CRF” and “ Liver Imaging CRF” and/or “Liver Biopsy CRF”, as 
applicable) should be completed as soon as possible.
3. ABC HSR CRF required only if event meets one of the ICH- E2A definitions of seriousness’.
The method of recording, evaluating and follow -up of AEs and SAE s plus procedures for 
completing and transmitting SAE reports to [COMPANY_004] are provided in the SPM.  Procedures 
for post -study  AEs/SAEs are provided in the SPM.
Procedures for documenting, transmitting and follow -up of medical device incidents 
along with the regulatory reporting requirements for medical devices are provided in the 
SPM.
[IP_ADDRESS]. Regulatory  Reporting Requirements for SA Es
Prompt notification of SAEs by  [CONTACT_895665].
[COMPANY_004] has a legal responsibility  to notify  both the local regulatory  authorit y and other 
regulatory  agencies about the safet y of a product under clinical investigation.  [COMPANY_004] will 
comply  with country  specific regulatory  requirements relating to safet y reporting to the 
regulatory  authorit y, IRB/ I EC and investigators.
Investigator safety  reports are prepared for suspected unexpected serious adverse 
reactions according to local regulatory  requirements and [COMPANY_004] policy  and are forwarded 
toinvestigators as necessary .
2013N161649_03 CONFIDENTIA L
ING117172
68An investigator who receives an investigator safety report describing a SAE(s) or other 
specific safet y information (e.g., summary or listing of SAEs) from [COMPANY_004] will file it with 
the IB and will notify  the I RB/IEC, if appropriat e according to local requirements.
6.4.15. Other Safety  Outcomes
Laboratory  Assessments
All protocol required laboratory  assessments, as defined in [ Table 4], must be performed 
by [CONTACT_2237] , Quest Diagnostics. Laboratory  assessments must be conducted 
in accordance with the Central Laboratory  Manual and Protocol Time and Events Table.
Laboratory  requisition forms must be completed and samples must be clearly  labeled 
with the subject number, protocol number, site/centre number, and visit date. Details for 
the preparation and shipment of samples will be provided b y Quest Diagnostics.
Reference ranges for all safet y parameters will be provided to the site by [CONTACT_895666].
If additional non -protocol specifie d laboratory  assessments are performed at the 
institution’s local laboratory  and result in a change in patient management or are 
considered clinically  significant by  [CONTACT_093] (e.g., SAE or AE or dose 
modification) the results must be recorded in the subject’s CRF. Refer to the SPM for 
appropriate processing and handling of samples to avoid duplicate and/or additional 
blood draws.
6.5. Health Outcomes
Health outcomes assessments will be conducted in all countries according the schedule in 
the Time and Events Table (Section 6.1).  Assessments are recommended to be 
administered at the beginning of the visit.
Health Related Quality  of L ife (HRQoL) will be assessed by  [CONTACT_20763] -12 (12 -Item Short 
Form Health Survey ) which was derived from the 36 -Item Short Form Health Survey  
(SF-36) and has been shown to provide adequate mental component summary  (MCS) and 
well as ph ysical component summary  (PCS) scores [ Ware , 1996]. The SF -12 has been 
studied in the HIV population and can discriminate between patients b y HIV disease 
severit y as measured b y CD4+ cell count and HIV -1 viral load.  The SF -12 will be 
administered as a paper questionnaire.
HIV TSQ: The HIV treatment satisfaction questionnaire (status version) [ Woodcoc k , 
2001; Woodcock , 2006] is a 10- item self -reported scale that measures overall satisfaction 
with treatment and b y specific domains e.g. convenience, f lexibility . The HIVTSQ will 
be administered as a paper questionnaire.  
6.5.1. Health Outcomes Endpoints
Change from Baseline in health related quality  of life using SF- 12 at Week 48.
2 0 1 3 N 1 6 1 6 4 9 _ 0 3 C O N FI D E N TI A L
I N G 1 1 7 1 7 2 
6 9 Treat me nt satisfacti o n f or s u bjects treate d wit h D T G/ A B C/ 3 T C F D C o nce dail y  a n d 
t h ose treate d wit h A T V + R T V + T D F/ F T C F D C o nce dail y at wee ks 4, 1 2, 2 4, a n d 4 8 
( or wit h dra wal fr o m t he st u d y ). 
6. 6. Vir al G e n ot y pi n g a n d P h e n ot y pi n g 
W h ole ve n o us bl o o d sa m ples will be o btai ne d fr o m eac h s u bject t o pr o vi de ‘ plas ma f or 
st ora ge sa m ples’ acc or di n g t o t he Ti me a n d E ve nts Sc he d ule i n Secti o n 6. 1 (f or p ote ntial 
viral ge n ot y pic a n d p he n ot y pic a nal ys es (‘ Plas ma f or st ora ge’ sa m ples). 
Details c o ncer ni n g t he ha n dli n g, la beli n g a n d s hi p pi n g of t hese sa m ples will be s u p plie d 
se paratel y . Ge n ot y pic a n d p he n ot y pic a nal ys es ma y  be carrie d o ut b y  M o n o gra m 
Bi oscie nces usi n g, b ut n ot li mite d t o, t heir Sta n dar d P he n ose nse a n d Ge n o S ure testi n g 
met h o ds f or pr otease ( P R O) a n d re verse tra nscri ptase ( R T) a n d I nte grase assa ys. 
For Scree ni n g vir ol o gic e val uati o ns, o nl y  viral ge n ot y pe will be a nal yz e d a n d t his will be 
perf or me d t hr o u g h Q uest Dia g n ostics. 
6. 6. 1. Vir ol o g y  E n d p oi nt s 
I n ci de nce of treat me nt -e mer ge nt ge n ot y pic a n d p he n ot y pic resista nce i n s u bjects 
w h o meet c o nfir me d vir ol o gic w it h dra wal criteria .
6. 6. 2. HI V- 1 P ol y m er a s e Vir al G e n ot y pi n g a n d P h e n ot y pi n g 
At Scree ni n g, sa m ples will be c ollecte d f or HI V -1 p ol y merase ( p ol) ge n ot y pe usi n g a 
Q uest Dia g n ostics ge n ot y pe assa y  a n d res ults will be pr o vi de d t o t he I n vesti gat or t o assist 
i n t he det er mi nati o n of s u bject eli gi bilit y  ( Secti o n 4. 3 ). 
S u bjects meeti n g ‘c o nfir me d vir ol o gic wit h dra wal criteri o n’ will ha ve plas ma sa m ples 
teste d f or HI V- 1 P R O a n d R T ge n ot y pe a n d p he n ot y pe a n d HI V -1 i nte grase ge n ot ype 
a n d p he n ot y pe fr o m b ot h Baseli ne sa m ples a n d fr o m sa m ples c ollecte d at t he ti me of 
meeti n g ‘s us pecte d vir ol o gic wit h dra wal criteri o n’ (a d diti o nal s u bse q ue nt sa m ples ma y  
be a nal yz e d); t hese res ults will be re p orte d t o t he I n vesti gat or as s o o n as a vaila bl e t o 
pr o vi de g ui da nce f or electi o n of a n alter nati ve re gi me n. 
C CI 
2013N161649_03 CONFIDENTIA L
ING117172
706.7. Pharmacogenetic Research
Inf ormation regarding PGx research is included in Appen dix 3(Section 11.3).  
TheIEC/I RB and, where required, the applicable regulatory  agency must approve the 
PGx assessments before these can be conducted at the site. The approval(s) must be in 
writing and will clearl y specify  approval of the PGx assessments (i.e., approval of 
Appen dix 3, Section 11.3).  In some cases, approval of the PGx assessments can occur 
after approval is obtained for the rest of the study . If so, then the written approval will 
clearl y indicate approval of the PGx assessments is being deferred and the study , except 
for PGx assessments, can be initiated. When PGx assessments will not be approved, then 
the approval for the rest of the study  will clearl y indicate this and therefore, PGx 
assessments will not be conducted.
7. DATA MANAG EMENT
For this study , subject data will be entered into [COMPANY_004] defined eCRFs, transmitted 
electronically  to [COMPANY_004] or designee and combined with data provided from other sources in 
a validated data s ystem.  
Management of clinical data will be performed in accordance with applicable [COMPANY_004] 
standards and dat a cleaning procedures to ensure the integrity of the data, e.g., removing 
errors and inconsistencies in the data.  Adverse events and concomitant medications 
terms will be coded using MedDRA and an internal validated medication dictionary , 
[COMPANY_004]Drug.  eCRFs (including queries and audit trails) will be retained b y [COMPANY_004], and 
copi[INVESTIGATOR_339182] y.  In all cases, 
subject initials will not be collected or transmitted to [COMPANY_004] according to [COMPANY_004] policy .
8. DATA ANALYSIS AND STA TISTICAL C ONSIDERA TIONS
8.1. Hypotheses
This study  is designed to show that the antiviral effect of the DTG/ABC/3TC FDC 
administered once daily  is non -inferior to once daily  ATV+RTV+TDF/FTC FDC. 
Non-inferiorit y can be concluded if the lower bound of a two -sided 95% confidence 
interval for the difference in response rates between the two treatment arms is greater 
than - 12%. If r d is the response rate on DTG/ABC/3TC FDC and r a is the response rate on 
ATV+RTV+TDF/FTC FDC then the hy potheses can be writte n as follows:
H0: r d– ra≤ -12% H1: r d– ra> -12%.
2013N161649_03 CONFIDENTIA L
ING117172
718.2. Stud y Design Considerations
8.2.1. Sample Size A ssumptions
Rationale for non -inferiority  margin
A non- inferiorit y  margin is set as 12% in this study. The rationale is shown in Table 7. 
The endpoint for the primary comparison is response rate, i.e. the proportion of subjects 
with plasma HIV -1 RNA below 50 c/mL  at Week 48. Table 7 shows the response rates 
from studies of dual -NRT I therapy  and dual -NRTI + third agent therapy . Though time 
points are different among the studies, the differences of response rates between dual -
NRTI  therapy  and dual -NRTI  + third agent are similar. These differences in response 
rates range from 34% to 49 % and all of the lower bounds of 95% confidence interval are 
no less than 0%, which shows that the additional effect of third agent therapy  in each 
study  is statistically  significant. Moreover, the pooled difference (the 95% confidence 
interval) of these r esponse rates is 39% (33%, 45%). A non- inferiorit y margin of 12% is 
small enough compared to the additional effect of third agent therap y, because the non -
inferiority  margin is much less than the half of the lower bound of 95% confidence 
interval for the p ooled difference.
Also the non- inferiorit y margin of 12% is in the mid -range of the margins described in a 
review of non -inferiority  trials in HIV conducted between 2000 and 2007, where the 
margins vary  between 10% and 15 % [Hill, 2008 ].This suggests further that a non-
inferiority  margin of 12% is reasonable.
Table 7 The proportion of subjects with plasma HIV -1 RNA  below 50 c/ml of 
dual-NRTI therapy and dual NRTI + third agent therapy
Study 
NumberN Endpoint Timepoi nt Dual -NRTI
TherapyDual -NRTI
Therapy + Third AgentDifferencea
(95% CI)
Response Rate Response Rate
PROAB3001 232 <50 c/ml Week 48 ZDV+3TC
1%(1/116)ZDV+3TC+APV
34%(40/116)34%
(20.7%,
45.7%)
CNAAB3003 173 <50 c/ml Week 48 ZDV+3TC
3%(3/86)ZDV+3T C+ABC
44%(38/87)40%
(26.2%,
53.3%)
AVANTI -2 103 <50 c/ml Week 52 ZDV+3TC(n=51)
6%ZDV+3TC+IDV(n=52)
48%42%
(24.2%,
58.8%)
AVANTI -3 105 <50 c/ml Week 28 ZDV+3TC(n=52)
10%ZDV+3TC+NFV(n=53)
58%49%
(31.7%,
64.7%)
a. Defined as the difference of response rate calculated by (dual -NRTI + third agent) -(dual -NRTI therapy)
Response Rate assumptions
In previous DTG and ATV/RTV studies, response rates in women have consistently  been 
lower than those seen in men. Results of DTG studies can be found in the most current 
version of the IB.
2013N161649_03 CONFIDENTIA L
ING117172
72In the SINGLE stud y (IN G114467) comparing DTG+ABC/3TC once dail y to Atripla 
once dail y in treatment naive subjects, the overall response rate <50 c/ml (ITT -E, 
Snapshot) at Week 48 for the DTG arm was 88% (364/414) with a 85% (57/67) response 
rate in women compared to 88% (307/347) in men. I n the SPRING -2 study  (ING113086) 
comparing DTG once daily  to RAL BID both in combination with a fixed dose dual 
NRTI  treatment, the overall response rate <50 c/ml (I TT-E, Snapshot) at Week 48 for the 
DTG arm was 88% (361/411) with a 84% (53/63) response rate in women compared to 
89% (308/348) in men. 
In the CASTLE stud y [Molina , 2008] comparing ATV+RTV+FTC once daily  to 
LPV/RTV +FTC once daily  in treatment naiv e subjects, the overall response rate <50c/ml 
(ITT, non completers = failure) was 78% (343/440) at Week 48 in the ATV/RTV arm. 
Gender differences in response rates were published for the Week 96 anal ysis [ Squires , 
2011 ] where the overall response rate <50 c/ml (ITT, non completers=failure) was 74% 
(327/440) with a 67% (93/138) response rate in women compared to 77% (234/302) in 
men. 
A recent study  [DeJesus , 2012] comparing ATV+RTV+FTC/TDF to Stribild 
(ELV/COBI/TDF/FTC) in HIV -1 infected ART naive subjects reported an overall 
response rate of 87% (308/355) <50 c/ml (ITT, Snapshot). The corresponding response 
rate in women was 82% (32/39) compared to 87% (276/316) in men. However, with so
few subjects included in the study , the estimate of the response rate in women is not 
robust. 
The response rates for the four studies are shown together in Table 8.
Table 8 The proportion of subjects with plasma HIV -1 RNA  below 50 c/ml
DTG Response Rates ATV/RTV Response Rates
SINGLEa
Week 48SPRING -2a
Week 48CASTLEb
Week 48CASTLEb
Week 96DeJesusa
Week 48
All 88% 80% 78% 74% 87%
Men 88% 89% - 77% 87%
Women 85% 84% - 67% 82%
a –ITT-E Snapshot 
b –ITT, non completers=failure
The discontinuation rates observed in women across HIV studies are higher than those 
observed in men and vary between studies. With a Snapshot anal ysis, subjects who 
discontinue from the study are considere d to be non- responders at subsequent visits and 
as such can have a substantial impact on the response rates observed. 
The overall discontinuation rates for women compared with men were 23% (30/130) 
versus 15% (105/703), and 18% (22/119) versus 11% (81/703 ) in the Week 48 anal yses 
from SINGLE and SPRING -2 studies, respectively . In the Week 48 anal ysis of the 
CASTL E study , the overall discontinuation rate was 12% (53/440). The gender 
2013N161649_03 CONFIDENTIA L
ING117172
73differences published for the Week 96 anal ysis show a higher rate in women of 22% 
(31/138) compared to 15% (45/302) in men. One of the few studies specifically designed 
to look at the outcomes by [CONTACT_547], the GRACE study  [Currier , 2010 ] using 
darunavir+RTV, reported a discontinuation rate of 33% (94/287) in women compared to 
23% (33/142) in men. However, it should be noted that this study  was in treatment -
experienced patients. The number of female subjects in these studies, with the exception 
of the GRACE study , was relativel y small and as such the estimates of response rates will 
not be as robust as those overall or for men. There has also been a wide range of 
discontinuation rates observed with a clear signal that the rates in women are higher than 
in men. I t may  be possible to reduce the number of avoidable discontinuations through 
careful and well thought out study  design and management but it is likely  that a higher 
rate of discontinuation will be seen in this study  than in previous mixed gender DTG 
studies.
The discontinuation rates for the se four studies are shown together in Table 9.
Table 9 Premature Discontinuation Rates
DTG Discontinuation Rates ATV/RTV Discontinuation Rates
SINGLE
Week 48SPRING -2
Week 48CASTLE 
Week 48CASTLE
Week 96GRACE
Week 48
All 16% 13% 12% 17% 30%
Men 15% 11% - 15% 23%
Women 23% 18% - 22% 33%
The primary  efficacy  endpoint will be the proportion of subjects achieving <50 c/ml in 
HIV-1 RNA at Week 48 using a Snapshot analy sis and an ITT -E population. Therefore, 
assuming an 80% response rate in both arms with a 12 % non -inferiority  margin and a 
2.5% level of significance, a sample size of 237 subjects per arm would provide 90% 
power.
8.2.2. Sample Size Sensitivity
Table [ADDRESS_1255734] 85% 
power if the assumptions of 80% response rate per arm vary  as indica ted.
2013N161649_03 CONFIDENTIA L
ING117172
74Table 10 Calculation of sample size and po wer based on assumptions for 
response rates
Week 48 Response Rate 
DTG vs. ATVSample Size per arm
(based on 90% power)Power
(based on 237 subjects per 
arm)
85% vs. 85% 194 95%
80% vs. 75% 129 99%
80% vs. 80% 237 90%
75% vs. 70% 146 99%
75% vs. 75% 275 85%
8.2.3. Sample Size Re -estimation
No sample size re -estimation is planned for this study .
8.3. Data Analysis Considerations
8.3.1. Analysis Populations
The following populations will be assess ed (the analy sis population for genoty pic and 
phenoty pic anal yses as well as for health outcomes assessments will be fully  described in 
the reporting and anal ysis plan [RAP]).
Intent -to-Treat Exposed (ITT -E) Population
This population will consist of all r andomised subjects who receive at least one dose of 
study  medication. Subjects will be assessed according to their randomised treatment, 
regardless of the treatment they  receive. Unless stated otherwise, the ITT -E population 
will be used for summaries of e fficacy .
Safety  Population
The Safet y Population is defined as all subjects who receive at least one dose of IP. 
Subjects will be analy zed according to the actual treatments received.
Per-Protocol Population
This population will consist of subjects in the ITT-E population with the exception of 
major protocol violators: e.g. violations which could affect the assessment of antiviral 
activity . The per protocol (PP) population will be used for sensitivity  anal yses of the 
primary  efficacy  endpoint.
2013N161649_03 CONFIDENTIA L
ING117172
75ITT Populatio n
This population will consist of all randomized subjects. Subjects will be assessed 
according to their randomized treatment even if no study  treatment was taken or the 
wrong treatment was received.
8.3.2. Analysis Data Sets
For the primary  efficacy  anal ysis, eac h subjects responses (e.g. <50 c/mL) will be 
calculated according to the FDA’s Snapshot algorithm. This algorithm treats all subjects 
without HI V RNA data at the visit of interest (due to missing data or discontinuation of 
IP prior to visit window) as non-responders, as well as subjects who switch their 
concomitant ART prior to the visit of interest as follows in certain scenarios. However, 
since changes in ART are not permitted in this protocol, all such subjects who change 
ART will be considered non- respo nders. Otherwise, virologic success or failure will be 
determined b y the last available HIV -[ADDRESS_1255735] window (to be specified in the RAP). Full details on this 
Snapshot algorithm will be contained in the RAP.
The observed case (OC) dataset, which uses onl y data that is available at a particular 
timepoint with no imputation for missing values, will be the primary  dataset for assessing 
safet y and will also be used for some anal yses of effic acy and health outcomes.
A last observation carried forward (LOCF) dataset in which missing values will be 
carried forward from previous, non- missing available on treatment assessments will be 
used in the anal ysis of health outcomes data. Further details w ill be provided in the RAP.
8.3.3. Treatment Comparisons
[IP_ADDRESS]. Primary  Comparisons of Interest
The primary  anal ysis will be based on the ITT- E population using the Snapshot dataset. 
The primary  comparison will be made at a one -sided 2.5% level of significance. 
Treatmen t with DTG/ABC/3TC FDC will be declared non- inferior to treatment with 
ATV+RTV+TDF/FTC FDC if the lower end of a two- sided 95% confidence interval for 
the difference between the two groups in response rates at Week 48 lies above -12%.
[IP_ADDRESS]. Other Comparisons of Interest
The anal ysis described above will also be performed using the PP population and the 
results will be compared for consistency  with the results from the ITT- E population. I f 
both analy ses show non -inferiorit y then the h ypothesis that the antiviral e ffect of 
treatment with DTG/ABC/3TC FDC is superior to treatment with ATV+RTV+TDF/FTC 
FDC will also be tested in the ITT- E population at the two -sided 5% level of significance. 
Superiority  will be declared if the lower end of the 95% confidence interval ca lculated in 
the ITT -E anal ysis is above 0%.  The primary  comparison will also be performed using 
the ITT population and will be compared for consistency  with the results from the I TT-E 
and PP populations.
2013N161649_03 CONFIDENTIA L
ING117172
768.3.4. Interim A nalysis
The main anal ysis will be conducte d to evaluate the primary  objective of the protocol 
when all subjects have completed their Week [ADDRESS_1255736] 
and anal ysis of the study  will not review any  summaries of data grouped by  [CONTACT_895667] 48 anal ysis.
[IP_ADDRESS]. Efficacy  Analyses
For the primary  comparison, adjusted estimates of the difference in the rate of responders 
between the two arms will be presented along with CI s based on a stratified anal ysis 
using Cochran -Mantel -Haenszel (CMH) weights. All CI s will be two- sided. For the 
statistical analy sis, four strata (subgroups) will be formed according to the combinations 
of levels of the following categorical variables: Baseline plasma HIV -1 RNA 
(≤vs.>100,000 c/ml) and Baseline CD4+ cell count (≤ vs. >350 cells/mm3).
The CMH estimate of the common difference in rates across strata will be calculated as 
the weighted average of the strata-specific estimates of the difference in response rates 
between the two arms as follows:
• If nk is the number of DTG/ABC/3TC FDC treated subjects, mk is the number 
of ATV+RTV+TDF/FTC FDC treated subjects, and Nk = nk + mk is the total 
number of subjects in the kth stratum, then the CMH estimate is given b y

kk k
cmh
Wd W
dˆ
ˆ
where
kk k
kNm nW
are CMH weights and kdˆ
are estimates of the differences in response rates 
between the t wo treatment arms, r d-ra, for the k th strata. 
The corresponding two -sided 95% CI will be calculated as
)ˆr(aˆv 96. 1ˆcmh cmh d d  
2013N161649_03 CONFIDENTIA L
ING117172
77using the variance estimator )ˆr(aˆvcmhd, given b y [Sato, 1989], which is consistent in both 
sparse data and large strata.  The full equation for this variance estimate is provided in the 
RAP.
The weighted least squares chi- squared statistic [ Fleiss , 1981] will be used to test for one -
way homogeneit y across the levels of each categorical variable, with each categorical 
variable considered separately . Following Lui and Kelly  [Lui, 2000], ½ will be added to 
each cell in an y strata for which the stratum- specific rate estimates of either r dor r aare 
zero, and tests will be one- sided. Full details will be contained in the RAP. Any  
heterogeneity  found to be statistically  significant will be explored and if necessary  results 
will be reported for each level of the categorical variable. Investigation of hetero geneity  
will be confined to the primary  endpoint using the Week 48 Snapshot analysis. Tests of 
homogeneity  will be assessed at the one -sided 10% level of significance.
Secondary  anal yses of plasma HIV -1 RNA and CD4+ cell count will be analy zed over 
time using the OC anal ysis dataset. The proportion of subjects with HIV -1 RNA below 
50/400 copi[INVESTIGATOR_014]/ml over time will be presented using both the Snapshot and OC datasets. 
The incidence of HIV -1 disease progression (AIDS and death) will be presented.  Further 
detai ls of secondary  efficacy  analy ses will be included in the RAP.
Data gathered after subjects withdraw from IP will be listed but will not be included in 
summary  tables. Data will be allocated to visit windows using actual visit dates rather 
than nominal visit numbers. Data collected from extra visits within a window will be 
listed and will be included in the derivation of the Snapshot response at analy sis visits of 
interest, but summary  tables using OC datasets will only  use the data captured closest to 
the target visit date. Detailed explanations of the derivation of visit windows will be 
included in the RAP. Any deviations from planned anal yses will be detailed in the 
clinical study  report (CSR).
[IP_ADDRESS]. Safety  Analyses
Exposure to study medication, measured by  [CONTACT_895668], will be 
summarized by  [CONTACT_1570]. The proportion of subjects reporting AEs will be 
tabulated for each treatment group. The following summaries of AEs will be provided:
Incidence and severit y of all AEs
Incidence and sev erity of treatment related AEs
Incidence and severit y of AEs leading to withdrawal
Incidence of SAEs
Laboratory  and vital signs data will be summarized by  [CONTACT_3232]. In 
addition, the number and percentage of subjects with graded laboratory  toxicities (based 
on DAIDS categories) will be summarized by  [CONTACT_1570]. The proportion of 
subjects experiencing changes from Baseline in their National Cholesterol Education 
Program (NCEP) lipid categories will be summarized by  [CONTACT_2939].
2013N161649_03 CONFIDENTIA L
ING117172
78Renal m arkers and bone markers will be summarized by  [CONTACT_895669].  Cardiovascular risk based on Framingham score will be summarized 
at Baseline based on an OC dataset. 
Further details of safet y analyses will be included in th e RAP.
[IP_ADDRESS]. Health Outcomes A nalyses
The SF -12 includes one scale measuring each of 8 health domains: phy sical functioning, 
role participation with phy sical health problems (role phy sical), bodily  pain, general 
health, vitality , social functioning, role partici pation with emotional health problems and 
mental health, with two factors for health status: one for ph ysical component summary  
(PCS) and mental component summary  (MCS).
Changes from Baseline in scores for PCS and the MCS will be compared between the 
two t reatment arms at each time point. Exploratory anal ysis will be done to assess which 
aspects of health are most impacted at the item level and health domain level.
The HIVTSQ was developed to evaluate treatments for HIV and patient satisfaction. The 
higher the score, the greater the improvement in treatment satisfaction as compared to the 
past few weeks. A smaller score represents a decline in treatment satisfaction compared 
to the past few weeks. 
The HIVTSQ items are summed up to produce a treatment satisf action score (0 to 60) 
and an individual satisfaction rating for each item (0 to 6) and two subscales: general 
satisfaction/clinical and lifesty le/ease subscales. These scores will be summarized and 
compared between the treatment groups in an exploratory  analysis at each time point.
[IP_ADDRESS]. Viral Genoty pi[INVESTIGATOR_007]/Phenoty pi[INVESTIGATOR_007] A nalyses
The incidence of treatment emergent genot ypic and phenoty pic resistance to NRTI s, 
protease inhibitors, and INI s will be summarized by  [CONTACT_2939]. Details of the 
analyses to be performed w ill be specified in the RAP.
[IP_ADDRESS]. Pharmacogenetic A nalyses
See Appen dix 3(Section 11.3) for details about the Pharmacogenetics Analysis Plan.
9. STUDY CONDUCT CONSID ERA TIONS
9.1. Posting of Information on Publicly  Available Clinical Trial 
Registers
Study  information from this protocol will be posted on publicly  available clinical trial 
registers before enrolment of subjects begins.
2013N161649_03 CONFIDENTIA L
ING117172
799.2. Regulatory  and Ethical Considerations, Including the 
Informed Consent Process
Prior to i nitiation of a study  site, [COMPANY_004] will obtain favorable opi[INVESTIGATOR_1649]/approval from the 
appropriate regulatory  agency  to conduct the study in accordance with I CH GCP and 
applicable country -specific regulatory  requirements.
The study  will be conducted in accordance with all applicable regulatory  requirements.
The study  will be conducted in accordance with ICH GCP, all applicable subject privacy  
requirements, and the ethical principles that are outlined in the Declaration of Helsinki 
2008, including, but not limited t o:
IRB/IEC review and favorable opi[INVESTIGATOR_1649]/approval of study  protocol and any 
subsequent amendments.
Subject informed consent.
Investigator reporting requirements.
[COMPANY_004] will provide full details of the above procedures, either verball y, in writing, or both.
Written informed consent must be obtained from each subject prior to participation in the 
study .
In approving the clinical protocol the IEC/I RB and, where required, the applicable 
regulatory  agency  are also approving the optional assessments e.g., PGx assess ments 
described in Appen dix 3, Section 11.3, unless otherwise indicated.  Where permitted by  
[CONTACT_10200], approval of the optional assessments can occur after approval is 
obtained for the rest o f the study .  If so, then the written approval will clearly  indicate 
approval of the optional assessments is being deferred and the study , except for the 
optional assessments, can be initiated.  When the optional assessments are not approved, 
then the appr oval for the rest of the study  will clearly  indicate this and therefore, the 
optional assessments will not be conducted.
9.3. Qualit y Control (Study  Monitoring)
In accordance with applicable regulations, GCP, and [COMPANY_004] procedures, [COMPANY_004] monitors 
will contact [CONTACT_23988], 
study  requirements, and their responsibilities to satisfy  regulatory , ethical, and [COMPANY_004] 
requirements.  When reviewing data collection procedures, the discussion will include 
identification, agreement and documentation of data items for which the CRF will serve 
as the source document.
[COMPANY_004] will monitor the study  to ensure that the:
Data are authentic, accurate, and complete.
Safety  and rights of subjects are being protected.
2013N161649_03 CONFIDENTIA L
ING117172
80Study  is conducted in accordance with the currently  approved protocol and any  other 
study  agreements, GCP, and all applicable regulatory  requirements.
The investigator and the head of the medical institution (where applicable) agrees to 
allow the monitor direct a ccess to all relevant documents.
9.4. Qualit y Assurance
To ensure compliance with GCP and all applicable regulatory  requirements, [COMPANY_004] may  
conduct a qualit y assurance assessment and/or audit of the site records, and the regulatory  
agencies may  conduct a regulato ry inspection at any  time during or after completion of 
the study . In the event of an assessment, audit or inspection, the investigator (and 
institution) must agree to grant the advisor(s), auditor(s) and inspector(s) direct access to 
all relevant documents and to allocate their time and the time of their staff to discuss the 
conduct of the stud y, an y findings/relevant issues and to implement any  corrective and/or 
preventative actions to address an y findings/issues identified.
9.5. Stud y and Site Closure
Unless terminated earl y, this study  will be considered com pleted after the last subject 
completes the last study -related clinic visit or assessment.  
Upon completion or termination of the study , the [COMPANY_004] monitor will conduct site closure 
activities with the investigator or site staff (as appropriate), in accordance with applicable 
regulations, GCP, and [COMPANY_004] Standard Operating Procedures.
[COMPANY_004] reserves the right to temporaril y suspend or terminate the stud y at an y time for 
reasons including (but not limited to) safet y issues, ethical issues, or severe non -
compliance.  If [COMPANY_004] determines that such action is required, [COMPANY_004] will discuss the 
reasons for taking such action with the investigator or head of the medical institution 
(where applicable).  When feasible, [COMPANY_004] will p rovide advance notice to the investigator 
or head of the medical institution of the impending action.
If a study is suspended or terminated for safety reasons, [COMPANY_004] will promptly inform all 
investigators, heads of the medical institutions (where applicable) ,and/or institutions 
conducting the study .  [COMPANY_004] will also promptly  inform the relevant regulatory  authorities 
of the suspension/termination along with the reasons for such action.  Where required b y 
applicable regulations, the investigator or head of the medical institution must inform the 
IRB/IEC promptly  and provide the reason(s) for the suspension/termination.
9.6. Records Retention
Following closure of the study , the investigator or head of the medical institution (where 
applicable) must maintain all site study  records (except for those required by  [CONTACT_24000]) in a safe and secure location.  The records must 
be easil y accessible when needed (e.g., for a [COMPANY_004] audit or regulatory inspection) and 
must be available for review in c onjunction with assessment of the facility , supporting 
systems, and relevant site staff.
2013N161649_03 CONFIDENTIA L
ING117172
81Where permitted b y local laws/regulations or institutional policy, some or all of the 
records may  be maintained in a format other than hard copy  (e.g., microfiche, sca nned, 
electronic); however, caution must be exercised before such action is taken.  The 
investigator must ensure that all reproductions are legible and are a true and accurate 
copy  of the original.  In addition, they  must meet accessibility  and retrieval s tandards, 
including regeneration of a hard cop y, if required.  The investigator must also ensure that 
an acceptable back -up of the reproductions exists and that there is an acceptable quality  
control procedure in place for creating the reproductions.
[COMPANY_004] w ill inform the investigator of the time period for retaining the site records in order 
to comply  with all applicable regulatory  requirements.  The minimum retention time will 
meet the strictest standard applicable to a particular site, as dictated b y local
laws/regulations, [COMPANY_004] standard operating procedures, and/or institutional requirements.
The investigator must notify  [COMPANY_004] of any  changes in the archival arrangements, including, 
but not limited to archival of records at an off- site facility  or transfer of ownership of the 
records in the event that the investigator is no longer associated with the site.
9.7. Provision of Study  Results to Investigators, Posting of 
Information on Publicly  Available Clinical Trials Registers 
and Publication
Where required b y applica ble regulatory  requirements, an investigator signatory  will be 
identified for the approval of the CSR.  The investigator will be provided reasonable 
access to statistical tables, figures, and relevant reports and will have the opportunity  to 
review the com plete study  results at a [COMPANY_004] site or other mutually -agreeable location.
[COMPANY_004] will also provide the investigator with the full summary  of the stud y results.  The 
investigator is encouraged to share the summary  results with the study  subjects, as 
appropriate.
The results summary  will be posted to the Clinical Study  Register no later than eight 
months after the final primary completion date, the date that the final subject was 
examined or received an intervention for the purposes of final collection of data for the 
primary  outcome.  In addition, a manuscript will be submitted to a peer reviewed journal 
for publication no later than [ADDRESS_1255737]’s last visit (L SLV).  When 
manuscript publication in a peer reviewed journal is not feasible, a sta tement will be 
added to the register to explain the reason for not publishing.
2013N161649_03 CONFIDENTIA L
ING117172
8210. REFERENCES
Atripla Product Information, April 2013 
Centers for Disease Control and Prevention (CDC) 1993 revised classification sy stem for 
HIV infection and expanded surveillan ce case definition for AIDS among adolescents 
and adults.  MMWR 1992;41(No. RR- 17):1-19.
Cockroft DW, Gault MH.  Pediction of creatinine clearance from serum creatinine.  
Nephron 1976;16:31-41.
Complera US Product Information, January , 2013
Cooper DA, Stei gbigel RT, Gatell JM, et al. Subgroup and resistance anal yses of 
raltegravir for resistant HIV -1 Infection. N Engl J Med. 2008;359:355-65. 
Currier J, Averitt Bridge D, Hagins D.  Sex- Based Outcomes of Darunavir –Ritonavir 
Therap y: The GRACE (Gender, Race, and Clinical Experience) Stud y; Ann I ntern Med. 
2010; 153(6): 349 –357. doi:  10.1059/0003-4819-153-6-201009210-[ZIP_CODE]
DeJesus E, Rockstroh JK, Henry  K, et al.  Co-formulated elvitegravir, cobicistat, 
emtricitabine, and tenofovir disoproxil fumarate versus r itonavir -boosted atazanavir plus 
co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of 
HIV-1 infection: a randomized, double -blind, phase 3, non -inferiority  trial.  Lancet
2012;379(9835):2429–2438.
Department of Health and Human Services (US DHHS) Food and Drug Administration 
Center for Drug Evaluation and Research (CDER). Guidance for Industry . Antiretroviral 
Drugs Using Plasma HIV RNA Measurements - Clinical Considerations for Accelerated 
and Traditional Approval.  October 2002
Department of Health and Human Services (US DHHS). Panel on Antiretroviral 
Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in 
HIV-1-infected adults and adolescents. Updated February  12, 2013. Available at 
http://www.aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf. 
European AIDS Clinical Society  (EACS) Guidelines for the clinical management and 
treatment of HIV Infected Adults in Europe, 2012. Available at 
http://www.europeanaidsclinicalsociet y.org/images/ stories/EACS -Pdf/EacsGuidelines-
v6.1-2edition.pdf.
Fleiss J.L . Statistical Methods for Rates and Proportions. 2 ed. [LOCATION_001]:John Wiley ; 
1981.  
GlaxoSmithKline Document Number 2017N352880_00: [COMPANY_004]1349572 Clinical 
Investigator's Brochure , Version 11, Supple ment 01, December 2017.
2013N161649_03 CONFIDENTIA L
ING117172
83GlaxoSmithKline Document Number 2017N352880_01: [COMPANY_004]1349572 Clinical 
Investigator's Brochure, Version 11, Supplement 02, June 2018.
GlaxoSmithKline Document Number RM2007/[ZIP_CODE]/11: [COMPANY_004]1349572 Clinical 
Investigator's Brochure. Version 11, October 2017.
Hazuda DJ, Miller MD, Ngu yen BY [CONTACT_895670] J. Resistance to the HIV -integrase 
inhibitor raltegravir: Analy sis of Protocol 005, a Phase II study  in patients with triple -
class resistant HIV -[ADDRESS_1255738] 8, XVI International HIV Drug Resistance 
Workshop. Antiviral Therapy. 2007a;12:510. 
Hill, A, Sabin, C. Designing and interpreting noninferiorit y trials in naïve and
experienced patients. AIDS. 2008;22(8):913 -921.
International AIDS Society  (IAS) –[LOCATION_003] Antiretroviral Treatment of Adult HIV Infection: 
2010 Recommendations of the International AIDS Society -[LOCATION_003] Panel. Thompson et al. 
JAMA. 2012;308(4):387 -402.
International AIDS Society  (IAS) –[LOCATION_003] . Update of the Drug Resistant Mutations in 
HIV-1: March 2013. Topi[INVESTIGATOR_124669] 2013;21 (1): 6-14.
Isentress EU Summary  of Product Characteristics, March [ADDRESS_1255739] Information, April 2013; 
Lennox J L, DeJesus E, Berger DS, et al.  Raltegravir Versus Efavirenz Regimens in 
Treatment -Naive HIV -1–Infected Patients: [ADDRESS_1255740] 2010;55(1):39 -48.
Lui K. -J., Kell y C. A Revisit on Tests for Homogeneity of the Risk Difference. 
Biometrics. 2000;56:[ADDRESS_1255741] generation 
integrase inhibitors:  I nsights from a Phase II study  of elvitegravir (GS -9137).  Abstract 
9, XVI International HIV Drug Resistance Workshop. Antiviral Therapy. 2007;12:S11. 
Molina J, L aMarca A, Andrade- Villanueva J, et al.  Efficacy  and safet y of once dail y 
elvitegravir versus twice daily raltegravir in treatment -experienced patients with HI V-1 
receiving a ritonavir -boosted protease inhibitor: randomised, double -blind, phase 3, non -
inferiority  study .  Lancet Infe ct Dis 2012;12: 27 –35.
Molina JM, Andrade -Villanueva J, Echevarria J, et al. Once -daily  atazanavir/Ritonavir 
versus twice -daily  lopi[INVESTIGATOR_054]/Ritonavir, each in combination with tenofovir and 
Emtricitabine, for management of antiretroviral -naïve HIV -1-infected patients: 48 week 
efficacy  and safet y results of the CASTL E study . Lancet. 2008; 372; 646 -655.
Oquendo MA, Mann J. Risk Factors for suicidal behaviour : utility  and limitations of 
research instruments (2003). In M.B. First [Ed] Standardized Evaluation in Clinical 
Practice, pp 103- 130.
2013N161649_03 CONFIDENTIA L
ING117172
84Paterson D, Swindells S, Mohr J, et. al. How Much Adherence is Enough? A Prospective 
Study  of Adherence to Protease Inhibitor Therapy  Using MEMSCaps. Abstract 92, 6th 
Conference on Retrovirus and Opportunistic Infections. 19 99; 84.
Reyataz EU Summary  of Product Characteristics, September 2012.
Reyataz US Product I nformation, April 2013.
Sato T. On the variance estimator for the Mantel -Haenszel risk difference. Biometrics. 
1989;45:1323-1324. 
Sax PE, DeJesus E, Mills A, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, 
and tenofovir versus co -formulated efavirenz, emtricitabine, and tenofovir for initial 
treatment of HIV -1 infection: a randomised, double -blind, Phase 3 trial, analy sis of 
results after 48 weeks.  Lancet2012;379 (9835):2439– 2448.
Squires KE, Johnson M, Yang R, et al. Comparative gender anal ysis of the efficacy  and 
safet y of atazanavir/ritonavir and lopi[INVESTIGATOR_054]/ritonavir at 96 weeks in the CASTL E study . J 
Antimicrob Chemother. 2011; 66: 363-370.
Stribild , Product I nformation, [ADDRESS_1255742] Information, July  2012
Ware JE, Kosinski M, and Keller SD. A 12- Item Short -Form Health Survey: 
Construction of scales and preliminary  tests of reliability  and validity . Medical Care, 
1996;34(3):220 -233. 
Woodcoc k A, Bradley  C(2001). Validation of the HIV Treatment Satisfaction 
Questionnaire (HIVTSQ). Quality of Life Research. 10:517-531.
Woodcock A, Bradley  C(2006). Validation of the Revised 10- item HIV Treatment 
Satisfaction Questionnaire Status Version and New Change Version . Value in Health.
9:320-333.
2013N161649_03 CONFIDENTIA L
ING117172
8511. APPENDICES
11.1. Appendix 1: CDC Classification Sy stem for HIV -1 Infections 
(1993)
Reference -1993 revised classification s ystem for HIV infection and expanded 
surveillance case definition for AIDS among adoles cents and adults. MMWR 1992;41 
(No. RR -17):1-19.
Clinical Categories
The clinical categories of HIV infection are defined as follows:
Category A
Category  A consists of one or more of the conditions listed below in an adolescent or 
adult (>13 years) with do cumented HIV infection.  Conditions listed in Categories B and 
C must not have occurred.
Asymptomatic HIV infection
Persistent generalized l ymphadenopath y
Acute (primary ) HIV infection with accompany ing illness or history  of acute HIV 
infection
Category B (Symptomatic non- AIDS conditions)
Category  B consists of symptomatic conditions in an HIV -infected adolescent or adult 
that are not included among conditions listed in clinical Category  C and that meet at least 
one of the following criteria:  a) the condit ions are attributed to HIV infection or are 
indicative of a defect in cell -mediated immunity ; or b) the conditions are considered by  
[CONTACT_124793] a clinical course or to require management that is complicated by  [CONTACT_339299].  Examples of conditions in clinical Category  B include, but are not limited 
to:
Bacillary  angiomatosis
Candidiasis, orophary ngeal (thrush)
Candidiasis, vulvovaginal; persistent, frequent, or poorly  responsive to therapy
Cervical d ysplasia (moderate or severe)/cervical carcinoma in situ
Constitutional sy mptoms, such as fever (38.5 C) or diarrhea lasting >1 month
Hairy  leukoplakia, oral
Herpes zoster (shingles), involving at least two distinct epi[INVESTIGATOR_895637]
Idiopathic thrombocy topenic purpura
2013N161649_03 CONFIDENTIA L
ING117172
86Listeriosis
Pelvi c inflammatory  disease, particularl y if complicated b y tubo -ovarian abscess
Peripheral neuropath y
For classification purposes, Category  B conditions take precedence over those in 
Category  A.  For example, someone previously  treated for oral or persistent v aginal 
candidiasis (and who has not developed a Category  C disease) but who is now 
asymptomatic should be classified in clinical Category  B.
Category C (AIDS indicator conditions as defined by  [CONTACT_339300]).
Category  C includes the cl inical conditions listed in the AIDS surveillance case 
definition.  For classification purposes, once a Category  C condition has occurred, the 
person will remain in Category  C.
Conditions in Category  C include:
Candidiasis of bronchi, trachea, or lungs
Candidiasis, esophageal
Cervical cancer, invasive
Coccidioidomy cosis, disseminated or extrapulmonary
Cryptococcosis, extrapulmonary
Cryptosporidiosis, chronic intestinal (>1 month’s duration)
Cytomegalovirus disease (other than liver, spleen, or nodes)
Cytome galovirus retinitis (with loss of vision)
Encephalopath y, HIV-related
Herpes simplex:  chronic ulcer(s) (>1 month’s duration);or bronchitis, pneumonitis, 
or esophagitis
Histoplasmosis, disseminated or extrapulmonary
Isosporiasis, chronic intestinal (>1 mon th’s duration)
Kaposi’s sarcoma
Lym phoma, Burkitt’s (or equivalent term)
Lym phoma, immunoblastic (or equivalent term)
Lym phoma, primary , of brain
Mycobacterium avium complex or M. kansasii, disseminated or extrapulmonary
Mycobacterium tuberculosis, any  site (pulmonary or extrapulmonary )
Mycobacterium, other species or unidentified species, disseminated or 
extrapulmonary
2013N161649_03 CONFIDENTIA L
ING117172
87Pneumocy stis carinii pneumonia
Pneumonia, recurrent
Progressive multifocal leukoencephalopathy
Salmonella septicemia, recurrent
Toxoplasmosis of brain
Wasting sy ndrome due to HIV
Non-CDC, HIV -associated conditions.
2013N161649_03 CONFIDENTIA L
ING117172
8811.2. Appendix 2: Division of A IDS Table for Grading the Severity  
of Adult and Pediatric A dverse Events
VERSION 1.0, DECEMBER 2004; CLA RIFICA TION AUG UST 2009
The Division of AIDS Table for Grading the Severity  of Adult and Pediatric Adverse 
Events (“DAIDS AE Grading Table”) is a descriptive terminology  which can be utilized 
for Adverse Event (AE) reporting. A grading (severity ) scale is provided for each AE 
term.
2013N161649_03 CONFIDENTIA L
ING117172
89CLINICAL
PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY LIFE -THREATENING
ESTIMATING SEVERITY GRADE1
Clinical adverse event NOT 
identified elsewhere in this DAIDS 
AE grading tableSymptoms causing no or minimal 
interference with usual social & 
functional activitiesSymptoms causing greater than 
minimal interference with usual 
social & functional activitiesSymptoms causing inability to 
perform usual social & functional 
activitiesSymptoms causing inability to perform 
basic self -care functions OR Me dical or 
operative intervention indicated to 
prevent permanent impairment, 
persistent disability, or death
SYSTEMIC
Acute systemic allergic reaction Localized urticaria (wheals) with 
no medical intervention indicatedLocalized urticaria with medical 
intervention indicated OR Mild 
angioedema with no medical 
intervention indicatedGeneralized urticaria OR 
Angioedema with medical 
intervention indicated OR 
Symptomatic mild bronchospasmAcute anaphylaxis OR Life -threatening 
bronchospasm OR laryngeal edema
Chills Symptoms causing no or minimal 
interference with usual social & 
functional activitiesSymptoms causing greater than 
minimal interference with usual 
social & functional activitiesSymptoms causing inability to 
perform usual social & functional 
activitie sNA
Fatigue
MalaiseSymptoms causing no or minimal 
interference with usual social & 
functional activitiesSymptoms causing greater than 
minimal interference with usual 
social & functional activitiesSymptoms causing inability to 
perform usual social & fu nctional 
activitiesIncapacitating fatigue/malaise 
symptoms
causing inability to perform basic self -
care functions
Fever (nonaxillary) 37.7 – 38.6C 38.7 – 39.3C 39.4 – 40.5C > 40.5 C
Pain (indicate body site)
DO NOT use for pain due to 
injection (See Injection Site 
Reactions: Injection site pain)
See also Headache, Arthralgia, 
and MyalgiaPain causing no or minimal 
interference with usual social & 
functional activitiesPain causing greater than minimal 
interference with usual social & 
functional activitiesPain causing inability to perform 
usual social & functional activitiesDisabling pain causing inability to 
perform basic self -care functions OR 
Hospi[INVESTIGATOR_059] (other than emergency 
room visit) indicated
Unintentional weight loss NA 5 –9% loss in body weight from 
baseline10 –19% loss in body weight from 
baseline20% loss in body weight from 
baseline OR Aggressive intervention 
indicated [e.g., tube feeding or total 
parenteral nutrition (TPN)]
2013N161649_03 CONFIDENTIA L
ING117172
90CLINICAL
PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY LIFE -THREATENING
INFECTION
Infection (any other than HIV 
infection)Localized, no systemic 
antimicrobial treatment indicated 
AND Symptoms causing no or 
minimal interference with usual 
social & functional activitiesSystemic antimicrobial treatment 
indicated OR Symptoms causing 
greater than minimal interference 
with usual social & functional 
activitiesSystemic antimicrobial treatment 
indicated AND Symptoms causing 
inability to perform usual social & 
functional activities OR Operative 
intervention (other than simple 
incision and drainage) indicatedLife-threatening consequen ces (e.g., 
septic shock)
INJECTION SITE REACTIONS
Injection site pain (pain without 
touching)
Or
Tenderness (pain when area is 
touched)Pain/tenderness causing no or 
minimal limitation of use of limbPain/tenderness limiting use of limb 
OR Pain/tendern ess causing 
greater than minimal interference 
with usual social & functional 
activitiesPain/tenderness causing inability to 
perform usual social & functional 
activitiesPain/tenderness causing inability to 
perform basic self -care function OR 
Hospi[INVESTIGATOR_059] (other than emergency 
room visit) indicated for management 
of pain/tenderness
Injection site reaction (localized)
Adult > 15 years Erythema OR Induration of 5x5 
cm – 9x9 cm (or 25 cm2–81cm2)Erythema OR Induration OR Edema 
> 9 cm any diameter (or > 81 cm2)Ulceration OR Secondary infection 
OR Phlebitis OR Sterile abscess OR 
DrainageNecrosis (involving dermis and deeper
tissue)
Pediatric 15 Years Erythema OR Induration OR 
Edema present but  2.5 cm 
diameterErythema OR Induration OR Edema 
> 2.5 cm diameter but < 50% 
surface area of the extremity 
segment (e.g., upper arm/thigh)Erythema OR Induration OR Edema 
involving 50% surface area of the 
extremity segment (e.g., upper 
arm/thigh) OR Ulceration OR 
Secondary infection OR Phlebitis OR 
Sterile a bscess OR DrainageNecrosis (involving dermis and deeper 
tissue)
Pruritis associated with injection
See also Skin: Pruritis (itching -no 
skin lesions)Itching localized to injection site 
AND Relieved spontaneously or 
with < 48 hours treatmentItching be yond the injection site but 
not generalized OR Itching localized 
to injection site requiring 48 hours 
treatmentGeneralized itching causing inability 
to perform usual social & functional 
activitiesNA
2013N161649_03 CONFIDENTIA L
ING117172
91CLINICAL
PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY LIFE -THREATENING
SKIN –DERMATOLOGICAL
Alopecia Thinning detectable by [CONTACT_8712] (or by [CONTACT_227429])Thinning or patchy hair loss 
detectable by [CONTACT_227430] –rash Localized macular rash Diffuse macular, maculopapular, or 
morbill iform rash OR Target lesionsDiffuse macular, maculopapular, or 
morbilliform rash with vesicles or 
limited number of bullae OR 
Superficial ulcerations of mucous 
membrane limited to one siteExtensive or generalized bullous 
lesions OR Stevens -Johnson 
syndro me OR Ulceration of mucous 
membrane involving two or more 
distinct mucosal sites OR Toxic 
epi[INVESTIGATOR_194] (TEN)
Hyperpi[INVESTIGATOR_227344] (itching –no skin lesions)
(See also Injection Site Reactions: 
Pruritis associated with injection)Itching causing no or minimal 
interference with usual social & 
functional activitiesItching causing greater than 
minimal interference with usual 
socia l & functional activitiesItching causing inability to perform 
usual social & functional activitiesNA
CARDIOVASCULAR
Cardiac arrhythmia (general)
(By [CONTACT_10871])Asymptomatic AND No 
intervention indicatedAsymptomatic AND Non -urgent 
medical i ntervention indicatedSymptomatic, non -life-threatening 
AND Non -urgent medical intervention 
indicatedLife-threatening arrhythmia OR Urgent 
intervention indicated
Cardiac -ischemia/infarction NA NA Symptomatic ischemia (stable 
angina) OR Testing consistent with 
ischemiaUnstable angina OR Acute myocardial 
infarction
Hemorrhage (significant acute 
blood loss)NA Symptomatic AND No transfusion 
indicatedSymptomatic AND Transfusion of 2 
units packed RBCs (for children 10 
cc/kg) indicatedLife-threatening h ypotension OR 
Transfusion of > 2 units packed RBCs 
(for children >10 cc/kg) indicated
Hypertension
Adult > 17 years
(with repeat testing at same 
visit)140 –159 mmHg systolic
OR
90 –99 mmHg diastolic160 –179 mmHg systolic
OR
100 – 109 mmHg dias tolic180 mmHg systolic
OR
110 mmHg diastolicLife-threatening consequences (e.g., 
malignant hypertension) OR 
Hospi[INVESTIGATOR_374] (other than 
emergency room visit)
2013N161649_03 CONFIDENTIA L
ING117172
92CLINICAL
PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY LIFE -THREATENING
Pediatric 17 Years
(with repeat testing at same 
visit)NA 91st –94thpercen tile adjusted for 
age, height, and gender (systolic 
and/or diastolic)95thpercentile adjusted for age, 
height, and gender (systolic and/or 
diastolic)Life-threatening consequences (e.g., 
malignant hypertension) OR 
Hospi[INVESTIGATOR_374] (other than 
emergency room visit)
Hypotension NA Symptomatic, corrected with oral 
fluid replacementSymptomatic, IV fluids indicated Shock requiring use of vasopressors or 
mechanical assistance to maintain 
blood pressure
Pericardial effusion Asymptomatic, small effusio n 
requiring no interventionAsymptomatic, moderate or larger 
effusion requiring no interventionEffusion with non -life threatening 
physiologic consequences OR 
Effusion with non -urgent intervention 
indicatedLife-threatening consequences (e.g., 
tamponade) OR Urgent intervention 
indicated
Prolonged PR interval
Adult > 16 years PR interval
0.21 – 0.25 secPR interval
> 0.25 secType II 2nddegree AV block OR 
Ventricular pause > 3.0 secComplete AV block
Pediatric 16 Years 1stdegree AV block (PR > norm al 
for age and rate)Type I 2nddegree AV block Type II 2nddegree AV block Complete AV block
Prolonged QTc
Adult > 16 years Asymptomatic, QTc interval 
0.45-0.47 sec OR Increase 
interval <0.03 sec above baselineAsymptomatic, QTc interval 
0.48-0.49 sec OR Increase in 
interval 0.03 –0.05 sec above 
baselineAsymptomatic, QTc interval 0.50 
sec OR Increase in interval 0.06 
sec above baselineLife-threatening consequences, e.g., 
Torsade de pointes or other associated 
serious ventricular dysrhythmia
Pediatric 16 years Asymptomatic, QTc interval 
0.450 –0.464 secAsymptomatic, QTc interval 
0.465 -0.479 secAsymptomatic, QTc
interval 0.480 secLife-threatening consequences, e.g., 
Torsade de pointes or other associated 
serious ventricular dysrhythmia
Thrombosis/embolism NA Deep vein thrombosis AND No 
intervention indicated (e.g., 
anticoagulation, lysis filter, invasive 
procedure)Deep vein thrombosis AND 
Intervention indicated (e.g., 
anticoagulation, lysis filter, invasive 
procedure)Embolic event (e.g., pulmonary 
embolism, life -threatening thrombus)
Vasovagal epi[INVESTIGATOR_1865] (associated 
with a procedure of any kind)Present without loss of 
consciousnessPresent with transient loss of 
consciousnessNA NA
Ventricular dysfunction 
(congestive heart failure)NA Asym ptomatic diagnostic finding 
AND intervention indicatedNew onset with symptoms OR 
Worsening symptomatic congestive 
heart failureLife-threatening congestive heart 
failure
2013N161649_03 CONFIDENTIA L
ING117172
93CLINICAL
PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY LIFE -THREATENING
GASTROINTESTINAL
Anorexia Loss of appetite without 
decreased oral intakeLoss of ap petite associated with 
decreased oral intake without 
significant weight lossLoss of appetite associated with 
significant weight lossLife-threatening consequences OR 
Aggressive intervention indicated [e.g., 
tube feeding or   total parenteral 
nutrition (TP N)]
Comment: Please note that, while the grading scale provided for Unintentional Weight Loss may be used as a guideline when grading anorexia, this is not a requirement and should 
not be used as a substitute for clinical judgment.
Ascites Asymptomatic Symptomatic AND Intervention 
indicated (e.g., diuretics or 
therapeutic paracentesis)Symptomatic despi[INVESTIGATOR_227345]-threatening consequences
Cholecystitis NA Symptomatic AND Medical 
intervention indicatedRadiologic, endoscopic, or operative 
interve ntion indicatedLife-threatening consequences (e.g., 
sepsis or perforation)
Constipation NA Persistent constipation requiring 
regular use of dietary modifications, 
laxatives, or enemasObstipation with manual evacuation 
indicatedLife-threatening conseque nces (e.g., 
obstruction)
Diarrhea
Adult and
Pediatric 1 yearTransient or intermittent epi[INVESTIGATOR_895638] 3 stools over baseline per 24 -
hour periodPersistent epi[INVESTIGATOR_227347] 4 –6 
stools over baseline per 24 -hour 
periodBloody diarrhea OR Increase of 7 
stools per 24 -hour period OR IV fluid 
replacement indicatedLife-threatening consequences (e.g., 
hypotensive shock)
Pediatric < 1 year Liquid stools (more unformed 
than usual) but usual numb er of 
stoolsLiquid stools with increased number 
of stools OR Mild dehydrationLiquid stools with moderate 
dehydrationLiquid stools resulting in severe 
dehydration with aggressive 
rehydration indicated OR Hypotensive 
shock
Dysphagia -
OdynophagiaSymptoma tic but able to eat usual 
dietSymptoms causing altered dietary 
intake without medical intervention 
indicatedSymptoms causing severely altered 
dietary intake with medical 
intervention indicatedLife-threatening reduction in oral intake
2013N161649_03 CONFIDENTIA L
ING117172
94CLINICAL
PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY LIFE -THREATENING
Mucositis/stomatit is (clinical 
exam )
Indicate site (e.g., larynx, oral)
See Genitourinary for 
Vulvovaginitis 
See also Dysphagia -Odynophagia 
and ProctitisErythema of the mucosa Patchy pseudomembranes or 
ulcerationsConfluent pseudomembranes or 
ulcerations OR Mucosal ble eding with 
minor traumaTissue necrosis OR Diffuse 
spontaneous mucosal bleeding OR 
Life-threatening consequences (e.g., 
aspi[INVESTIGATOR_1516], choking)
Nausea Transient (< 24 hours) or 
intermittent nausea with no or 
minimal interference with oral 
intakePersistent n ausea resulting in 
decreased oral intake for 24 –48 
hoursPersistent nausea resulting in 
minimal oral intake for > 48 hours OR 
Aggressive rehydration indicated 
(e.g., IV fluids)Life-threatening consequences (e.g., 
hypotensive shock)
Pancreatitis NA Symp tomatic AND Hospi[INVESTIGATOR_227348] (other than emergency 
room visit)Symptomatic AND Hospi[INVESTIGATOR_373] (other than emergency 
room visit)Life-threatening consequences (e.g., 
circulatory failure, hemorrhage, sepsis)
Proctitis (functional -symptomatic)
Also see Mucositis/stomatitis for 
clinical examRectal discomfort AND No 
intervention indicatedSymptoms causing greater than 
minimal interference with usual 
social & functional activities OR 
Medical intervention indicatedSymptoms causing inabi lity to 
perform usual social & functional 
activities OR Operative intervention 
indicatedLife-threatening consequences (e.g., 
perforation)
Vomiting Transient or intermittent vomiting 
with no or minimal interference 
with oral intakeFrequent epi[INVESTIGATOR_895639] 
(e.g., IV fluids)Life-threatening consequences (e.g., 
hypotensive shock)
2013N161649_03 CONFIDENTIA L
ING117172
95CLINICAL
PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY LIFE -THREATENING
NEUROLOGIC
Alteration in personality -behavior 
or in mood (e.g., agitation, 
anxiety, depression, mania, 
psychosis)Alteration causing no or minimal 
interference with usual social & 
functional activitiesAlteration causing greater than 
minimal interference with usual 
social & functional activitiesAlteration causing inability to perform 
usual social & functional activitiesBehavior potentially harmful to self or 
others (e.g., suicidal and homicidal 
ideation or attempt, acute psychosis) 
OR Causing inability to perform basic 
self-care functions
Altered Mental S tatus
For Dementia, see Cognitive and 
behavioral/attentional disturbance 
(including dementia and attention 
deficit disorder)Changes causing no or minimal 
interference with usual social & 
functional activitiesMild lethargy or somnolence 
causing greater t han minimal 
interference with usual social & 
functional activitiesConfusion, memory impairment, 
lethargy, or somnolence causing 
inability to perform usual social & 
functional activitiesDelirium OR obtundation, OR coma
Ataxia Asymptomatic ataxia detectab le 
on exam OR Minimal ataxia 
causing no or minimal interference 
with usual  social & functional 
activitiesSymptomatic ataxia causing greater 
than minimal interference with usual 
social & functional activitiesSymptomatic ataxia causing inability 
to perfor m usual social & functional 
activitiesDisabling ataxia causing inability to 
perform basic self -care functions
Cognitive and 
behavioral/attentional disturbance 
(including dementia and attention 
deficit disorder)Disability causing no or minimal 
interferen ce with usual social & 
functional activities OR 
Specialized resources not 
indicatedDisability causing greater than 
minimal interference with usual 
social & functional activities OR 
Specialized resources on part -time 
basis indicatedDisability causing inab ility to perform 
usual social & functional activities OR 
Specialized resources on a full -time 
basis indicatedDisability causing inability to perform 
basic self -care functions OR 
Institutionalization indicated
CNS ischemia (acute) NA NA Transient ischemic attack Cerebral vascular accident (CVA, 
stroke) with neurological deficit
Developmental delay
–Pediatric 16 YearsMild developmental delay, either 
motor or cognitive, as determined 
by [CONTACT_7425] a 
developmental screening tool 
appropriate for the settingModerate developmental delay, 
either motor or cognitive, as 
determined by [CONTACT_7425] a 
developmental screening tool 
appropriate for the settingSevere developmental delay, either 
motor or cognitive, as determined by 
[CONTACT_7425] a developme ntal 
screening tool appropriate for the 
settingDevelopmental regression, either motor 
or cognitive, as determined by 
[CONTACT_7425] a developmental 
screening tool appropriate for the 
setting
2013N161649_03 CONFIDENTIA L
ING117172
96CLINICAL
PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY LIFE -THREATENING
Headache Symptoms causing no or minimal 
interference with usua l social & 
functional activitiesSymptoms causing greater than 
minimal interference with usual 
social & functional activitiesSymptoms causing inability to 
perform usual social & functional 
activitiesSymptoms causing inability to perform 
basic self -care functions OR 
Hospi[INVESTIGATOR_374] (other than 
emergency room visit) OR Headache 
with significant impairment of alertness 
or other neurologic function
Insomnia NA Difficulty sleepi[INVESTIGATOR_227350] & functio nal activitiesDifficulty sleepi[INVESTIGATOR_114750] & functional 
activitiesDisabling insomnia causing inability to 
perform basic self -care functions
Neuromuscular weakness 
(including myopathy & 
neuropathy)Asymptomatic with decre ased 
strength on exam OR Minimal 
muscle weakness causing no or 
minimal interference with usual 
social & functional activitiesMuscle weakness causing greater 
than minimal interference with usual 
social & functional activitiesMuscle weakness causing inabil ity to 
perform usual social & functional 
activitiesDisabling muscle weakness causing 
inability to perform basic self -care 
functions OR Respi[INVESTIGATOR_339193] (including 
paresthesia and painful 
neuropathy )Asymptomatic with sensory 
alteration on exam or minimal 
paresthesia causing no or minimal 
interference with usual social & 
functional activitiesSensory alteration or paresthesia 
causing greater than minimal 
interference with usual social & 
functional activitiesSensory alteration or paresthesia 
causing inability to perform usual 
social & functional activitiesDisabling sensory alteration or 
paresthesia causing inability to perform 
basic self -care functions
Seizure: ( new onset )
–Adult 18 years
See al so Seizure: (known pre -
existing seizure disorder)NA 1 seizure 2 –4 seizures Seizures of any kind which are 
prolonged, repetitive (e.g., status 
epi[INVESTIGATOR_7397]), or difficult to control (e.g., 
refractory epi[INVESTIGATOR_002])
Seizure: ( known pre -existing 
seizure disorde r)
–Adult 18 years
For worsening of existing epi[INVESTIGATOR_339194].NA Increased frequency of pre -existing 
seizures (non -repetitive) without 
change in seizure character OR 
Infrequent break -through seizures 
while on stable medication in a 
previously controlled seizure 
disorderChange in seizure character from 
baseline either in duration or quality 
(e.g., severity or focality)Seizures of any kind which are 
prolonged, repet itive (e.g., status 
epi[INVESTIGATOR_7397]), or difficult to control (e.g., 
refractory epi[INVESTIGATOR_002])
2013N161649_03 CONFIDENTIA L
ING117172
97CLINICAL
PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY LIFE -THREATENING
Seizure
–Pediatric < 18 yearsSeizure, generalized onset with or 
without secondary generalization, 
lasting < 5 minutes with < [ADDRESS_1255743] ictal stateSeizure, general ized onset with or 
without secondary generalization, 
lasting 5 –20 minutes with <[ADDRESS_1255744] ictal stateSeizure, generalized onset with or 
without secondary generalization, 
lasting >20 minutesSeizure, generalized onset with or 
without Secondary genera lization, 
requiring intubation and sedation
Syncope (not associated with a 
procedure)NA Present NA NA
Vertigo Vertigo causing no or minimal 
interference with usual social & 
functional activitiesVertigo causing greater than 
minimal interference with usu al 
social & functional activitiesVertigo causing inability to perform 
usual social & functional activitiesDisabling vertigo causing inability to 
perform basic self -care Functions
RESPI[INVESTIGATOR_111092] (acute) FEV1 or peak flow reduced to 
70-80%FEV1 or peak flow 50 –69% FEV1 or peak flow 25 –49% Cyanosis OR FEV1 or peak flow < 25% 
OR Intubation
Dyspnea or respi[INVESTIGATOR_111093] 14 years Dyspnea on exertion with no or 
minimal interference with usual 
social & functional activitiesDyspnea on exe rtion causing 
greater than minimal interference 
with usual social & functional 
activitiesDyspnea at rest causing inability to 
perform usual social & functional 
activitiesRespi[INVESTIGATOR_227353] < 14 years Wheezi ng OR minimal increase in 
respi[INVESTIGATOR_227354] 90 –
95%Dyspnea at rest causing inability to 
perform usual social & functional 
activities OR Pulse oximetry < 90%Respi[INVESTIGATOR_895640] & 
functional activitiesJoint pain causing greater than 
minimal interference with usual 
social & functional activitiesJoint pain causing inability to perform 
usual social & functional activitiesDisabling joint pain causing inability to 
perform basic self -care Functions
Arthritis
See also ArthralgiaStiffness or joint swelling causing 
no or minimal interference with 
usual social & functional activitiesStiffness or joint swelling causing 
greater than minimal interference 
with usual social & functional 
activitiesStiffness or joint swelling causing 
inability to perform usual social & 
functional activitiesDisabling joint stiffness or swelling 
causing inability to perform basic self -
care functions
2013N161649_03 CONFIDENTIA L
ING117172
98CLINICAL
PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY LIFE -THREATENING
Bone Mineral Loss
Adult 21 years BMD t -score -2.5 to -1.0 BMD t -score < -2.5 Pathological fracture (including loss 
of vertebral height)Pathologic fracture causing life -
threatening Consequences
Pediatric < 21 years BMD z -score -2.5 to -1.0 BMD z -score < -2.5 Pathological fracture (including loss 
of vertebral height)Pathologic fracture causing life -
threatening Consequences
Myalgia ( non-injection site ) Muscle pain causing no or 
minimal interference with usual 
social & functional activitiesMuscle pain causing greater than 
minimal interference with usual 
social & functional activitiesMuscle pain causing inability to 
perform usual social & functional 
activitiesDisabling muscl e pain causing inability 
to perform basic self -care functions
Osteonecrosis NA Asymptomatic with radiographic 
findings AND No operative 
intervention indicatedSymptomatic bone pain with 
radiographic findings OR Operative 
intervention indicatedDisabling b one pain with radiographic 
findings causing inability to perform 
basic self -care functions
GENITOURINARY
Cervicitis ( symptoms )
(For use in studies evaluating 
topi[INVESTIGATOR_144491])
For other cervicitis see Infection: 
Infection (any other than HIV 
infect ion)Symptoms causing no or minimal 
interference with usual social & 
functional activitiesSymptoms causing greater than 
minimal interference with usual 
social & functional activitiesSymptoms causing inability to 
perform usual social & functional 
activiti esSymptoms causing inability to perform 
basic self -care functions
Cervicitis ( clinical exam )
(For use in studies evaluating 
topi[INVESTIGATOR_144491])
For other cervicitis see Infection: 
Infection (any other than HIV 
infection)Minimal cervical abnormalitie s on 
examination (erythema,
Mucopurulent discharge, or 
friability) OR Epi[INVESTIGATOR_111100] < 
25% of total surfaceModerate cervical abnormalities on 
examination (erythema, 
mucopurulent discharge, or 
friability) OR Epi[INVESTIGATOR_111101] 
25 –49% total s urfaceSevere cervical abnormalities on 
examination (erythema, 
mucopurulent discharge, or friability) 
OR Epi[INVESTIGATOR_111100] 50 –75% 
total surfaceEpi[INVESTIGATOR_111100] > 75% total 
surface
Inter-menstrual bleeding (IMB) Spotting observed by [CONTACT_895671]-menstrual bleeding not greater 
in duration or amount than usual 
menstrual cycleInter-menstrual bleeding greater in 
duration or amount than usual 
menstrual cycleHemorrhage with li fe-threatening 
hypotension OR Operative intervention 
indicated
2013N161649_03 CONFIDENTIA L
ING117172
99CLINICAL
PARAMETER GRADE [ADDRESS_1255745] obstruction (e.g., 
stone)NA Signs or symptoms of urinary tract 
obstruction without hydronephrosis 
or renal dysfunctionSigns or symptoms of urinary tract 
obstruction with hydron ephrosis or 
renal dysfunctionObstruction causing life -threatening 
consequences
Vulvovaginitis ( symptoms )
(Use in studies evaluating topi[INVESTIGATOR_111097]) 
For other vulvovaginitis see 
Infection: Infection (any other than 
HIV infection)Symptoms causing no or minimal 
interference with usual social & 
functional activitiesSymptoms causing greater than 
minimal interference with usual 
social & functional activitiesSymptoms causing inability to 
perform usual social & functional 
activitiesSymptoms causing i nability to perform 
basic self -care functions
Vulvovaginitis ( clinical exam )
(Use in studies evaluating topi[INVESTIGATOR_111097])
For other vulvovaginitis see 
Infection: Infection (any other than 
HIV infection)Minimal vaginal abnormalities on 
examination O R Epi[INVESTIGATOR_111098] <25% of total surfaceModerate vaginal abnormalities on 
examination OR Epi[INVESTIGATOR_111099] 25 -49% total surfaceSevere vaginal abnormalities on 
examination OR Epi[INVESTIGATOR_111100] 
50 -75% total surfaceVaginal perforation O R Epi[INVESTIGATOR_111098] > 75% total surface
OCULAR/VISUAL
Uveitis Asymptomatic but detectable on 
examSymptomatic anterior uveitis OR 
Medical intervention indicatedPosterior or pan -uveitis OR Operative 
intervention indicatedDisabling visual loss in aff ected eye(s)
Visual changes (from baseline) Visual changes causing no or 
minimal interference with usual 
social & functional activitiesVisual changes causing greater 
than minimal interference with usual 
social & functional activitiesVisual changes causi ng inability to 
perform usual social & functional 
activitiesDisabling visual loss in affected eye(s)
ENDOCRINE/METABOLIC
Abnormal fat accumulation (e.g., 
back of neck, breasts, abdomen)Detectable by [CONTACT_111186] (or 
by [CONTACT_895672])Detectable on physical exam by 
[CONTACT_895673][INVESTIGATOR_10820]-threatening consequences (e.g., 
ketoacidosis, hyperosmolar non -ketotic 
coma)
2013N161649_03 CONFIDENTIA L
ING117172
100CLINICAL
PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY LIFE -THREATENING
Gynecomastia Detectable by [CONTACT_895674] (for young children and 
disabled adults)Detectable on physical exam by 
[CONTACT_339302] & f unctional activities OR 
Thyroid suppression therapy 
indicatedSymptoms causing inability to 
perform usual social & functional 
activities OR Uncontrolled despi[INVESTIGATOR_111102]-threatening consequences (e.g., 
thyroid storm)
Hypothyroidism Asym ptomatic Symptomatic causing greater than 
minimal interference with usual 
social & functional activities OR 
Thyroid replacement therapy 
indicatedSymptoms causing inability to 
perform usual social & functional 
activities OR Uncontrolled despi[INVESTIGATOR_206800] m odificationLife-threatening consequences (e.g., 
myxedema coma)
Lipoatrophy (e.g., fat loss from the 
face, extremities, buttocks)Detectable by [CONTACT_111186] (or 
by [CONTACT_227432])Detectable on physical exam by 
[CONTACT_544972] h care providerDisfiguring OR Obvious on casual 
visual inspectionNA
1. Basic Self -care Functions –Adult: Activities such as bathing, dressing, toileting, transfer/movement, continence, and feeding.
Basic Self -care Functions –Young Children: Activities th at are age and culturally appropriate (e.g., feeding self with culturally appropriate eating implement).
Usual Social & Functional Activities –Adult: Adaptive tasks and desirable activities, such as going to work, shoppi[INVESTIGATOR_007], cooking, use of transportation, pursuing a hobby, etc.
Usual Social & Functional Activities –Young Children: Activities that are age and culturally appropriate (e.g., social interactions, play activities, learning task s, etc.).
2013N161649_03 CONFIDENTIA L
ING117172
101LABORATORY
PARAMETER GRADE [ADDRESS_1255746] International Units are listed in italics
Absolute CD4+ count
–Adult and Pediatric
> 13 years
(HIV NEGATIVE ONLY)300 –400/mm3
300 – 400/µL200 –299/mm3
200 – 299/µL100 –199/mm3
100 –199/µL< 100/mm3
< 100/µL
Absolute lymphocyte
count
–Adult and Pediatric
> 13 years
(HIV NEGATIVE ONLY)600 –650/mm3
0.600 x 109–
0.650 x 109/L500 –599/mm3
0.500 x 109–
0.599 x 109/L350 –499/mm3
0.350 x 109–
0.499 x 109/L< 350/mm3
<0.350 x 109/L
Comment:   Values in children 13 years are not given for the two parameters above because the absolute counts are variable.
Absolute neutrophil count (ANC)
Adult and Pediatric,
> 7 days1,000 –1,300/mm3
1.000 x 109 –
1.300 x 109/L750 –999/mm3
0.750 x 109 –
0.999 x 109/L500 –749/mm3
0.500 x 109 –
0.749 x 109/L< 500/mm3
< 0.500 x 109/L
Infant*†, 2 –7 days 1,250 –1,500/mm3
1.250 x 109 –
1.500 x 109/L1,000 –1,249/mm3
1.000 x 109 –
1.249 x 109/L750 –999/mm3
0.750 x 109–
0.999 x 109/L< 750/mm3
< 0.750 x 109/L
Infant*†, 1 day 4,000 –5,000/mm3
4.000 x 109–
5.000 x 109/L3,000 –3,999/mm3
3.000 x 109–
3.999 x109/L1,500 –2,999/mm3
1.500 x 109–
2.999 x 109/L< 1,500/mm3
< 1.500 x 109/L
Fibrinogen, decreased 100 –200 mg/dL
1.00 – 2.00 g/L
OR
0.75 – 0.99 x LLN75 –99 mg/dL
0.75 – 0.99 g/L
OR
0.50 – 0.74 x LLN50 –74 mg/dL
0.50 – 0.74 g/L
OR
0.25 – 0.[ADDRESS_1255747]< 50 mg/dL
< 0.50 g/L
OR
< 0.[ADDRESS_1255748]
OR
Associated with gross bleeding
2013N161649_03 CONFIDENTIA L
ING117172
102LABORATORY
PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRAD E 3
SEVEREGRADE 4
POTENTIALLY
LIFE -THREATENING
Hemoglobin (Hgb)
Adult and Pediatric
57 days
(HIV POSITIVE ONLY)8.5 –10.0 g/dL
5.24 – 6.23 mmol/L7.5 –8.4 g/dL
4.62 – 5.23 mmol/L6.50 –7.4 g/dL
4.03 – 4.61 mmol/L< 6.5 g/dL
< 4.03 mmol/L
Adult and Pediatric
57 days
(HIV NEGATIVE ONLY)10.0 –10.9 g/dL
6.18 – 6.79 mmol/L
OR
Any decrease
2.5 – 3.4 g/dL
1.58 – 2.13 mmol/L9.0 –9.9 g/dL
5.55 – 6.17 mmol/L
OR
Any decrease
3.5 – 4.4 g/dL
2.14 – 2.78 mmol/L7.0 –8.9 g/dL
4.34 – 5.54 mmol/L
OR
Any decrease
4.5 g/dL
2.79 mmol/L< 7.0 g/dL
< 4.34 mmol/L
Infant*†, 36 –56 days
(HIV POSITIVE OR NEGATIVE)8.5 –9.4 g/dL
5.24 – 5.86 mmol/L7.0 –8.4 g/dL
4.31 – 5.23 mmol/L6.0 –6.9 g/dL
3.72 – 4.30 mmol/L< 6.00 g/dL
< 3.72 mmol/L
Infant*†, 22 –35 days
(HIV POSITIVE OR NEGATIVE )9.5 –10.5 g/dL
5.87 – 6.54 mmol/L8.0 –9.4 g/dL
4.93 – 5.86 mmol /L7.0 –7.9 g/dL
4.34 – 4.92 mmol/L< 7.00 g/dL
< 4.34 mmol/L
Infant*†, 21 days
(HIV POSITIVE OR NEGATIVE )12.0 –13.0 g/dL
7.42 – 8.09 mmol/L10.0 –11.9 g/dL
6.18 – 7.41 mmol/L9.0 –9.9 g/dL
5.59 – 6.17 mmol/L< 9.0 g/dL
< 5.59 mmol/L
International Normalized
Ratio of prothrombin time
(INR)1.1 –1.[ADDRESS_1255749] 1.6 –2.[ADDRESS_1255750] 2.1 –3.[ADDRESS_1255751] > 3.[ADDRESS_1255752]
Methemoglobin 5.0 –10.0% 10.1 –15.0% 15.1 –20.0% > 20.0%
Prothrombin Time (PT) 1.1 –1.[ADDRESS_1255753] 1.26 –1.[ADDRESS_1255754] 1.51 –3.[ADDRESS_1255755] > 3.[ADDRESS_1255756]
Partial Thromboplastin
Time (PTT)1.1 –1.[ADDRESS_1255757] 1.67 –2.[ADDRESS_1255758] 2.34 –3.[ADDRESS_1255759] > 3.[ADDRESS_1255760]
Platelets, decreased 100,000 –
124,999/mm3
100.000 x 109–
124.999 x 109/L50,000 –
99,999/mm3
50.000 x 109–
99.999 x 109/L25,000 –
49,999/mm3
25.000 x 109–
49.999 x 109/L< 25,000/mm3
< 25.000 x 109/L
WBC, decreased 2,000 –2,500/mm3
2.000 x 109–
2.500 x 109/L1,500 –1,999/mm3
1.500 x 109–
1.999 x 109/L1,000 –1,499/mm3
1.000 x 109–
1.499 x 109/L< 1,000/mm3
< 1.000 x 109/L
2013N161649_03 CONFIDENTIA L
ING117172
103LABORATORY
PARAMETER GRADE [ADDRESS_1255761] In ternational Units are listed in italics
Acidosis NA pH < normal, but  7.3 pH < 7.3 without life -threatening 
consequencespH < 7.3 with life -threatening 
consequences
Albumin, serum, low 3.0 g/dL –< LLN
30 g/L – < LLN2.0 –2.9 g/dL
20 –29 g/L< 2.0 g/d L
< 20 g/LNA
Alkaline Phosphatase 1.25 –2.[ADDRESS_1255762]† 2.6 –5.[ADDRESS_1255763]† 5.1 –10.[ADDRESS_1255764]† > 10.[ADDRESS_1255765]†
Alkalosis NA pH > normal, but  7.5 pH > 7.5 without life -threatening 
consequencespH > 7.5 with life -threatening 
consequences
ALT (SGPT) 1.25 –2.[ADDRESS_1255766] 2.6 –5.[ADDRESS_1255767] 5.1 –10.[ADDRESS_1255768] > 10.[ADDRESS_1255769] (SGOT) 1.25 –2.[ADDRESS_1255770] 2.6 –5.[ADDRESS_1255771] 5.1 –10.[ADDRESS_1255772] > 10.[ADDRESS_1255773]
Bicarbonate, serum, low 16.0 mEq/L –< LLN
16.0 mmol/L –< LLN11.0 –15.9 mEq/L
11.0 – 15.9 mmol/L8.0 –10.9 mEq/L
8.0 – 10.9 mm ol/L< 8.0 mEq/L
< 8.0 mmol/L
Bilirubin (Total)
Adult and Pediatric >14 days 1.1 –1.[ADDRESS_1255774] 1.6 –2.[ADDRESS_1255775] 2.6 –5.[ADDRESS_1255776] > 5.[ADDRESS_1255777]
Infant*†, 14 days (non-
hemolytic)NA 20.0 –25.0 mg/dL
342 – 428 µmol/L25.1 –30.0 mg/dL
429 – 513 µmol/L> 30. 0 mg/dL
>513.0 µmol/L
Infant*†, 14 days (hemolytic) NA NA 20.0 –25.0 mg/dL
342 – 428 µmol/L> 25.0 mg/dL
> 428 µmol/L
Calcium, serum, high (corrected for albumin)
Adult and Pediatric  7 days 10.6 –11.5 mg/dL
2.65 – 2.88 mmol/L11.6 –12.5 mg/dL
2.89 – 3.13 mmol/L12.6 –13.5 mg/dL
3.14 – 3.38 mmol/L> 13.5 mg/dL
> 3.38 mmol/L
Infant*†, < 7 days 11.5 –12.4 mg/dL
2.88 – 3.10 mmol/L12.5 –12.9 mg/dL
3.11 – 3.23 mmol/L13.0 –13.5 mg/dL
3.245 – 3.38 mmol/L> 13.5 mg/dL
> 3.38 mmol/L
Calcium, ser um, low 
Adult and Pediatric  7 days 7.8 –8.4 mg/dL
1.95 – 2.10 mmol/L7.0 –7.7 mg/dL
1.75 – 1.94 mmol/L6.1 –6.9 mg/dL
1.53 – 1.74 mmol/L< 6.1 mg/dL
< 1.53 mmol/L
Infant*†, < 7 days 6.5 –7.5 mg/dL
1.63 – 1.88 mmol/L6.0 –6.4 mg/dL
1.50 – 1.62 m mol/L5.50 –5.90 mg/dL
1.38 – 1.51 mmol/L< 5.50 mg/dL
< 1.38 mmol/L
Cardiac troponin I (cTnI) NA NA NA Levels consistent with myocardial 
infarction or unstable angina as defined 
by [CONTACT_3455]
2013N161649_03 CONFIDENTIA L
ING117172
104LABORATORY
PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRAD E 3
SEVEREGRADE 4
POTENTIALLY
LIFE -THREATENING
Cardiac troponin T (cTnT) NA NA NA 0.20 ng/mL
OR
Levels consistent with myocardial 
infarction or unstable angina as defined 
by [CONTACT_514731] (fasting)
Adult 18 years 200 –239 mg/dL
5.18 – 6.19 mmol/L240 –300 mg/dL
6.20 – 7.77 mmol/L> 300 mg/dL
> 7.77 mmol/LNA
Pediatric < 18 years 170 –199 mg/dL
4.40 – 5.15 mmol/L200 –300 mg/dL
5.16 – 7.77 mmol/L> 300 mg/dL
> 7.77 mmol/LNA
Creatine Kinase 3.0 –5.[ADDRESS_1255778]† 6.0 –9.[ADDRESS_1255779]† 10.0 –19.[ADDRESS_1255780]†20.[ADDRESS_1255781]†
Creatinine 1.1 –1.[ADDRESS_1255782]† 1.4 –1.[ADDRESS_1255783]† 1.9 –3.[ADDRESS_1255784]†3.5 x UL N†
Glucose, serum, high
Nonfasting 116 –160 mg/dL
6.44 – 8.88 mmol/L161 –250 mg/dL
8.89 – 13.88 mmol/L251 –500 mg/dL
13.89 – 27.75 mmol/L> 500 mg/dL
> 27.75 mmol/L
Fasting 110 –125 mg/dL
6.11 – 6.94 mmol/L126 –250 mg/dL
6.95 – 13.88 mmol/L251 –500 mg/dL
13.89 – 27.75 mmol/L> 500 mg/dL
> 27.75 mmol/L
Glucose, serum, low
Adult and Pediatric  1 month 55 –64 mg/dL
3.05 – 3.55 mmol/L40 –54 mg/dL
2.22 – 3.06 mmol/L30 –39 mg/dL
1.67 – 2.23 mmol/L< 30 mg/dL
< 1.67 mmol/L
Infant*†, < 1 m onth 50 –54 mg/dL
2.78 – 3.00 mmol/L40 –49 mg/dL
2.22 – 2.77 mmol/L30 –39 mg/dL
1.67 – 2.21 mmol/L< 30 mg/dL
< 1.67 mmol/L
Lactate ULN -< 2.[ADDRESS_1255785] without 
acidosis2.[ADDRESS_1255786] without
acidosisIncreased lactate with pH < 7.3 without life -
threateni ng consequencesIncreased lactate with pH <7.3 with life -
threatening consequences
LDL cholesterol (fasting)
Adult 18 years 130 –159 mg/dL
3.37 – 4.12 mmol/L160 –190 mg/dL
4.13 – 4.90 mmol/L190 mg/dL
4.91 mmol/LNA
Pediatric > 2 -< 18 years 110 –129 mg/dL
2.85 – 3.34 mmol/L130 –189 mg/dL
3.35 – 4.90 mmol/L190 mg/dL
4.91 mmol/LNA
Lipase 1.1 –1.[ADDRESS_1255787] 1.6 –3.[ADDRESS_1255788] 3.1 –5.[ADDRESS_1255789] > 5.[ADDRESS_1255790]
2013N161649_03 CONFIDENTIA L
ING117172
105LABORATORY
PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRAD E 3
SEVEREGRADE 4
POTENTIALLY
LIFE -THREATENING
Magnesium, serum, low 1.2 –1.4 mEq/L
0.60 – 0.70 mmol/L0.9 –1.1 mEq/L
0.45 – 0.59 mm ol/L0.6 –0.8 mEq/L
0.30 – 0.44 mmol/L< 0.60 mEq/L
< 0.30 mmol/L
Pancreatic amylase 1.1 –1.[ADDRESS_1255791] 1.6 –2.[ADDRESS_1255792] 2.1 –5.[ADDRESS_1255793] > 5.[ADDRESS_1255794]
Phosphate, serum, low
Adult and Pediatric > 14 years 2.5 mg/dL –< LLN
0.81 mmol/L –< LLN2.0 –2.4 mg/dL
0.65 – 0.80 mmol/L1.0 –1.9 mg/dL
0.32 – 0.64 mmol/L< 1.00 mg/dL
< 0.32 mmol/L
Pediatric 1 year –14 years 3.0 –3.5 mg/dL
0.97 – 1.13 mmol/L2.5 –2.9 mg/dL
0.81 – 0.96 mmol/L1.5 –2.4 mg/dL
0.48 – 0.80 mmol/L< 1.50 mg/dL
< 0.48 mmol/L
Pediatric < 1 year 3.5 –4.5 mg/dL
1.13 – 1.45 mmol/L2.5 –3.4 mg/dL
0.81 – 1.12 mmol/L1.5 –2.4 mg/dL
0.48 – 0.80 mmol/L< 1.50 mg/dL
< 0.48 mmol/L
Potassium, serum, high 5.6 –6.0 mEq/L
5.6 – 6.0 mmol/L6.1 –6.5 mEq/L
6.1 – 6.5 mmol/L6.6 –7.0 mEq/L
6.6 – 7.0mmol/L> 7.0 mEq/L
> 7.0 mmol/L
Potassium, serum, low 3.0 –3.4 mEq/L
3.0 – 3.4 mmol/L2.5 –2.9 mEq/L
2.5 – 2.9 mmol/L2.0 –2.4 mEq/L
2.0 – 2.4 mmol/L< 2.0 mEq/L
< 2.0 mmol/L
Sodium, serum, high 146 –150 mEq/L
146 – 150 mmol/L151 –154 mEq/L
151 – 154 mmol/L155 –159 mEq/L
155 – 159 mmol/L160 mEq/L
160 mmol/L
Sodium, serum, low 130 –135 mEq/L
130 – 135 mmol/L125 –129 mEq/L
125 – 129 mmol/L121 –124 mEq/L
121 – 124 mmol/L120 mEq/L
120 mmol/L
Triglycerides (fasting) NA 500 –750 mg/dL
5.65 – 8.48 mmol/L751 –1,200 mg/dL
8.49 – 13.56 mmol/L> 1,200 mg/dL
> 13.56 mmol/L
Uric acid 7.5 –10.0 mg/dL
0.45 – 0.59 mmol/L10.1 –12.0 mg/dL
0.60 – 0.71 mmol/L12.1 –15.0 mg/dL
0.72 – 0.89 mmol/L> 15.0 mg/dL
> 0.89 mmol/L
URINALYSIS Standard International Units are listed in italics
Hematuria (microscopic) 6 –10 RBC/HPF > 10 RBC/HPF Gross, with or without clots OR with RBC 
castsTransfusion indicated
Proteinuria, random
Collection1 + 2 –3 + 4 + NA
2013N161649_03 CONFIDENTIA L
ING117172
106LABORATORY
PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRAD E 3
SEVEREGRADE 4
POTENTIALLY
LIFE -THREATENING
Proteinuria, 24 hour collection
Adult and Pediatric  10 years 200 –999 mg/24 h
0.200 – 0.999 g/d1,000 –1,999 mg/24 h
1.000 – 1.999 g/d2,000 –3,500 mg/24 h
2.000 – 3.500 g/d> 3,500 mg/24 h
> 3.500 g/d
Pediatric > 3 mo -< 10 years 201 –499 mg/m2/24 h
0.201 – 0.499 g/d500 –799 mg/m2/24 h
0.500 – 0.799 g/d800 –1,000 mg/m2/24 h
0.800 – 1.000 g/d> 1,000 mg/ m2/24 h
> 1.000 g/d
Values are for term infants.  Preterm infants should be assessed using local normal ranges.
† Use age and sex appropriate values (e.g., bilirubin).
2013N161649_03 CONFIDENTIA L
ING117172
[ZIP_CODE].3. Appendix 3: Pharmacogenetic Research
Pharmacogenetics –Background
Pharmacogenetics (PGx) is the study  of variability in drug response due to hereditary  
factors in populations.  There is increasing evidence that an individual's genetic 
background (i.e., genot ype) may  impact the pharmacokinetics (absorption, distribution, 
metabolism, elimination), pharmacod ynamics (relationship between concentrations and 
pharmacologic effects or the time course of pharmacologic effects) and/or clinical 
outcome (in terms of effica cy and/or safety  and tolerability ).  Some reported examples of 
PGx associations with safety /adverse events include:
2013N161649_03 CONFIDENTIA L
ING117172
108Drug Disease Gene Variant Outcome
Abacavir HIV 
[Hetherington , 
2002; Mallal , 
2002; 
Mallal ,2008]HLA-B* 57:01 
(Human 
Leukocyte 
Antigen B)Carriage of the HLA-B*57:01 variant has been 
shown to increase a patient's risk for 
experiencing hypersensitivity to abacavir.  
Prospec tive HLA-B*57:01 screening and 
exclusion of HLA-B*57:[ADDRESS_1255795] labeling in the [LOCATION_002] 
and Europe now re commend (US) or require 
(EU) prospective HLA-B*57:01 screening prior 
to initiation of abacavir to reduce the incidence 
of abacavir hypersensitivity.  HLA-B*57:[ADDRESS_1255796] clinical risk management strategies for 
abacavir hypersensitivity.
Carbamaze
pi[INVESTIGATOR_339197], Bipolar 
disorders & 
Analgesia Chung , 
2010; Ferrell , 
2008HLA-B*15:[ADDRESS_1255797] Asian anc estry who carry HLA-B*15:[ADDRESS_1255798] updated the 
carbamazepi[INVESTIGATOR_895641]-B*15:02 prior to initiating 
treatment with carbamazepi[INVESTIGATOR_050].
Irinotecan Cancer 
[Innocenti , 2004; 
Liu, 2008; 
Schulz , 2009]UGT1A1*28 Variations in the UGT1A1 gene can influence 
a patient’s ability to break down irinotecan, 
which can lead to increased blood levels of the 
drug and a higher risk of side effects. A dose 
of irinotec an that is safe for one patient with a 
particular UGT1A1 gene variation might be too 
high for another patient without this variation, 
raising the risk of certain side -effects that 
include neutropenia following initiation of 
Irinotecan treatment.  The irino tecan drug 
label indicates that individuals who have two 
copi[INVESTIGATOR_23932]1A1*[ADDRESS_1255799] of clinical studies.
2013N161649_03 CONFIDENTIA L
ING117172
109Collection of whole blood samples, even when no a priori hypothesis has been identified, 
may enable PGx anal ysis to be conducted if at any time it appears that there is a potential 
unexpected or unexplained variation in response to DTG or an y of the HIV medicines 
included in this study . 
Pharmacogenetic Research Objectives
The objective of the PGx research (if there is a potential unexpected or unexplained 
variation) is to investigate a relatio nship between genetic factors and response to DTG or 
any of the HIV medicines included in this study .  If at an y time it appears there is 
potential variability  in response in this clinical study  or in a series of clinical studies with 
DTG, the following ob jectives may  be investigated – the relationship between genetic 
variants and stud y treatment with respect to:
Relationship between genetic variants and the pharmacokinetics and/or 
pharmacod ynamics of DTG or other medicines used in this study
Relationship b etween genetic variants and safet y and/or tolerability  of DTG or other 
medicines used in this study
Relationship between genetic variants and efficacy of DTG or other medicines used 
in this study
Study Population
Any subject who is enrolled in the clinical study , can participate in PGx research.  Any  
subject who has received an allogeneic bone marrow transplant must be excluded from 
the PGx research.
Subject participation in the PGx research is voluntary  and refusal to participate will not 
indicate withdraw al from the clinical study  or result in any  penalty  or loss of benefits to 
which the subject would otherwise be entitled.
Study Assessments and Procedures
Blood samples can be taken for Deox yribonucleic acid (DNA) extraction and used in 
PGx assessments.
Inaddition to any  blood samples taken for the clinical study , a whole blood sample (6 ml) 
will be collected for the PGx research using a tube containing EDTA.  It is recommended 
that the blood sample be taken at the first opportunity  after a subject has bee n randomized 
and provided informed consent for PGx research, but may  be taken at any  time while the 
subject is participating in the clinical study .
The PGx sample is labelled (or “coded”) with a study  specific number that can be 
traced or linked back to the subject b y the investigator or site staff.  Coded samples 
do not carry  personal identifiers (such as name [CONTACT_24004] y number).  The 
blood sample is taken on a single occasion unless a duplicate sample is required due 
to inability  to utilize the or iginal sample.   
2013N161649_03 CONFIDENTIA L
ING117172
110The DNA extracted from the blood sample may  be subjected to sample quality  control 
analysis.  This anal ysis will involve the genot ypi[INVESTIGATOR_23933] y of individual samples.  If inconsistencies are note d in the analy sis, then those 
samples may  be destroy ed.
The need to conduct PGx anal ysis may  be identified after a study  (or a set of studies) of 
DTG (or an y of the H IV medicines included in this study ) has been completed and the 
clinical study  data review ed.  In some cases, the samples may not be studied. e.g., no 
questions are raised about how people respond to DTG (or an y of the H IV medicines 
included in this study ).
Samples will be stored securel y and may be kept for up to [ADDRESS_1255800] subjec t 
completes the study  or [COMPANY_004] may  destro y the samples sooner.  [COMPANY_004] or those working 
with [COMPANY_004] (for example, other researchers) will use samples collected from the study  for 
the purpose stated in this protocol and in the informed consent form.  
Subjects can request their sample to be destro yed at any  time.
Subject Withdrawal from Study
If a subject who has consented to participate in PGx research withdraws from the clinical 
study  for any  reason other than being lost to follow -up, the subject will be given a c hoice 
of one of the following options concerning the PGx sample, if alread y collected:
Continue to participate in the PGx research with the PGx sample retained for 
analysis 
Withdraw from the PGx research and destro y the PGx sample 
If a subject withdraws consent for PGx research or requests sample destruction for any  
reason, the investigator must complete the appropriate documentation to request sample 
destruction within the timeframe specified b y [COMPANY_004] and maintain the documentation in 
the site study  records. The investigator should forward the Pharmacogenetic Sample 
Destruction Request Form to [COMPANY_004] as directed on the form. This can be done at any  time 
when a subject wishes to withdraw from the PGx research or have their sample destro yed 
whether during the st udy or during the retention period following close of the main study .
Screen and Baseline Failures
If a blood sample for PGx research has been collected and it is determined that the 
subject does not meet the entry  criteria for participation in the clinica l study, then the 
investigator should instruct the participant that their PGx sample will be destroy ed. No 
forms are required to complete this process as it will be completed as part of the consent 
and sample reconciliation process.  In this instance a sample destruction form will not be 
available to include in the site files.
Pharmacogenetics A nalyses
1.Specific genes may  be studied that encode the drug targets, or drug mechanism of 
action pathway s, drug metabolizing enzymes, drug transporters or which may  
2013N161649_03 CONFIDENTIA L
ING117172
111underpin adverse events, disease risk or drug response. These candidate genes may  
include a common set of ADME (Absorption, Distribution, Metabolism and 
Excretion) genes that are studied to determine the relationship between gene variants 
or treatment respo nse and/or tolerance. 
In addition, continuing research may  identify  other enzy mes, transporters, proteins or 
receptors that may  be involved in response to DTG or any  of the HIV medicines included 
in this study .  The genes that may  code for these proteins may also be studied.
2.Genome -wide scans involving a large number of poly morphic markers (e.g., single 
nucleotide poly morphisms) at defined locations in the genome, often correlated with 
a candidate gene, may  be studied to determine the relationship between genetic 
variants and treatment response or tolerance. This approach is often employ ed when 
a definitive candidate gene(s) does not exist and/or the potential genetic effects are 
not well understood. 
If applicable and PGx research is conducted, appropriate statistical anal ysis methods will 
be used to evaluate pharmacogenetic data in the context of the other clinical data. Results 
of PGx investigations will be reported either as part of the main clinical study  report or as 
a separate report. Endpoints of interest from all comparisons will be descriptively  and/or 
graphicall y summarised as appropriate to the data.  A detailed description of the anal ysis 
to be performed will be documented in the study  reporting and anal ysis plan (RAP) or in 
a separate pharmacoge netics RAP, as appropriate.  
Informed Consent
Subjects who do not wish to participate in the PGx research may  still participate in the 
clinical study .  PGx informed consent must be obtained prior to an y blood being taken for 
PGx research.
Provision of Stu dy Results and Confidentiality  of Subject’s PGx Data
[COMPANY_004] may  summarize the PGx research results in the clinical study  report, or separatel y, 
or may  publish the results in scientific journals. 
[COMPANY_004] does not inform the investigator, subject, or any one else ( e.g., family  members, 
study  investigators, primary  care ph ysicians, insurers, or emplo yers) of individual 
genot ypi[INVESTIGATOR_23934]’s medical care at the 
time of the study , unless required b y law. This is due to th e fact that the information 
generated from PGx studies is generall y preliminary in nature, and therefore the 
significance and scientific validity  of the results are undetermined.
2013N161649_03 CONFIDENTIA L
ING117172
112References
Chung WH, Hung SL , Chen YT. Genetic predisposition of life -threate ning antiepi[INVESTIGATOR_23935] -
induced skin reactions.  Expert Opin. Drug Saf. 2010; 9: 15-21.
Ferrell PB, McLeod HL.  Carbamazepi[INVESTIGATOR_050], HLA -B*1502 and risk of Stevens -Johnson 
syndrome and toxic epi[INVESTIGATOR_23936]: US FDA recommendations.  
Pharmacogenomics. 2008; 9: 1543-1546.
Hetherington S, Hughes AR, Mosteller M, Shortino D, Baker KL, Spreen W, Lai E, 
Davies K, Handley  A, Dow DJ, Fling ME, Stocum M, Bowman C, Thurmond L M, Roses 
AD. Genetic variations in HLA- B region and h ypersensitivity  reactions to abacavir. 
Lancet. 2002; 359:1121-1122.
Innocenti F, Undevia SD, Iy er L, Chen PX, Das S, Kocherginsky  M, Karrison T, Janisch 
L, Ramirez J, Rudin CM, Vokes EE, Ratain MJ.  Genetic variants in the UDP -
glucuronosy ltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J 
Clin Oncol 2004; 22: 1382 -1388.
Liu CY, Chen PM, Chiou TJ, L iu JH, Lin JK, L in TC, Chen WS, Jiang JK, Wang HS, 
Wang WS.  UGT1A1*28 poly morphism predicts irinotecan- induced severe toxicities 
without affecting treatment outcome and survival in patients with metastatic colorectal 
carcinoma.  Cancer. 2008; 112: 1932 -1940.
Mallal S, Nolan D, Witt C, Masel G, Martin AM, Moore C, Say er D, Castley  A, Mamotte 
C, Maxwell D, James I .  Association between presence of HLA- B*5701, HLA -DR7, and 
HLA -DQ3 and h ypersensitivity  to HIV -1 reverse -transcriptase inhibitor abacavir.  
Lancet. 2002; 359:727 -732.
Mallal S, Phillips E, Carosi G, Molina JM, Workman C, Tomazic J, Jägel -Guedes E, 
Rugina S, Kozy rev O, Cid JF, Hay  P, Nolan D, Hughes S, Hughes A, Ry an S, Fitch N , 
Thorborn D, Benbow A; PREDI CT-1 Study  Team.  HLA -B*5701 screening for 
hypersensitivity  to abacavir. N Engl J Med. 2008; 358; 568 -579
Schulz C, Heinemann V, Schalhorn A, Moosmann N, Zwingers T, Boeck S, Giessen C, 
Stemmler HJ. UGT1A1 gene pol ymorphism: I mpact on toxicity  and efficacy  of 
irinotecan -based regimens in metastatic colorectal cancer.  World J. Gastroenterol. 2009; 
15: 5058-5066.
2013N161649_03 CONFIDENTIA L
ING117172
[ZIP_CODE].4. Appendix 4: Liver Safety  Drug Restart or Rechallenge 
Guidelines
VSLC GUIDELINES FOR DRUG RESTART OR RECHA LLENGE A FTER
STOP FOR LIVER CRITERIA
1.Drug rechallenge may  be considered for a subject exhibiting compelling benefit for 
a critical medicine following drug -induced liver injury , if favorable benefit: risk and 
no alternative medicine available ( Table 11 , Figure 4)
2.In Phase III, drug restart may be considered for liver events with a clear underly ing 
cause (e.g. biliary , pancreatic events, hy potension, acute viral hepatitis), if not 
associa ted with drug -induced liver injury , alcoholic hepatitis or hy persensitivity , and 
drug not associated with HLA marker of liver injury , when liver chemistries improve 
to within 1.5x baseline and AL T<3xUL N)(Table 12,Figure 5).
Background: Following drug- induced liver injury, drug rechallenge is associated with 
a 13% mortality across all drugs in prospective studies .  Clinical outcomes vary  by 
[CONTACT_9934], with nearl y 50% fatality  with halothane re -administered in one month of initial 
injury  [Andrade , 2009].  However, some drugs seldom result in recurrent liver injury  or 
fatality .
Risk factors for a fatal drug rechallenge outcome include:
hypersensi tivity  with initial liver injury  (e.g. fever, rash, eosinophilia) [ Andrade , 
2009]
jaundice or bilirubin 2xULN with initial liver injury
prior serious adverse event or fatality  has earlier been observed with drug 
rechalle nge [ Papay , 2009; Hunt , 2010]
evidence of drug- related preclinical liability  (e.g. reactive metabolites; 
mitochondrial impairment [ Hunt , 2010])
VSLC Decisio n Process for Drug Rechallenge A pproval or 
Disapproval ( Figure 4)
Principal I nvestigator (PI) requests consideration of drug rechallenge for a 
subject receiving compelling benefit from a critical or life -saving dru g, who 
exhibits liver chemistry elevation meeting subject stoppi[INVESTIGATOR_3418], with no 
alternative treatment
By [CONTACT_339303]ïve subjects will only  be considered for rechallenge if 
they were infected with a multi -resistant virus.
Medical Monitor an d Global Clinical Safety  and Pharmacovigilance (GCSP) 
Physician to review the subject’s rechallenge risk factors (consultation with the 
Hepatotoxicity  Panel is available) and complete checklist (Table 11) .
2013N161649_03 CONFIDENTIA L
ING117172
114The Medi cal Monitor and GCSP Phy sician are accountable to review and agree
on:
–compelling benefit of the investigational product (IP) for this subject and no 
alternative therapy
–must present source data defining the patient’s current resistance profile 
with docum ented evidence of extensive drug resistance and previous drug 
history 
–Relative benefit -risk of drug rechallenge, with consideration of the following 
high risk factors:
Initial liver injury  event included: fever, rash, eosinophilia, or bilirubin 
2xULN (o r direct bilirubin >35% of total, if available)
subject currently exhibits severe liver injury  defined by : [CONTACT_42386] 3xUL N, 
bilirubin 2xUL N (direct bilirubin >35% of total, if available), or INR1.5
SAE or fatality  has earlier been observed with IP rechallenge
IP associated with known preclinical hepatic liability / injury
Relevant phy sicians must review and agree on request for drug rechallenge:
Safety  Team Leader, VP, or Senior Safet y Physician
Medicines Development Leader and Project Ph ysician Leader ([COMPANY_004]) or
Clinical L ead and Medical and Development Group L ead ([COMPANY_007]).
Request is taken to full VSL C for final decision 
2013N161649_03 CONFIDENTIA L
ING117172
115Figure 4 VSLC process for drug rechallenge approval or disapproval
The local operating company  (LOC) medical direc tor (ViiV and [COMPANY_004] where applicable) 
should be informed that study  drug rechallenge is under consideration and of the final 
decision, whether or not to proceed.
Table [ADDRESS_1255801] for drug rechallenge for critical medicine (Follo wing drug -
induced liver injury , drug rechallenge is associated with 13% 
mortality  across all drugs in prospective studies)
Yes No
Compelling benefit of the investigational product (IP) for this subject andno 
alternative therapy .  Provide brief explanation:
Relative benefit -risk favorable for drug rechallenge , after considering the 
following high risk factors :
Initial liver injury event included: 
ofever, rash, eosinophilia, or hypersensitivity
oor bilirubin 2xULN (direct bilirubin >35% of total)
oSubject currently exhibits ALT 3xULN, bilirubin 2xULN 
(direct bilirubin >35% of total, if available), orINR1.5
oSAE or fatality has earlier been observed with IP rechallenge
If yes, please provide brief explanation :
oIP associated with known preclin ical hepatic liability/ injury
oSource data defining the patients current resistance profile
oPrevious drug history
2013N161649_03 CONFIDENTIA L
ING117172
116Drug Restart
Phase III “drug restart” can be approved b y the VSL C for transient, defined non -drug -
induced liver injury if no evidenc e of:
•immunoallergic injury  /HLA association with injury
•drug-induced liver injury  (DILI)
•alcoholic hepatitis
Study  is drug held while labs and evaluation is completed to assess diagnosis.
VSLC Decision Process for Drug Restart A pproval or Disapproval 
(Figure 5 ):
PI [INVESTIGATOR_339199] -initiation for a subject stable or improving 
on IP, who exhibits liver chemistry  elevation meeting subject stoppi[INVESTIGATOR_3418], 
which is transient, non -drug-related, a nd liver chemistries improve to within 
1.5x baseline and AL T<3xULN. 
[COMPANY_004] Medical Monitor and Clinical Safety  Physician to review the subject’s 
diagnosis, restart risk factors and complete checklist ( Table 12).
–must present source data defining the patient’s current resistance profile 
with documented evidence of extensive drug resistance and previous drug 
history .
The LOC medical director (ViiV and [COMPANY_004] where applicable) should be 
informed that study  drug restart is under consideration and of the final decision, 
whether or not to proceed.
Table [ADDRESS_1255802] for Phase III drug restart after well -explained liver injury  
(e.g. biliary, pancreatic, hy potensive events, congestive heart 
failure, acute viral hepatitis), improving to liver chem 1.5x baseline 
& ALT<3xULN
Yes No
Is subject stable or improving on the investigational product (IP)?
Do not restart if the following risk factors at initial liver injury :
fever, rash, eosinophilia, or hype rsensitivity 
drug-induced liver injury 
alcoholic hepatitis (AST>ALT, typi[INVESTIGATOR_897] <10xULN)
IP has an HLA genetic marker associated with liver injury (e.g. 
lapatinib, abacavir, amoxicillin/clavulanate)
Source data defining the patients current re sistance profile
Previous drug history
2013N161649_03 CONFIDENTIA L
ING117172
117Relevant phy sicians must review and agree on request for drug restart:  
Safety  Team Leader, VP, or Senior Safet y Physician
Medicines Development Leader and Project Ph ysician Leader ([COMPANY_004]) or 
Clinical L ead and Medical and Development Group L ead ([COMPANY_007]).
Hepatotoxicity  Panel consultation is available.
Justification for drug restart outlining the benefit and risk for this subject must 
be recorded b y GCSP Physician and sent to the VSL C Secretary .
VSL C must approve drug re -initiation and dosing regimen
Figure 5 VSLC process for drug restart approval or disapproval
1. Andrade , 2009; 2. Papay, 2009; 3. Hunt, 2010
Medical monitor, GCSP Phy sician and PI [INVESTIGATOR_895642] (Global Clinical Safety and Pharmacovigilance) GCSP 
Physician A ctions
Medical Monitor must notify  PI [INVESTIGATOR_339201]’s rechallenge (or restart) decision and 
recommended dosing regimen in writing and Medical Monitor must record note 
in study  files.
2013N161649_03 CONFIDENTIA L
ING117172
118The Safet y Review Team must record rechallenge (or restart) outcomes and the 
GCSP Phy sician must send these to the VSL C
All severe reactions ( rechallenge associated with bilirubin>2xUL N or jaundice, 
or INR 1.5), SAEs or fatalities with drug rechallenge (or restart) must be 
immediately  reported to Line Management, VSLC Chair, VP Global Medical 
Strategy  and EU Qualified Person for Pharm acovigilance. 
Principal Investigator A ctions:
The PI  [INVESTIGATOR_699877] I nstitutional Review Board approval of 
drug rechallenge or restart, as required. 
If drug re -initiation VSLC -approved, the patient must provide informed consent 
with a cl ear description of possible benefits and risks of drug administration 
including recurrent, more severe liver injury  or possible death.
–Targeted drug rechallenge or drug restart consent form must be used.
The patient’s informed consent must be recorded in t he study  chart, and the drug 
administered at agreed dose, as communicated b y Medical Monitor.
Liver chemistries must be followed twice weekly for ‘rechallenge’ cases and 
once weekly for ‘restart’ cases for one month or for as long as clinicall y 
indicated following drug re -initiation.  If subject exhibits protocol -defined liver 
chemistry  elevations, IP should be discontinued as protocol specified.
VSLC and the IRB/IEC must be informed of the patient’s outcome following drug 
rechallenge or restart.
Rechalleng e/restart safety  outcomes :
0 = no liver chemistry  elevation
1 = recurrent liver chemistry  elevation not meeting subject stoppi[INVESTIGATOR_3418]
2 = recurrent liver chemistry  elevation meeting subject stoppi[INVESTIGATOR_3418]
3 = serious adverse event
4 = fatalit y
Refe rences:
Andrade RJ, Robles M, Lucena MI.  Rechallenge in drug -induced liver injury : the 
attractive hazard.  Expert Opin Drug Saf. 2009;8:709-714.
Hunt, CM.  Mitochondrial and immunoallergic injury  increase risk of positive drug 
rechallenge after drug -induc ed liver injury : A s ystematic review.  Hepatol. 2010;52:2216-
2222. 
Papay  JI, Clines D, Rafi R, Yuen N, Britt SD, Walsh JS, Hunt CM.  Drug -induced liver 
injury  following positive drug rechallenge.  Regul Tox Pharm. 2009;54:84 -90. 
2013N161649_03 CONFIDENTIA L
ING117172
[ZIP_CODE].5. Appendix 5: Country  Speci fic Requirements
[LOCATION_008]
This requirement has been included based on requests from the Medicines and Healthcare 
products Regulatory  Agency  (MHRA) to include information on the specific duration of 
the Continuation Phase /Study  Treatment for similar P hase III trials being conducted with 
dolutegravir.
Study Duration
In this stud y, the date of last study treatment administration in the [LOCATION_006] will be determined 
by [CONTACT_663954] [ADDRESS_1255803] 
enrolled (i t will not be determined by  [CONTACT_895675]). The 
last subject will be enrolled by  [CONTACT_30097]  2015, and hence the last study  treatment 
administration will occur by  28 February  2016.
(Note: The Continuation Phase is intended to provi de subjects on DTG/ABC/3TC FDC 
with post -study  access to DTG/ABC/3TC FDC until it becomes available in their 
countries. For subjects in the [LOCATION_006], the Continuation Phase is anticipated to conclude b y 
31March 2015, when DTG/ABC/3TC FDC is anticipated to become available).
2013N161649_03 CONFIDENTIA L
ING117172
[ZIP_CODE].6. Appendix 6: Modified List of Highly  Effective Methods for 
Avoiding Pregnancy  in Females of Reproductive Potential 
(FRP)
The list does not apply  to FRP with same sex partners or for subjects who are and will 
continue to be abstinent from penile -vaginal intercourse on a long term and persistent 
basis, when this is their preferred and usual lifest yle. Periodic abstinence (e.g. calendar, 
ovulation, sy mptothermal, post -ovulation methods) and withdrawal are not acceptable 
methods of contraception.
1.  Contraceptive subdermal implant
2.  Intrauterine device or intrauterine s ystem
3.  Combined estrogen and progestogen oral contraceptive [ Hatcher , 2011])
4.  Injectable progestogen [ Hatcher , 2011]
5.  Con traceptive vaginal ring [ Hatcher , 2011]
6.  Percutaneous contraceptive patches [ Hatcher , 2011]
7.  Male partner sterilisation with documentation of azoospermia prior to the female 
subject's entry  into the study , and this male is the sole partner for that subject 
[Hatcher , 2011]. The documentation on male sterility  can come from the site 
personnel’s review of subject’s medical records, medical examination, and/or semen 
analysis, or medi cal history  interview provided b y her or her partner.
These allowed methods of contraception are only  effective when used consistently , 
correctly  and in accordance with the product label. The investigator is responsible for 
ensuring that subjects understand how to properl y use these methods of contraception.
Reference
Hatcher RA, Trussell J, Nelson AL, et al, editors. Contraceptive Technology . 
20thedition. Atlanta, Georgia: Ardent Media, Inc., 2011: 50. Table 3-2. 
2013N161649_03 CONFIDENTIA L
ING117172
[ZIP_CODE].7. Appendix 7: Protocol Changes
11.7.1. Protocol Amendment 01 (12-AUG -2013)
This protocol amendment applies to all participating sites.
Rationale for Protocol Amendment 01:
i.For cl arification purposes, the Child -Pugh Classification has been removed as a method 
to determine thedegree of hepatic impairment (Exclusi on Criterion Number 5). Of 
note, t here is no change to the intended study  population as a result of this change (i.e. 
subjects with any  degree of hepatic impairment are still excluded). The Child- Pugh 
Classification is intended to grade hepatic im pairment in subjects alread y known to 
have hepatic impairment.  Application of this tool to subjects with no hepatic 
impairment willresult in a score of at least 5 and a classification of ‘mild hepatic 
impairment’, therefore it is not a suitable screening toolfor populations which include 
those with no hepatic impairment.  
ii.For c larification purposes, Figure 2, in Section 4.5.1. Virologic Criteria for Subject 
Management at Week 24, has been updated to differentiate between the two scenarios 
in which re -testing f or HIV -1 RNA levels is required and to match central laboratory  
wording to be provided to sites when subjects meet virologic management criteria . Of 
note, the amendment does not result in a nychange in action for sites .
iii.Removal of the assessment forbone marker anal ytes during the Continuation Phase 
(every  12 weeks after W eek 48) :  This requirement was included in the Time and 
Events Schedule in error.  Subjects on the ATV+RTV+TDF /FTC arm will have 
completed the study  at Week 48 and m onitoring of bon e marker anal ytes for subjects 
on the DTG/ABC/3TC arm beyond Week 48 isnot considered necessary . Since this
assessment is not part of a primary  or key  safety  endpoint, the removal of this 
assessment at this timepoint was previously  documented in a Study  File Note and is 
now included in this protocol amendment for completeness.
iv.Inclusion of a reference omitted in the original protocol [IAS [LOCATION_003], 2013].
v.For clarification purposes, corrections have been made to formatting issues and 
typographical errors and tomaintai n consistency  inuse of wording and terms between 
sections .
The term ‘virologic failure’ has been replaced with ‘confirmed virologic withdrawal 
criteria’ to maintain consistency  with wording for virologic criteria for subject 
management in Section 4.5.1.
Alist of specific changes is provided below. Un less stated otherwise, new text is 
represented in bold font, and deleted text in strikethrough font.
2013N161649_03 CONFIDENTIA L
ING117172
122Protocol Summary , Secondary  Objectives , bullet 3
The following text has been revised:
To assess the development of viral resistance in subjects experiencing virologic 
failure who meet confirmed virologic withdrawal criteria ;
Protocol Summary , Study Endpoints/ Assessments , paragraph 5
The following text has been revised:
Virology  endpoints will include th e incidence of treatment emergent genot ypic and 
phenoty pic resistance in subjects experiencing virologic failure who meet confirmed 
virologic withdrawal criteria .
2. Objectives, Secondary  Objectives , bullet 3
The following text has been revised:
To assess the development of viral resistance in subjects experiencing virologic failure 
who meet confirmed virologic withdrawal criteria
4.3. Exclusion Criteria
The following text has been revised:
5.Subjects with any  degree of hepatic impairment , (Class A or grea ter) as determined 
by [CONTACT_2751] -Pugh classification (Section 11.2). For subjects requiring anticoagulation 
therap y, discussion with the study medical monitor will be required ;
16.Any evidence of primary viral resistance based on the presence of any  major 
resistance -associated mutation [I AS [LOCATION_003], 201 23] in the Screening result or, if 
known, an y historical resistance test result. Note: retests of Screening genotypes are 
not allowed;
2013N161649_03 CONFIDENTIA L
ING117172
1234.5.1. Virologic Criteria for Subject Management and Viral Resistance 
Testing, Fi gure 2. Virologic Criteria for Subject Management at 
Week 24
The following Figure has been revised:
Original Figure 2:
Week 24 
Visit
HIV-1 RNA is <50 c/mL HIV-1 RNA is 50c/mL
Maintain scheduled visit at Week 36Perform an unschedul ed visit in 
approximately [ADDRESS_1255804] has met “4 to 6 Week HIV -1 RNA 
Testing Criterion”
Proceed to Figure 3
Revised Figure 2:
Week 24 Visit
HIV-1 RNA is 
<50c/mLHIV-1 RNA is 50c/mL 
but <400 c/mLHIV-1 RNA is 400c/mL
Maintain 
scheduled visit 
at Week 36Perform an unscheduled visit in 
approximately [ADDRESS_1255805] has met “4 to 6 Week 
HIV-1 RNA Testing Criterion”
Proceed to Figure 3Perform an unscheduled 
visit in approximately [ADDRESS_1255806] has met 
“Suspected Virologic 
Withdrawal Criterion”
Proceed to Figure 3
5.1.2. Tablet Formulations of A TV, RTV, TDF/FTC FDC , paragraph 2
The following text has been revised:
Tenofovir disoproxil fumarate/ emtricitabine fixed dose combination (TDF/ 3TCFTC
FDC [Truvada])
2013N161649_03 CONFIDENTIA L
ING117172
1246.1. Time and Events Schedule , Table 3 Time and Events Table
The following text has been revised:
Child -Pugh Classification: Deletion of the row representing the ‘Child -Pugh 
Classification’.
Bone marker anal ytes:  Deletion of ‘X’ representing the assessment for bone marker 
analytes during the Continuation Phase.  
The following text (footnote) has been deleted:
x: Child -Pugh Score should be calculated using results from the Scr eening Visit.
6.6.1. Virology  Endpoints
Incidence of treatment -emergent genot ypic and phenotypic resistance in subjects
experiencing virologic failure who meet confirmed virologic withdrawal criteria .
10. References
The title of the following reference wa s formatted incorrectly  and is corrected below :
Hill, A, Sabin, C. Designing and interpreting noninferiorit y trials in naïve and 
experienced patients. AIDS. 2008;22(8):913 -921.
The following text ( reference )has been added:
International AIDS Society (IAS)– [LOCATION_003]. Update of the Drug Resistant Mutations in 
HIV -1: March 2013. Topi[INVESTIGATOR_124669] 2013; 21(1): 6 -14.
11.2 A ppendix 2: Child -Pugh Classification
The following text has been deleted:
11.2 A ppendix 2: Child -Pugh Classification
A subject is classified with mild hepatic impairment (Class A) if their overall sum of 
scores is 5-6 points, moderate hepatic impairment (Class B) if their overall sum of scores 
is7-9 points, and severe hepatic impairment (Class C) if their overall sum of scores is 10-
15based o n the Child -Pugh s ystem [ Pugh , 1973] scoring described in the following table
(Table 11).  For subjects requiring anticoagulation therap y, discussion with the study 
medical monitor will be required.
2013N161649_03 CONFIDENTIA L
ING117172
125Table 11 Child -Pugh System
Finding Points Scored for Eac h Observed Finding 
1 2 3
Encephalopathy Grade1 None 1 or 2 3 or 4
Ascites Absent Slight Moderate
Serum bilirubin, SI units (μmol/L), 
Serum bilirubin, conventional units (mg/dL) <34
<234 to 52
2 to 3>52
>3
Serum albumin, SI units (g/L) 
Serum al bumin, conventional units (mg/dL) >35
>3.528 to 35
2.8 to 3.5<28
<2.8
Prothrombin Time (seconds prolonged) or 
INR <4
<1.74 to 6
1.7 to 2.3>6
>2.3
1. Grade 0: normal consciousness, personality, neurological examination, electroencephalogram
Grade 1: restless, sleep disturbed, irritable/agitated, tremor, impaired handwriting, 5 cycles per second waves
Grade 2: lethargic, time -disoriented, inappropriate, asterixis, ataxia, slow triphasic waves
Grade 3: somnolent, stuporous, place -disoriented, hyperacti ve reflexes, rigidity, slower waves
Grade 4: unrousable coma, no personality/behavior, decerebrate, slow 2 -3 cycles per second delta activity
[Pugh,1973 ; Lucey , 1997]
Lucey  MR, Brown KA, Everson GT, Fung JJ, Gish R, Keeffe EB, et al. Minimal Criteria
for Placement of Adults on the L iver Transplant Waiting L ist Liver Transplantation ans
Surgery , Vol. 3, No 6 (November), 1997:pp 628 -637
Pugh RNH, Murray -Lyon IM, Dawson J L, Pi[INVESTIGATOR_9051], Williams R. Transection of the
oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60: 649-649.
Section, Appendix and Table numbers affected b y deletion of the Child -Pugh 
Classification have been updated accordingl y.
11.7.2. Protocol changes for A mendment 02 (11 -AUG -2014) from 
Amendment 01 (12 -AUG -2013)
This protocol amend ment applies to sites in the [LOCATION_006] only.  The amendment was 
initially implemented as a ‘alternative’ format amendment, and was brought into 
the main protocol text at the time of Protocol Amendment 03.
Rationale for Protocol Amendment 0 2:
The [LOCATION_006] Medicines and Healthcare products Regulatory  Agency (MHRA) requested the 
following changes to the [LOCATION_006] country  specific information on study duration 
(Appendix 5): i) a specific end date for treatment for subjects in the [LOCATION_006], and ii) removal 
of the term ‘commercially  avail able’ in reference to treatment ending when 
investigational product is ‘commercially  available’.
The medical monitor information in the Sponsor Information Page has also been updated.
2 0 1 3 N 1 6 1 6 4 9 _ 0 3 C O N FI D E N TI A L
I N G 1 1 7 1 7 2 
1 2 6 LI S T O F S P E CI FI C C H A N G E S :
S p o ns or I nf or m ati o n P a ge; Me dic al M o nit or C o nt act I nf or m ati o n a n d Seri o us 
A d verse E ve nts ( S A E) C o nt act I nf or m ati o n: 
Ori gi n al Ver b ati m Te xt 
, M D 
I n fecti o us Diseases T A U, 
Gla x o S mit h Kli ne 
5 M o ore Dri ve, N 2. 2 2 1 3 
Researc h Tria n gle Par k, N C 2 7 7 0 9, U S A 
Tele p h o ne: 
M o bile: 
Facsi mile: 
e- mail: 
A m e n de d Te xt 
, M D 
I n fecti o us Diseases T A U, 
Gla x o S mit h Kli ne 
5 M o ore Dri ve, 
Researc h Tria n gle Par k, N C 2 7 7 0 9, U S A 
Tele p h o ne: 
M o bile: 
Facsi mile: 
e- mail: 
A p pe n di x 5: C o u ntr y S pecific Re q uire me nts 
Ori gi n al Ver b ati m Te xt 
U nit e d Ki n g d o m 
T his re q uire me nt has bee n i ncl u de d base d o n re q uests fr o m t he Me dici nes a n d Healt hcare 
pr o d ucts Re g ulat or y  A ge nc y  ( M H R A) t o i ncl u de i nf or mati o n o n t he s pecific d urati o n of 
t he O pe n - La bel/ C o nti n uati o n P hase f or si milar P hase III trials bei n g c o n d ucte d wit h 
d ol ute gra vir. 
St u d y D ur ati o n 
T he C o nti n uati o n P hase is i nte n de d t o pr o vi de access t o D T G/ A B C/ 3 T C F D C u ntil 
D T G/ A B C/ 3 T C F D C recei ves l ocal ( b y c o u ntr y ) Re g ulat or y  a p pr o val a n d bec o mes 
c o m merciall y a vaila ble. T heref ore, t he d urati o n of t he C o nti n uati o n P hase will var y  fr o m 
c o u ntr y  t o c o u ntr y  a n d is de pe n de nt o n t he recr uit me nt ti me f or t he st u d y  a n d t he ti me 
ta ke n t o ac hie ve l ocal a p pr o val f or mar keti n g. F or s u bjects i n t he U K, esti mati n g a n 1 8 
m o nt h recr uit me nt peri o d, Mar keti n g A p plicati o n A ut h orisati o n ( M A A) s u b missi o n i n 
2 0 1 3, a n d all o wi n g f or re g ulat or y  re vie w ti me of t he M A A, t he C o nti n uati o n P hase is P P D 
P P D 
P P D 
P P D 
P P D 
P P D 
P P D 
P P D 
P P D 
P P D 
2013N161649_03 CONFIDENTIA L
ING117172
127anticipated to conclude in th e [LOCATION_006] in approximately 1Q2015, and subjects who complete 
the randomized phase of the study  after this date are expected transition directly  to 
commercial supplies.
Amended Text
[LOCATION_008]
This requirement has been included based on requests from the Me dicines and Healthcare 
products Regulatory  Agency  (MHRA) to include information on the specific duration of 
the Continuation Phase /Study  Treatment for similar Phase III trials being conducted with 
dolutegravir.
Study Duration
In this stud y, the date of last study  treatment administration in the [LOCATION_006] will be determined 
by [CONTACT_663954] [ADDRESS_1255807] 
enrolled (it will not be determined by  [CONTACT_895675]). The 
last subject will be enrolled by  [CONTACT_30097]  2015, and hence the last study  treatment 
administration will occur by  28 February  2016.
(Note: The Continuation Phase is intended to provide subjects on DTG/ABC/3TC FDC 
with post -study  access to DTG/ABC/3TC FDC until it becomes availa ble in their 
countries. For subjects in the [LOCATION_006], the Continuation Phase is anticipated to conclude b y 
31March 2015, when DTG/ABC/3TC FDC is anticipated to become available).
11.7.3. Protocol changes for A mendment 03 ( 19-JUN-2018 ) from 
Amendment 02 (11 -AUG -2014)
This protocol amendment applies to all participating sites.
Rationale for Protocol Amendment 03:
Changes were made to the protocol to manage and mitigate risks following identifica tion 
of a potential safety  issue related to neural tube defect in infants born to women with 
exposure to dolutegravir at the time of conception.
The Risk Assessment table (Section 1.3.1.) was updated to include language 
regarding risk and mitigation of neural tube defects .
Inclusion criterion #2 (Section 4.2.) was updated to exclude the double barrier method 
of contraception, and refer to the Modified List of Highl y Effective Methods for 
Avoiding Pregnancy  in Females of Reproductive Potential.
The withdrawal criteria (Section 4.5.) were updated to include a reminder that 
females of r eproductive potential who change their minds and desire to be pregnant, 
or who state they  no longer are willing to compl y with the approved pregnancy  
avoidance methods, should also be withdrawn from the study .
2 0 1 3 N 1 6 1 6 4 9 _ 0 3 C O N FI D E N TI A L
I N G 1 1 7 1 7 2 
1 2 8 T he Ti me a n d E ve nts ta ble ( Secti o n 6. 1. ) was up date d t o i ncl u de a re mi n der f or 
i n vesti gat ors t o c hec k at e ver y  visit t hat fe males of re pr o d ucti ve p ote ntial are 
a v oi di n g pre g na nc y .
A p pe n di x 6 was a d de d: M o difie d L ist of Hi g hl y Effecti ve Met h o ds f or A v oi di n g 
Pre g na nc y  i n Fe males of Re pr o d ucti ve P ote ntia l
A d mi nistrati ve u p dates were ma de 
LI S T O F S P E CI FI C C H A N G E S 
U nless st ate d ot her wise, ne w te xt is re prese nte d i n b ol d f o nt, a n d delete d te xt i n 
stri ket hr o u g h f o nt. 
A ut h ors 
 
S p o ns or I nf or m ati o n P a ge; Me dic al M o nit or C o nt act I nf or m a ti o n a n d Seri o us 
A d verse E ve nts ( S A E) C o nt act I nf or m ati o n: 
, M D 
I n fecti o us Diseases T A U, 
Gla x o S mit h Kli ne 
5 M o ore Dri ve, N 2. 2 2 1 3 
Researc h Tria n gle Par k, N C 2 7 7 0 9, U S A 
Tele p h o ne: 
M o bile: 
Facsi mile: 
e- mail: 
, M D 
Vii V Healt hcare, 
5 M o ore Dri ve, 
Researc h Tria n gle Par k, N C 2 7 7 0 9, U S A 
M o bile: 
Facsi mile: 
e- mail: 
A b bre vi ati o ns 
F R P Fe m ales of Re pr o d ucti ve P ote nti al P P D 
P P D 
P P D 
P P D 
P P D 
P P D 
P P D 
P P D 
P P D 
P P D 
2013N161649_03 CONFIDENTIA L
ING117172
129Section 1.3.1. Risk Assessment
Potential Risk of 
Clinical 
SignificanceData/Rationale for Risk Mitigation Strategy1
Investigational Product (IP) [DTG/ABC/3TC] 
Refer to IB for additional information on DTG and DTG/ABC/3TC
Refer to approved country produ ct label for additional information on ABC/3TC
DTG: Neural tube 
defectsIn one ongoing birth outcome surveillance 
study in Botswana, early results from an 
unplanned interim analysis show that 
4/426 (0.9%) of women who were taking 
DTG when they became preg nant had 
babies with neural tube defects compared 
to a background rate of 0.1%.1.A female subject is eligible to 
participate if she is not pregnant , 
not la ctating, and, if she is a f emale 
of reproductive potential, agrees to 
follow one of the options listed in 
the Modified List of Highly Effective 
Methods for Avoiding Pregnancy in 
Females of Reproductive Potential 
(FRP) (see Appendix 6, Section
11.6), until at least 2 weeks after 
discontinuation of IP
2.Women who are breastfeeding or 
plan to become pregnant or
breastfeed during the study are 
excluded;
3.Women who become pregnant, or 
who desire to be pregnant while in 
the study, or who state they no 
longer are willing to comply with 
the approved pregnancy avoidance 
methods, will have study treatment 
discontinued and withdrawn from 
the study.
4. Females of reproductive potential 
are reminded re: pregnancy 
avoidance and adherence to 
contraception requirements at 
every study visit.
5.Pregnancy status is monitored at 
every study visit
Section 4.2. Inclusion Criteria
2. A female, may  be eligible to enter and participate in the study  if she: 
a.is of non -child- bearing potential either defined as post -menopausal (12 months of 
spontaneous amenorrhea and ≥ 45 y ears of age) or phy sicall y incapable of 
becoming pregnant with documen ted tubal ligation, hy sterectom y or bilateral 
oophorectom y or, 
b. is of child -bearing potential with a negative pregnancy  test at both Screening and 
Day 1 and agrees to use one of the following methods of contraception to avoid 
pregnancy :
2013N161649_03 CONFIDENTIA L
ING117172
130Refer to Appendix 6, Section 11.6 : Modified List of Highly Effective 
Methods for Avoiding Pregnancy in Females of Reproductive Potential . 
Complete abstinence from intercourse from [ADDRESS_1255808] 2 weeks after di scontinuation of 
all study  medications;
Double barrier method (male condom/spermicide, male condom/diaphragm, 
diaphragm/spermicide);
Any intrauterine device (IUD) with published data showing that the expected 
failure rate is <1% per year (not all IUDs meet this criterion, see the SPM for 
an example listing of approved IUDs);
Male partner sterilization prior to the female subject’s entry into the study  
and this male is the sole partner for that subject;
Any other method with published data showing that the e xpected failure rate 
is <1% per year.
Approved hormonal contraception for subjects randomized to the 
DTG/ABC/3TC arm (see the SPM for a listing of examples of approved 
hormonal contraception).
Approved hormonal contraception and a barrier method for subjec ts 
randomized to the ATV+RTV+TDF/FTC arm.  
Any contraception method must be used consistently , in accordance with the approved 
product label and for at least 2 weeks after discontinuation of I P.  The investigator is 
responsible for ensuring that subjects understand how to properly use these 
methods of contraception.
Section 4.5. Withdrawal Criteria
Subjects must beprematurely discontinued from the study  for any  of the following 
reasons:
Pregnancy  (intrauterine), regardless of termination status of pregnan cy.  As a 
reminder, females of reproductive potential who changed their minds and 
desire to be pregnant , or who state they no longer are willing to comply with the 
approved pregnancy avoidance methods, should also be withdrawn from the 
study.
Section 6.1. Time and Events Schedule
h.  Pregnancy testing. Women of childbearing potential only. S=serum, U=urine .Remind females of 
reproductive potential of the need to avoid pregnancy while in study and adherence to the 
study’s contraception requirements.
Section 10. References
GlaxoSmithKline Document Number 2017N352880_00: [COMPANY_004]1349572 Clinical 
Investigator's Brochure, Version 11, Supplement 01, December 2017.
2013N161649_03 CONFIDENTIA L
ING117172
131GlaxoSmithKline Document Number 2017N352880_01: [COMPANY_004]1349572 Clinical 
Investigator's Brochure, Version 11, Supplement 02, June 2018.
GlaxoSmithKline Document Number RM2007/[ZIP_CODE]/0611: [COMPANY_004]1349572 Clinical 
Investigator's Brochure. February  2013. Version 11, October 2017.
References to the DTG IB were also updated throughout the protocol to reference the 
current DTG IB.
Section 11.6, Appendix 6
A new Section 11.6, Appendix 6 was inserted ; the previous Appendix 6 (Section 11.6, 
Appendix 6 Protocol Changes) was updated to Section 11.7, Appendix 7.
Appendix 6: Modified List of Highly Effective Methods for Avoidi ng Pregnancy in 
Females of Reproductive Potential (FRP)
The list does not apply to FRP with same sex partners or for subjects who are and 
will continue to be abstinent from penile-vaginal intercourse on a long term and 
persistent basis, when this is their preferred and usual lifestyle. Periodic abstinence 
(e.g. calendar, ovulation, symptothermal, post -ovulation methods) and withdrawal 
are not acceptable methods of contraception.
1.  Contraceptive subdermal implant
2.  Intrauterine device or intrauterine sy stem
3.  Combined estrogen and progestogen oral contraceptive [ Hatcher , 2011])
4.  Injectable progestogen [ Hatcher , 2011]
5.  Contraceptive vaginal ring [ Hatcher , 2011]
6.  Percutaneous contraceptive patches [ Hatcher , 2011]
7.  Male partner sterilisation w ith documentation of azoospermia prior to the female 
subject's entry into the study, and this male is the sole partner for that subject 
[Hatcher , 2011]. The documentation on male sterility can come from the site 
personnel’s review of subject’s medical rec ords, medical examination, and/or 
semen analysis, or medical history interview provided by [CONTACT_163596].
These allowed methods of contraception are only effective when used consistently, 
correctly and in accordance with the product label. The invest igator is responsible 
for ensuring that subjects understand how to properly use these methods of 
contraception.
Reference
Hatcher RA, Trussell J, Nelson AL, et al, editors. Contraceptive Technology. 
20thedition. Atlanta, Georgia: Ardent Media, Inc., 2011 : 50. Table 3-2. 